

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C07F 15/00, 19/00, A61K 31/28, A61P 35/00		A1	(11) International Publication Number: WO 00/56743 (43) International Publication Date: 28 September 2000 (28.09.00)
(21) International Application Number: PCT/CA00/00294			(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 17 March 2000 (17.03.00)			
(30) Priority Data: 60/125,166 19 March 1999 (19.03.99) US			
(71) Applicant: ANORMED INC. [CA/CA]; #200 – 20353 64th Avenue, Langley, British Columbia V2Y 1N5 (CA).			
(72) Inventors: FRICKER, Simon; 5882 237A Street, Langley, British Columbia V2Z 1A6 (CA). ABRAMS, Michael, J.; 9543 Stern Road, Custer, WA 98240 (US). BRIDGER, Gary; 445 S. Garden Street, Bellingham, WA 98225 (US). SKERLIJ, Renato; Shearwater Road, Blaine, WA 98230 (US). BAIRD, Ian; 7972 Inverness Street, Vancouver, British Columbia V5X 4H7 (US). CAMERON, Beth, R.; 20910 51st Avenue, Langley, British Columbia V3A 5C1 (US).			Published <i>With international search report.</i>
(74) Agents: ROBINSON, J., Christopher et al.; Fetherstonhaugh & Co., Box 11560, Suite 2200, 650 West Georgia Street, Vancouver, British Columbia V6B 4N8 (CA).			
(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING METAL COMPLEXES			
(57) Abstract			
A compound of the formula $[M_a(X_bL)_cY_dZ_e]^{n\pm}$ wherein: M is a metal ion or a mixture of metal ions; X is a cation or a mixture of cations; L is a ligand, or mixture of ligands each containing at least two different donor atoms selected from the elements of Group IV, Group V or Group VI of the Periodic Table; Y is a ligand or a mixture of the same or different ligands each containing at least one donor atom or more than one donor atom selected from the elements of Group IV, Group V or Group VI of the Periodic Table; and Z is a halide or pseudohalide ion or a mixture of halide ions and pseudohalide ions; and wherein: a=1-3; b=0-12; c=0-18; d=0-18; e=0-18; and n=0-10; provided that at least one of c, d and e is 1 or more; wherein c is 0: b is also 0; wherein a is 1: c, d and e are not greater than 9; and wherein a is 2: c, d and e are not greater than 12.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**PHARMACEUTICAL COMPOSITIONS
COMPRISING METAL COMPLEXES**

TECHNICAL FIELD

5 This invention relates to new pharmaceutical compositions and to pharmaceutical compositions having activity against diseases caused by, or related to, overproduction of localised high concentrations of reaction oxygen species, including nitric oxide, in the body.

BACKGROUND

10 Nitric oxide (NO) plays a varied and vital role in the body of a human or other mammals. For example, NO plays a vital role in the control of blood pressure: it acts as a neurotransmitter; it plays a role in inhibition of platelet aggregation (important in thrombosis or blockages of the blood vessels) and in cytostasis (important in fighting of tumours). Overproduction of NO however, has been implicated in a number of
15 disease states, including vascular/pressor diseases such as septic shock, post-ischaemic cerebral damage, migraine and dialysis induced renal hypotension: immunopathologic diseases such as hepatic damage in inflammation and sepsis allograft rejection, graft versus host diseases, diabetes and wound healing: neurodegenerative diseases such as cerebral ischaemia, trauma, chronic epilepsy,
20 Alzheimer's disease, Huntington's disease, and AIDS dementia complex; and side effects of treatment such as restenosis following angioplastic treatment and secondary hypotension following cytokine therapy.

 Pharmacological modulation of nitric oxide or other reactive oxygen species in any of these disease states should prove extremely beneficial.

25 One above-mentioned disease relating to overproduction of NO is septic shock. This is precipitated by local septicaemia or endotoxaemia, (high local levels of bacterial endotoxins). The result is activation of macrophages, lymphocytes, endothelial cells and other cell types capable of producing NO further mediated by cytokine production by these cells. The activated macrophages produce excess NO
30 which causes vasodilation of the blood vessels, and results in local vascular damage and vascular collapse. This destruction of vascular integrity may be so great that it leads to the collapse of haemodynamic homeostasis, the end result being death.

Current ideas for pharmacological modulation of nitric oxide in such diseases are based on dealing with the mediators of septic shock such as cytokines, endotoxins and platelet activating factor (PAF). The approaches include use of antibodies to cytokines such as tumour necrosis factor (TNF) receptor antagonists such as

5 interleukin I (IL-1) antibodies to lipopolysaccharide (the endotoxins produced by Gram negative bacteria) and PAF antagonists. All such approaches while challenging a factor mediating septic shock do not attempt to deal with the aetiology or cause of the disease. Recent advances in understanding of NO have lead to the proposal that

10 inhibitors of the NO synthase enzyme such as N^G-monomethyl-L-arginine (L-NMMA) may be useful in the treatment of septic shock and other NO overproduction related to diseases since they inhibit NO production. While these inhibitors have shown some utility in animal models and preliminary clinical studies they have the disadvantage of undesirably inhibiting total NO synthesis in the body.

An aim of the present invention is to provide new compositions which are able


15 to modulate levels of NO and other reactive oxygen species in the body. Examples of other reactive species include superoxide, hydroxyl radical, peroxide, peroxynitrite, and other oxides of nitrogen including protein adducts. The compositions of metal complexes described herein are able to carry out the important role of reducing levels of these harmful species by scavenging.

20 SUMMARY OF THE INVENTION

Some metal complexes are known in pharmaceutical compositions for the treatment of diseases of the body of a human or other mammal. For example certain complexes of platinum and ruthenium have been used or indicated in the treatment of cancer. Metal complexes have not however been previously indicated in the treatment

25 of disease relating to the overproduction of reactive oxygen species (including the overproduction of NO).

This invention provides for the use of a neutral anionic or cationic metal complex having at least one site for coordination with NO of Formula I



30 in the manufacture of a medicament for the attenuation of NO levels and other reactive oxygen species when implicated in disease.

where:

M is a metal ion or a mixture of metal ions:

X is a cation or a mixture of cations:

L is a ligand, or mixture of ligands each containing at least two different donor atoms selected from the elements of Group IV, Group V or Group VI of the Periodic

5 Table;

Y is a ligand or a mixture of the same or different ligands each containing at least one donor atom or more than one donor atom which donor atom is selected from the elements of Group IV, Group V or Group VI of the Periodic Table:

And

10 Z is a halide or pseudohalide ion or a mixture of halide ions and pseudohalide ions:

a=1-3; b=0-12; c=0-18; d=0-18; e=0-18; and n=0-10; provided that at least one of c, d and e is 1 or more.

And where c is 0: b is also 0;

15 And where a is 1: c, d and e are not greater than 9;

And where a is 2: c, d and e are not greater than 12.

By "complex" in this specification is meant a neutral complex or anionic or cationic species.

The term "Group" which is used herein is to be understood as a vertical 20 column of the periodic table in which elements of each Group have similar physical and chemical properties. The definition of the Periodic Table is that credited to Mendeleev; Chamber Dictionary of Science and Technology, 1974 Published by W & R Chambers Ltd. The nomenclature of the compounds as disclosed herein are based upon common usage. The names of the compounds according to nomenclature of the 25 American Chemical Abstracts Service (American Chemical Society) are also provided in Table 5.

This invention may also be stated as providing a method of attenuation of reactive oxygen species when implicated in diseases of the human body or the bodies of other mammals. Thus the invention comprises administering a pharmaceutical 30 composition containing a neutral, anionic or cationic metal complex of Formula I.

This invention may also provide for the use of a neutral anionic or cationic metal complex of formula I in the manufacture of a medicament for the treatment of

diseases in which reactive oxygen species are overproduced.

This invention may also be stated as providing a method of attenuation of nitric oxide when implicated in diseases of the human body or bodies of other mammals. Thus the invention comprises administering a pharmaceutical composition 5 containing a neutral, anionic or cationic metal complex of Formula I.

This invention may also be stated as providing a method of treatment of diseases of a body of a human or other mammals resultant of overproduction of NO in the body comprising administering a pharmaceutical composition containing a neutral anionic or cationic metal complex of formula I.


10 Where the formula I represents an anionic species a cation will also be present. Where formula I represent a cationic species an anion will also be present. The metal complexes may be hydrated.

15 Preferably M is a first, second or third row transition metal ion. For example M may be an Rh, Ru, Os, Mn, Co, Cr or Re ion, and is preferably an Rh, Ru or Os ion.

Suitably M is in an oxidation state III. We have found surprisingly that when the metal ion for example ruthenium is in oxidation state III, the rate at which it binds with NO is significantly faster than when it is in oxidation state II.

20 X may be any cation, such as mono-, di- or tri-valent cation. Suitable cations may be H^+ , K^+ , Na^+ , NH_4^+ or Ca^{2+} . Conveniently X may be H^+ , K^+ , or Na^+ .

Preferably L is a polyaminocarboxylate ligand described herein by the general formulae A and B:



25 Where:

V' , W' , X' , Y' and Z' are independently selected selected from H, phenyl,

heteroaryl, C₁-6alkyl, C₁-6alkylhydroxy, C₁-6alkylthiol, C₁-6alkylaryl, C₁-6alkylheteroaryl, C₁-6alkylheterocycl and derivatives thereof. Preferred alkylheterocyclic groups are pyridinylmethylene, pyrazinylmethylene, pyrimidinylmethylene. The aromatic and heteroaromatic groups may be suitably substituted in single or multiple positions with halide, C₁-6alkyl, C₁-6alkoxy, C₁-6alkoxyaryl or benzyloxy, hydroxy, C₁-hydroxyalkyl, thiol, carboxylic acid, carboxyalkylC₁-6, carboxamide, carboxamidoalkylC₁-6, anilide.

P' = CH_2 , $(\text{CH}_2)_2$, $\text{CHOHCH}_2\text{CH}(\text{OC}_{1-6}\text{alkyl})\text{CH}_2$

V', W', X', Y' and Z' may also be methylenecarboxylic acid,

10 methylenecarboxyC₁₋₆alkyl, methylenecarboxamideC₁₋₆alkyl or heterocyclyl, methylenecarboxanilide, methylenecarboxamido derivatives of an aminoacid or peptide, methylenehydroxamic acid, methylene phosphonic acid, C₁₋₆alkylthiol.


In the above formulae, the ligands may be optionally fused with a heterocyclic ring R (n= 0 or 1). Preferred heterocyclic groups are pyridine, pyrimidine, pyrazine, 15 imidazole, thiazole, oxazole.

More preferably L is a ligand such as ethylenediamine-N,N'-diacetic acid (edda), ethylenediaminetetraacetic acid (edta), nitrilotriacetic acid (nta), dipicolinic acid (dipic), picolinic acid (pic), diethylenetri-aminepentaacetic acid (dtpa), thiobis(ethylenenitrilo)tetraacetic acid (tedta),
20 dithioethanebis(ethylenenitrilo)tetraacetic acid (dtedta), and N-(2-hydroxethyl)ethylenediamine-triacetic acid (hedtra).

Preferably Y is a ligand containing nitrogen, oxygen, sulphur, carbon or phosphorus donor groups. Suitable nitrogen donor groups may be for example ammine, amine, nitrile and nitride or derivations thereof. Suitable oxygen donor groups may be for example carboxylic acid, ester or derivations thereof, water, oxide, sulphoxide, hydroxide, acetate, lactate, propionate, oxalate and maltolate. Suitable sulphur donor groups may be for example sulphoxide, dialkylsulphide, dithiocarbamate or dithiophosphate. Suitable carbon donor groups may be for example carbon monoxide or isocyanide. Suitable phosphorus donor groups may be for example trialkylphosphine.

Z may be any halide and is preferably chloride, bromide or iodide. Most conveniently, Z is chloride.

Examples of metal complexes for use according to the present invention include optionally hydrated ruthenium complexes of Formula II



where L^{II} is a polyaminocarboxylate ligand as already described herein by the

5 general formulae A and B, more preferably a polydentate aminocarboxylate ligand such as, for example edta, nta, dipic, pic, edda, tropolone, dtpa, hedtra, teda or dteda or diamide of edta or dtpa (or an amide or ester derivative thereof) or a mixture of any of these and Y is as defined above and may for example be selected from:
10 acetylacetone (acac) a β -diketonate; water; dimethylsulphoxide (dmso); carboxylate; bidentate carboxylate; catechol; kojiic acid; maltol; hydroxide; tropolone; malonic acid; oxalic acid; 2,3-dihydroxynaphthalene; squaric acid; acetate; a sulphate and a glycolate.

The skilled artisan will be able to substitute other known ligands at Y and which will fall within the scope of the inventions.

15 Preparative methods of teda, dteda and diamide of edta and dtpa are described in the following references respectively:

P Tse & JE Powell, Inorg Chem, (1985), 24, 2727

G Schwartzenbach, H Senner, G Anderegg, Helv Chim Acta 1957, 40, 1886



MS Konings, WC Dow, DB Love, KN Raymond, SC Quay and SM Rocklage,
20 Inorg Chem (1990), 29, 1488-1491

PN Turowski, SJ Rodgers, RC Scarro and KN Raymond, Inorg Chem (1988), 27, 474-481.

Where the complex of Formula II is an anion, a cation will be required. For example the complexes of Formula II are present in

25 $\text{K}[\text{Ru}(\text{Hedta})\text{Cl}]2\text{H}_2\text{O}$
 $[\text{Ru}(\text{H}_2\text{edta})(\text{acac})]$
 $\text{K}[\text{Ru}(\text{hedtra})\text{Cl}]\text{H}_2\text{O}$
 $\text{K}[\text{Ru}(\text{dipic})_2]\text{H}_2\text{O}$
 $(\text{H}_2\text{pic})[\text{RuCl}_2(\text{pic})_2](\text{Hpic})\text{H}_2\text{O}$


30 $\text{K}[\text{Ru}(\text{H}_2\text{edta})\text{Cl}_2]\text{H}_2\text{O}$
 $\text{K}[\text{Ru}(\text{Hnta})_2]\frac{1}{2}\text{H}_2\text{O}$
 $\text{K}[\text{Ru}(\text{H}_2\text{dtpa})\text{Cl}]\text{H}_2\text{O}$




Complexes of formula II have not to the best of our knowledge been

5 previously indicated in any pharmaceutical composition. Therefore the present invention also provides a pharmaceutical composition containing an optionally hydrated ruthenium complex of Formula II.

Further examples of metal complexes for use according to the present invention include optionally hydrated complexes of Formula III



where Y is a sulphur donor ligand. For example, such complex is present in







Complexes of Formula III in which Y is a sulphur donor ligand have not to the 15 best of our knowledge been previously indicated in any pharmaceutical composition. Therefore, the present invention also provides a pharmaceutical composition containing an optionally hydrated complex of Formula III when Y is a sulphur donor ligand.

Yet further examples of metal complexes for use according to the present 20 invention include optionally hydrated complexes of ruthenium of Formula III



where M^{III} is ruthenium and Y^{III} is an oxygen-donor ligand such as acetate, lactate, water, oxide, propionate (COEt), oxalate (ox), or maltol (maltol) or a combination of these. For example complexes of Formula III are present in




Some complexes of Formula III have not to the best of our knowledge been previously indicated in any pharmaceutical composition. Therefore the present invention also provides a pharmaceutical composition containing an optionally hydrated complex of ruthenium of Formula III wherein M^{III} is ruthenium and Y^{III} is an 5 oxygen-donor ligand selected from the group acetate, lactate, oxide, propionate and maltolate.

Further examples of metal complexes for use according to the present invention include optionally hydrated complexes of ruthenium of Formula IV



10 where Y^{IV} is a nitrogen-donor ligand such as: ammine; ethylenediamine (en); pyridine (py); 1,10-phenanthroline (phen); 2,2-bipyridine (bipy) or 1,4,8,11-tetraazacyclotetradecane (cyclam); 1,4,7-triazacyclononane; 1,4,7-triazacyclononane tris acetic acid; 2,3,7,8,12,13,17,18-octaethylporphyrin (oep); or a combination of these. For example complexes of Formula IV are present in







Some complexes of Formula IV have not to the best of our knowledge been 25 previously indicated in any pharmaceutical composition. Therefore the present invention also provides a pharmaceutical composition containing an optionally hydrated complex of ruthenium of Formula IV wherein Y^{IV} is a nitrogen-donor ligand selected from the group en, py, phen, bipy, cyclam and oep. Derivations of these ligands can be prepared by a skilled artisan and which will fall within the scope of the 30 inventions.

Still further examples of metal complexes for use according to the present invention include optionally hydrated complexes of ruthenium or osmium of general Formula V



5 where Y^V is a combination of donor ligands such as are described hereinabove, for example ammine, dmso, oxalate, bipy, acac and methyl cyanide. Complexes of Formula V are present in for example



15 The complex ions of the latter two compounds above have not to the best of our knowledge been previously indicated in any pharmaceutical composition.

Therefore the present invention also provides a pharmaceutical composition containing an optionally hydrated complex of formula $[\text{Os}(\text{ox})(\text{bipy})_2]$; and further a pharmaceutical composition containing an optionally hydrated complex of formula $[\text{Ru}(\text{acac})_2(\text{MeCN})_2]^+$.

20 In use the complexes of the present invention may be included as an active component in a pharmaceutical composition containing an optionally hydrated complex of any of Formulae I-V, in admixture with a pharmaceutically acceptable carrier or diluent. Said pharmaceutical composition may be formulated according to well known principles, and may be in the form of a solution or suspension for

25 parenteral administration in single or repeat doses or be in capsule, tablet, dragee, or other solid composition or as a solution or suspension for oral administration, or formulated into pessaries or suppositories, or sustained release forms of any of the above. The solution or suspension may be administered by a single or repeat bolus injection or continuous infusion, or any other desired schedule. Suitable diluents,

30 carriers, excipients and other components are known. Said pharmaceutical composition may contain dosages determined in accordance with conventional pharmacological methods, suitable to provide active complexes in the dosage range in

humans of 1mg to 10g per day and dosages in other mammals as determined by routine clinical veterinary practice. Actual required dosage is largely dependent on where in the body there is the excess concentration of NO or other reactive oxygen species and for how long overproduction continues or attenuation of the levels of NO 5 or reactive oxygen species, where such reactive oxygen species is implicated in disease, is required.

BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing aspects and many of the attendant advantages of this invention will become more readily appreciated as the same becomes better understood by 10 reference to the following detailed description, when taken in conjunction with the accompanying drawings, wherein:

FIGURE 1 illustrates pressure changes induced by the compounds of the present invention, which reflect a reduction in available nitric oxide compared with control

levels.

15 FIGURE 2 shows the available nitric oxide concentration (micromoles/liter) following reaction of nitric oxide with compounds of the present invention as compared with control levels.

FIGURE 3 demonstrates the inhibition of tumour growth by AMD6245 and AMD6221.

20 FIGURE 4A-4G provides chemical structural formulas for the AMD-numbered compounds disclosed.

FIGURE 5A-5C provides chemical structural formulas for the AMD-numbered compounds disclosed.

DETAILED DESCRIPTION OF THE INVENTION


25 Introduction and General Description of the Invention

This invention is directed to metal complexes which are useful in binding nitric oxide with sufficiently high affinity as to make such complexes useful as pharmaceutical compositions for the treatment of diseases in mammals, preferably in the human body.

30 Some metal complexes are known in pharmaceutical compositions for the treatment of diseases in mammals, preferably in diseases of the human body. For example certain complexes of platinum and ruthenium have been used or indicated in

the treatment of cancer. Metal complexes have not however been previously indicated in the treatment of disease relating to the overproduction of reactive oxygen species (including the overproduction of NO). This invention provides for the use of a neutral anionic or cationic metal complex having at least one site for coordination with NO of

5 Formula I



in the manufacture of a medicament for the attenuation of NO levels and other reactive oxygen species when implicated in disease.

where:

10 M is a metal ion or a mixture of metal ions:

X is a cation or a mixture of cations:

L is a ligand, or mixture of ligands each containing at least two different donor atoms selected from the elements of Group IV, Group V or Group VI of the Periodic Table;

15 Y is a ligand or a mixture of the same or different ligands each containing at least one donor atom or more than one donor atom which donor atom is selected from the elements of Group IV, Group V or Group VI of the Periodic Table:

And

20 Z is a halide or pseudohalide ion or a mixture of halide ions and pseudohalide ions:

a=1-3; b=0-12; c=0-18; d=0-18; e=0-18; and n=0-10; provided that at least one of c, d and e is 1 or more.

And where c is 0: b is also 0;

And where a is 1: c, d and e are not greater than 9;

25 And where a is 2: c, d and e are not greater than 12.

By "complex" in this specification is meant a neutral complex or anionic or cationic species.

30 The term "Group" which is used herein is to be understood as a vertical column of the periodic table in which elements of each Group have similar physical and chemical properties. The definition of the Periodic Table is that credited to Mendeleev; Chamber Dictionary of Science and Technology, 1974 Published by W & R Chambers Ltd. The nomenclature of the compounds as disclosed herein are based

upon common usage. The names of the compounds according to nomenclature of the American Chemical Abstracts Service (American Chemical Society) are also provided in Table 5.

This invention may also be stated as providing a method of attenuation of 5 reactive oxygen species when implicated in diseases in mammals, preferably in diseases of the human body. Thus the invention comprises administering a pharmaceutical composition containing a neutral, anionic or cationic metal complex of Formula I.

This invention may also provide for the use of a neutral anionic or cationic 10 metal complex of formula I in the manufacture of a medicament for the treatment of diseases in mammals, preferably in diseases of the human body in which reactive oxygen species are overproduced.

This invention may also be stated as providing a method of attenuation of nitric oxide when implicated in diseases in mammals, preferably in diseases of the 15 human body. Thus the invention comprises administering a pharmaceutical composition containing a neutral, anionic or cationic metal complex of Formula I.

This invention may also be stated as providing a method of treatment of diseases of the human body resultant of overproduction of NO in the human body comprising administering a pharmaceutical composition containing a neutral anionic 20 or cationic metal complex of formula I.


Where the formula I represents an anionic species a cation will also be present. Where formula I represent a cationic species an anion will also be present. The metal complexes may be hydrated.

Preferably M is a first, second or third row transition metal ion. For example 25 M may be an Rh, Ru, Os, Mn, Co, Cr or Re ion, and is preferably an Rh, Ru or Os ion.

Suitably M is in an oxidation state III. We have found surprisingly that when the metal ion for example ruthenium is in oxidation state III, the rate at which it binds with NO is significantly faster than when it is in oxidation state II.

30 X may be any cation, such as mono-, di- or tri-valent cation. Suitable cations may be H^+ , K^+ , Na^+ , NH_4^+ or Ca^{2+} . Conveniently X may be H^+ , K^+ , or Na^+ .

Preferably L is a polyaminocarboxylate ligand described herein by the general formulae A and B:



5 Where:

V', W', X', Y' and Z' are independently selected from H, phenyl, heteroaryl, C₁-6alkyl, C₁-6alkylhydroxy, C₁-6alkylthiol, C₁-6alkylaryl, C₁-6alkylheteroaryl, C₁-6alkylheterocycl and derivatives thereof. Preferred alkylheterocyclic groups are pyridinylmethylene, pyrazinylmethylene, pyrimidinylmethylene. The aromatic and heteroaromatic groups may be suitably substituted in single or multiple positions with halide, C₁-6alkyl, C₁-6alkoxy, C₁-6alkoxyaryl or benzyloxy, hydroxy, C₁-6hydroxyalkyl, thiol, carboxylic acid, carboxyalkylC₁-6, carboxamide, carboxamidoalkylC₁-6, anilide.

P' = CH₂, (CH₂)₂, CHOCH₂, CH(OC₁₋₆alkyl)CH₂

V', W', X', Y' and Z' may also be methylenecarboxylic acid, methylenecarboxyC₁₋₆alkyl, methylenecarboxamideC₁₋₆alkyl or heterocyclyl, methylenecarboxanilide, methylenecarboxamido derivatives of an aminoacid or peptide, methylenehydroxamic acid, methylene phosphonic acid, C₁₋₆alkylthiol.


In the above formulae, the ligands may be optionally fused with a heterocyclic ring R (n= 0 or 1). Preferred heterocyclic groups are pyridine, pyrimidine, pyrazine, imidazole, thiazole, oxazole.

More preferably L is a ligand such as ethylenediamine-N,N'-diacetic acid (edda), ethylenediaminetetraacetic acid (edta), nitrilotriacetic acid (nta), dipicolinic acid (dipic), picolinic acid (pic), diethylenetri-aminepentaacetic acid (dtpa), thiobis(ethylenenitrilo)tetraacetic acid (teda),
25 dithioethanebis(ethylenenitrilo)tetraacetic acid (dteda), and N-(2-hydroxethyl)ethylenediamine-triacetic acid (hedtra).

Preferably Y is a ligand containing nitrogen, oxygen, sulphur, carbon or phosphorus donor groups. Suitable nitrogen donor groups may be for example ammine, amine, nitrile and nitride or derivations thereof. Suitable oxygen donor groups may be for example carboxylic acid, ester or derivations thereof, water, oxide, 5 sulphoxide, hydroxide, acetate, lactate, propionate, oxalate and maltolate. Suitable sulphur donor groups may be for example sulphoxide, dialkysulphide, dithiocarbamate or dithiophosphate. Suitable carbon donor groups may be for example carbon monoxide or isocyanide. Suitable phosphorus donor groups may be for example trialkylphosphine.

10 Z may be any halide and is preferably chloride, bromide or iodide. Most conveniently, Z is chloride.

Examples of metal complexes for use according to the present invention include optionally hydrated ruthenium complexes of Formula II



15 where L^{II} is a

Preferably L is a polyaminocarboxylate ligand as already described herein by the general formulae A and B. More preferably, L is a polydentate aminocarboxylate ligand, for example edta, nta, dipic, pic, edda, tropolone, dtpa, hedra, tedita or dtedita or diamide of edta or dtpa (or an amide or ester derivative thereof) or a mixture of any 20 of these and Y is as defined above and may for example be selected from: acetylacetone (acac) a β -diketonate; water; dimethylsulphoxide (dmso); carboxylate; bidentate carboxylate; catechol; kojiic acid; maltol; hydroxide; tropolone; malonic acid; oxalic acid; 2,3-dihydroxynaphthalene; squaric acid; acetate; a sulphate and a glycolate. The skilled artisan will be able to substitute other known ligands at Y and 25 which will fall within the scope of the inventions.

Preparative methods of tedita, dtedita and diamide of edta and dtpa are described in the following references respectively:

P Tse & JE Powell, Inorg Chem, (1985), 24, 2727

G Schwartzenbach, H Senner, G Anderegg, Helv Chim Acta 1957, 40, 1886

30 MS Konings, WC Dow, DB Love, KN Raymond, SC Quay and SM Rocklage, Inorg Chem (1990), 29, 1488-1491

PN Turowski, SJ Rodgers, RC Scarrow and KN Raymond, Inorg Chem (1988), 27, 474-481.

Where the complex of Formula II is an anion, a cation will be required. For example the complexes of Formula II are present in

5 K[Ru(Hedta)Cl]2H₂O
 [Ru(H₂edta)(acac)]
 K[Ru(hedtra)Cl]H₂O
 K[Ru(dipic)₂]H₂O
 (H₂pic)[RuCl₂(pic)₂](Hpic)H₂O

10 K[Ru(H₂edta)Cl₂]H₂O
 K[Ru(Hnta)₂]½H₂O
 K[Ru(H₂dtpa)Cl]H₂O
 [Ru(Hhedtra)acac]H₂O
 [Ru(Hhedtra)trop]

15 [Ru(H₃dtpa)Cl]

Complexes of formula II have not to the best of our knowledge been previously indicated in any pharmaceutical composition. Therefore the present invention also provides a pharmaceutical composition containing an optionally hydrated ruthenium complex of Formula II.

20 Further examples of metal complexes for use according to the present invention include optionally hydrated complexes of Formula III



where Y is a sulphur donor ligand. For example, such complex is present in
[Ru(mtc)₃] (mtc = 4-morpholinocarbodithioic acid)

25 Ru(S₂CNCH₂CH₂NMeCH₂CH₂)₃½H₂O

Complexes of Formula III in which Y is a sulphur donor ligand have not to the best of our knowledge been previously indicated in any pharmaceutical composition. Therefore, the present invention also provides a pharmaceutical composition containing an optionally hydrated complex of Formula III when Y is a sulphur donor ligand.

Yet further examples of metal complexes for use according to the present invention include optionally hydrated complexes of ruthenium of Formula III



where M^{III} is ruthenium and Y^{III} is an oxygen-donor ligand such as acetate, lactate, water, oxide, propionate ($COEt$), oxalate (ox), or maltol or a combination of these. For example complexes of Formula III are present in

- 5 $[Ru_3O(OAc)_6](OAc)$
- $[Ru_3O(lac)_6](lac)$
- $[Ru_2(OAc)_4]NO_3$
- $[Ru_2(OCOEt)_4]NO_3$
- $K_3[Ru(ox)_3]$
- 10 $[Ru_2(OAc)_4]Cl$
- $[Ru(maltol)_3]$

Some complexes of Formula III have not to the best of our knowledge been previously indicated in any pharmaceutical composition. Therefore the present invention also provides a pharmaceutical composition containing an optionally 15 hydrated complex of ruthenium of Formula III wherein M^{III} is ruthenium and Y^{III} is an oxygen-donor ligand selected from the group acetate, lactate, oxide, propionate and maltol.

Further examples of metal complexes for use according to the present invention include optionally hydrated complexes of ruthenium of Formula IV



where Y^{IV} is a nitrogen-donor ligand such as: ammine; ethylenediamine (en); pyridine (py); 1,10-phenanthroline (phen); 2,2-bipyridine (bipy) or 1,4,8,11-tetraazacyclotetradecane (cyclam); 2,3,7,8,12,13,17,18-octaethylporphyrin (oep); or a combination of these. For example complexes of Formula IV are present in

- 25 $[Ru(HN_3)_5Cl]Cl_2$
- $[Ru(en)_3]I_3$
- trans- $[RuCl_2(py)_4]$
- $K[Ru(phen)Cl_4]$
- $[Ru(cyclam)Cl_2]Cl$
- 30 $K[Ru(bipy)Cl_4]$
- $[Ru(NH_3)_6]Cl_3$
- $[Ru(NH_3)_4Cl_2]Cl$


Ru(oep)Ph

Some complexes of Formula IV have not to the best of our knowledge been previously indicated in any pharmaceutical composition. Therefore the present invention also provides a pharmaceutical composition containing an optionally hydrated complex of ruthenium of Formula IV wherein Y^{IV} is a nitrogen-donor ligand selected from the group en, py, phen, bipy, cyclam and oep. Derivations of these ligands can be prepared by a skilled artisan and which will fall within the scope of the inventions.

Still further examples of metal complexes for use according to the present invention include optionally hydrated complexes of ruthenium or osmium of general Formula V



where Y^V is a combination of donor ligands such as are described hereinabove, for example ammine, dmso, oxalate, bipy, acac and methyl cyanide. Complexes of Formula V are present in for example



The complex ions of the latter two compounds above have not to the best of our knowledge been previously indicated in any pharmaceutical composition. Therefore the present invention also provides a pharmaceutical composition containing an optionally hydrated complex of formula [Os(ox)(bipy)₂]⁺; and further a pharmaceutical composition containing an optionally hydrated complex of formula [Ru(acac)₂(MeCN)₂]⁺.

In use the complexes of the present invention may be included as an active component in a pharmaceutical composition containing an optionally hydrated complex of any of Formulae I-V, in admixture with a pharmaceutically acceptable carrier or diluent. Said pharmaceutical composition may be formulated according to well known principles, and may be in the form of a solution or suspension for

parenteral administration in single or repeat doses or be in capsule, tablet, dragee, or other solid composition or as a solution or suspension for oral administration, or formulated into pessaries or suppositories, or sustained release forms of any of the above. The solution or suspension may be administered by a single or repeat bolus

5 injection or continuous infusion, or any other desired schedule. Suitable diluents, carriers, excipients and other components are known. Said pharmaceutical composition may contain dosages determined in accordance with conventional pharmacological methods, suitable to provide active complexes in the dosage range in humans of 1mg to 10g per day. Actual required dosage is largely dependent on where

10 in the body there is the excess concentration of NO or other reactive oxygen species and for how long overproduction continues or attenuation of the levels of NO or reactive oxygen species, where such reactive oxygen species is implicated in disease, is required. It will be understood that the present invention may be used in combination with any other pharmaceutical composition useful for this purpose.

15 Citation of the above documents is not intended as an admission that any of the foregoing is pertinent prior art. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents. Further, all documents referred to throughout this

20 application are incorporated in their entirety by reference herein. Terms as used herein are based upon their art recognized meaning unless otherwise indicated and should be clearly understood by the ordinary skilled artisan.

EXAMPLES

Having now generally described the invention, the same will be more readily

25 understood through reference to the following examples which are provided by way of illustration, and are not intended to be limiting of the present invention, unless specified.

A number of commercially available compounds, and compounds prepared by routes known in the literature, containing the complexes of the present invention were

30 tested *in vitro*, *in vitro* cell culture, and *ex vivo* in order to determine ability to coordinate with NO. The complexes tested were as follows:

Table 1

Example	Compound	Literature Reference for Preparation
1	K[Ru(hedta)Cl]2H ₂ O	AA Diamantis & JV Dubrawski, Inorg. Chem. (1981) 20:1142-50
2	[Ru(H ₂ edta)(acac)]	AA Diamantis & JV Dubrawski, Inorg. Chem. (1983) 22:1934-36
3	K[Ru(hedtra)Cl]H ₂ O	HC Bajaj & R van Eldik, Inorg. Chem. (1982) 28:1980-3
4	K[Ru(dipic) ₂]H ₂ O	NH Williams & JK Yandell, Aust. J. Chem. (1983) 36(12):2377-2386
5	(H ₂ pic)[RuCl ₂ (pic) ₂](Hpic)H ₂ O	JD Gilbert, D Rose & G Wilkinson, J. Chem. Soc. (A) (1970):2765-9
6	K[Ru(H ₂ edta)Cl ₂]H ₂ O	AA Diamantis & JV Dubrawski, Inorg. Chem. (1981) 20:1142-50
7	K[Ru(hnta) ₂]½H ₂ O	MM Taqui Khan, A Kumar & Z Shirin, J. Chem. Research (M), (1986):1001-1009
8	K[Ru(H ₂ dtpa)Cl]H ₂ O	MM Taqui Khan, A Kumar & Z Shirin, J. Chem. Research (M), (1986):1001-1009
9	[Ru ₃ O(lac) ₆](lac)	A Spencer & G Wilkinson, J. Chem. Soc. Dalton Trans (1972):1570-77
10	[Ru ₃ O(OAc) ₆](OAc)	A Spencer & G Wilkinson, J. Chem. Soc. Dalton Trans (1972):1570-77
11	[Ru ₂ (OAc) ₄]NO ₃	M Mukaida, T Nomura & T Ishimori, Bull. Chem. Soc. Japan (1972) 45:2143-7
12	[Ru ₂ (OCOEt) ₄]NO ₃	A Bino, FA Cotton & TR Felthouse, Inorg. Chem. (1979) 18:2599-2604
13	K ₃ [Ru(ox) ₃]	CM Che, SS Kwong, CK Poon, TF Lai & TCW Mak, Inorg. Chem. (1985) 24:1359-63
14	[Ru ₂ (OAc) ₄]Cl	RW Mitchell, A Spencer & G Wilkinson, J. Chem. Soc. Dalton Trans. (1973) 846-54
15	[Ru(NH ₃) ₅ Cl]Cl ₂	AD Allen, F Bottomley, RO Harris, VP Reinsalu & CV Senoff, J. Amer. Chem. Soc. (1967) 89:5595-5599
16	[Ru(en) ₃]I ₃	TJ Meyer & H Taube, Inorg. Chem. (1968) 7:2369-2379
17	K[RuCl ₄ (phen)]H ₂ O	BR James & RS McMillan, Inorg. Nucl. Chem. Lett. (1975) 11(12):837-9
18	[Ru(cyclam)Cl ₂]Cl	PK Chan, DA Isabirye & CK Poon, Inorg. Chem. (1975) 14:2579-80
19	K[RuCl ₄ (bipy)]	BR James & RS McMillan, Inorg. Nucl. Chem. Lett. (1975) 11(12):837-9
20	[RuCl ₃ (dmso) ₂ (NH ₃)]	Patent: International Publication No. WO 91/13553
21	[Ru(NH ₃) ₆]Cl ₃	Matthey Catalogue Sales: Cat No [190245]
22	Cis-[RuCl ₂ (dmso) ₄]	EA Alessio, G Mestroni, G Nardin, WM Attia, M Calligaris, G Sava & S Zorgetto, Inorg. Chem. (1988) 27:4099-4106

Example	Compound	Literature Reference for Preparation
23	Cis-[RuCl ₂ (dmso) ₃ (NH ₃)]	M Henn, E Alessio, G Mestrini, M Calligaris & WM Attia, Inorg. Chim. Acta (1991) 187:39-50
24	[RuCl ₃ (dmso) ₃]	E Alessio, G Balducci, M Calligaris, G Costa, WM Attia & G Mestrini, Inorg. Chem. (1991) 30:609-618
25	[Ru(mtc) ₃]	AR Hendrickson, JM Hope & RL Martin, J. Chem. Soc. Dalton Trans. (1976) 20:2032-9
26	[Ru(maltol) ₃]	WP Griffith & SJ Greaves, Polyhedron (1988) 7(10):1973-9
27	[Ru(acac) ₂ (MeCN) ₂]CF ₃ SO ₃	Y Kasahara, T Hoshino, K Shimizu & GP Sato, Chem. Lett. (1990) 3:381-4
28	K ₂ [RuCl ₅ (H ₂ O)]	Matthey Catalogue Sales: Cat No [190094]
29	[Os(ox)(bipy) ₂]·H ₂ O	DA Buckingham, FP Dwyer, HA Goodwin & AM Sargeson, Aust. J. Chem. (1964) 325-336 GM Bryant, JE Fergusson & HKJ Powell, Aust. J. Chem. (1971) 24(2):257-73
30	[Ru(NH ₃) ₄ Cl ₂]Cl	SD Pell, MM Sherban, V Tramintano & MJ Clarke, Inorg Synth (1989) 26:65
31	[Ru(Hedtra)(dppm)]	MM Taqui Khan, K Venkatasubramanian, Z Shirin, MM Bhadbhade, J Chem Soc Dalt Trans (1992) 885-890
32	Ru(oep)Ph	M Ke, SJ Rettig, BR James & D Dolphin, J Chem Soc Chem Commun (1987) 1110

A number of new compounds were prepared according to the following protocols. The first four compounds are examples of ruthenium complexes of formula $[Ru(H_{0.6}L^{II})_{1.3}Y_{0.2}Cl_{0.4}]^{(0-4)\pm}$ (Formula II), the subsequent two are examples of $[M_{1-3}Y_{1-8}Cl_{0-18}]^{(0-6)\pm}$ (formula III).

Preparation of [Ru(Hedtra)acac]·H₂O

Excess acetylacetone (1cm³) was added to an aqueous solution (5cm³) of K[Ru(hedtra)Cl] (0.5g). The solution color changed to violet. The mixture was 10 warmed for 20 minutes then left to stand at room temperature for 20 minutes. The violet solution was extracted with chloroform (20cm³). The extraction was repeated twice more. A violet product precipitated from the aqueous fraction. The product was filtered, washed in acetone and dried *in vacuo*, yield 0.1g (18%).

Anal. Calc. For C₁₅H₂₅O₁₀N₂Ru: C, 36.43; H, 5.11; N, 5.70. Found: C, 15 36.16; H, 5.42; N, 5.61%.

Preparation of {Ru(Hhedtra)trop]2H₂O

A three-fold excess of tropolone (0.78g) dissolved in 50:50 water/absolute ethanol (5cm³) was added to a warm aqueous solution of K[Ru(hedtra)Cl] (10cm³). The mixture was heated for 1 hour. On cooling, the dark green mixture was extracted 5 with 3 x 20cm³ portion of dichloromethane. On standing, a dark green product precipitated from the aqueous fraction. The product was filtered, washed with water (1cm³), ether and dried *in vacuo*, yield 0.4g (36%).

Anal. Cal. For C₁₇H₂₂N₂O₉Ru·2H₂O: C, 38.13; H, 4.86; N, 5.23. found: C, 38.55; H, 4.67; N, 5.28%.

10

Preparation of [Ru(H₃dtpa)Cl]

K₂[RuCl₅H₂O]·xH₂O (1g) was suspended in HClO₄ (15cm³, 1mM) and diethylenetriaminepentaacetic acid (1.05g) added. The reaction mixture was heated under reflux for 1.5 hours forming a yellow/brown solution. On cooling a yellow 15 product crystallised which was collected by filtration, washed with 90% absolute ethanol/water, diethyl ether and dried *in vacuo*, yield 0.75g, 53%.

Anal. calcd. for C₁₄H₂₁N₃O₁₀ClRu: C, 31.85; H, 3.98; N, 7.96; Cl, 6.73.
Found: C, 29.77; H, 3.81; N, 7.36; Cl, 6.64.

20 **Preparation of K[RuHHBEDCl]3H₂O**

0.41g of K₂[RuCl₅]xH₂O was dissolved in water (20ml). To this solution was added 1 equivalent (0.39g) of N,N'-di(2-hydroxy-benzyl)ethylene-diamine N,N-diacetic acid (hbcd) dissolved in water (50ml) with KOH (0.12g) and MeOH (1ml). This mixture was heated at reflux for 90 minutes. Upon cooling a dark, insoluble 25 precipitate formed. This material was removed by filtration and the resulting red-violet solution was taken to dryness by rotary evaporation. Trituration with water and washing with acetone yielded 90mg of a dark solid.

Anal. Calcd. for C₁₈H₂₂N₂O₉RuClK: C, 36.89; H, 3.96; N, 4.78; Cl, 6.04.
Found: C, 37.09; H, 4.23; N, 4.92; Cl, 6.28.

30

Preparation of Ru(S₂CNCH₂CH₂NMeCH₂CH₂)₃½H₂O

Me₄N[S₂CNCH₂CH₂NMeCH₂CH₂] was made by the standard method and crystallised from methanol-ether in 71% yield.

RuCl₃·xH₂O, 0.50g, 2.15mmol was refluxed in 30ml of methanol for 10 minutes and cooled. 1.87g, 7.50mmol of Me₄N[S₂CNCH₂CH₂NMeCH₂CH₂] was added and the mixture refluxed for 16 hours. After cooling 0.72g of crude product was filtered off, dissolved in dichloromethane and filtered. The filtrate was loaded into 15cc of basic alumina and eluted with dichloromethane. Removal of solvent and crystallisation from dichloromethane with ether by vapour-phase diffusion gave 0.51g, 0.80mmol, 37% of brown-black crystals, Ru(S₂CNCH₂CH₂NMeCH₂CH₂)₃½H₂O.

Analysis for C₁₈H₃₄N₆O₅RuS₆: Calc: C, 34.00; H, 5.39; N, 13.22; S, 30.25. Found: C, 34.21; H, 5.47; N, 13.12; S, 30.36.

15 Preparation of Ru[S₂P(OC₂H₂OC₂H₄OMe)₂]₃

K[S₂P(OC₂H₄OC₂H₄OMe)₂]₃] was made by standard method and crystallised from methanol in 76% yield.

RuCl₃·xH₂O, 1.00g, 4.30mmol was refluxed in 50ml of 0.1 N HCl with 1ml of ethanol for 20 minutes and cooled. To this solution was added 5.28g (excess) K[S₂P(OC₂H₄OC₂H₄OMe)₂]₃] and the mixture stirred at 30°C for 1 hour. The reaction mixture was extracted with dichloromethane and the solvent removed. The residue was extracted with ether-hexane and solvents removed. This residue was crystallised from 25ml of hot ether by cooling to -20°C giving 2.98g of red crystals. 2.41g of the crude product was purified by chromatography on 60cc of silica gel with 5% ethanol in ether. The first band was collected, reduced to dryness and crystallised from ether by cooling to -20°C. The yield of red crystals, Ru(S₂P[OC₂H₄OC₂H₄OMe]₂]₃), was 2.16g, 56%.

Analysis for C₃₀H₆₆O₁₈P₃RuS₆: Calc: C, 32.72; H, 6.04; S, 17.47. Found: C, 32.68; H, 6.08; S, 17.16.

In the *in vitro* tests, which were carried out in an atmosphere of argon, each compound (1 x 10⁴ moles) was dissolved in double-distilled deionized and deoxygenated water. The resulting solution was placed in a three-necked pear-shaped

flask and stirred by a magnetic stirrer at constant speed of 1000rpm, at a constant temperature in the range 20°C-24°C. A manometer was attached to the flask, and purified, dried nitric oxide gas (known volume in the range 3-5cm³) was introduced via a septum, using a gas syringe, at atmospheric pressure into the headspace above 5 the reaction solution. The pressure within the flask was recorded periodically over a period of one hour.

A control experiment was carried out according to the above but without any complex present.

10 The recorded pressures in association with the results of the control experiment were analysed in order to determine the rate of NO uptake as a function of time for each compound tested.

On completion of each *in vitro* test, the reaction solution was freeze-dried. An infrared spectrum of the freeze-dried product provided information on metal-NO bond formation.

15 In the *in vitro* cell culture tests, murine (RAW264) macrophage cell lines, which can be induced to produce nitric oxide, were seeded, 10⁶ cells/well, onto 24 well culture plates of 2ml volume per well, in Eagles modified minimal essential medium (MEM) plus 10% fetal bovine serum without phenol red.

20 The cells were activated to produce nitric oxide, with 10µg/ml lipopolysaccharide and 100 units/ml interferon γ for 18 hours. Concurrently, test compounds made up in MEM were added at non-cytotoxic concentrations. Control cells as above, which were activated to produce nitric oxide as above, but to which no test compound was added, were used as a measure of the amount of nitric oxide produced by the cells during the tests. (See S.P. Fricker, E. Slade, N. A. Powell, O. J. Vaughan, G. R. Henderson, B. A. Murrer, I. L. Megson, S. K. Bisland, F. W. Flitney, Ruthenium complexes as nitric oxide scavengers: a potential therapeutic approach to nitric oxide-mediated diseases, *Br. J. Pharmacol.*, 1997, 122, 1441-1449.)

Background nitric oxide was assessed by measurement of nitrate and nitrite in cells which were not activated.

30 Cell viability was confirmed by Trypan blue dye exclusion at the end of the incubation period.

Nitric oxide was determined by measurement of nitrate and nitrite in the cell supernatant. These anions are the stable end-products of reactions of NO in solution. Such reactions may or may not be catalysed in biological systems. The sum of nitrite and nitrate concentrations gives the total NO production. Nitrite was determined 5 using the Griess reaction in which nitrite reacts with 1% sulphanilamide in 5% H₃PO₄/0.1% naphthylethylenediamine dihydrochloride to form a chromophore absorbing at 540nm. Nitrate was determined by reducing nitrate to nitrite with a bacterial nitrate reductase from *Pseudomonas oleovorans* and then measuring nitrite with the Griess reaction. In the absence of test compounds nitrite concentration plus 10 nitrate concentration is equal to total nitric oxide production. The effect of test compounds on available nitric oxide (measured as nitrite + nitrate) was determined. The reduction in available nitric oxide compared with the control level may be taken as an indication of the degree of binding of NO by the test compounds.

In the *ex vivo* tests, segments of rat tail artery (0.8-1.5cm) were dissected free 15 from normotensive adult Wistar rats. The arteries were internally perfused with Krebs solution (mM: NaCl 118, KCl 4.7, NaHCO₃ 25, NaH₂PO₄ 1.15, CaCl₂ 2.5, MgCl₂ 1.1, glucose 5.6 and gassed with 95% O₂/5% CO₂ to maintain a pH of 7.4) in a constant flow perfusion apparatus. A differential pressure transducer located upstream of the vessel detected changes in back pressure. The rat tail artery 20 preparation was pre-contracted with 6.5μM phenylephrine to give a physiologically normal pressure of 100-120mm Hg. The pre-contracted vessels were then perfused with the test compound. The arteries were perfused with Krebs solution between applications of test compound to wash out the test compound.

Pressure changes in the system served to indicate artery vasoconstriction. The 25 vasoconstriction is a direct result of the removal of endogenous nitric oxide (edrf) from the endothelial cells of the rat tail artery.

RESULTS

The results of the *in vitro*, *in vitro* cell culture and *ex vivo* tests were as 30 follows:

IN VITRO TESTSEXAMPLE 1: K[Ru(hedta)Cl]2H₂O

A pressure decrease indicated binding of NO to the metal compound. This is illustrated in Figure 1.

5 The IR spectrum showed a peak at 1897cm⁻¹, indicating the presence of a Ru-NO bond.

EXAMPLE 2: [Ru(H₂edta)(acac)]

10 The IR spectrum showed a peak at 1896cm⁻¹, indicating the presence of a Ru-NO bond.

EXAMPLE 3: K[Ru(hedtra)Cl]H₂O

A pressure decrease indicated binding of NO to the metal compound. This is illustrated in Figure 1.

15 The IR spectrum showed a peak at 1889cm⁻¹, indicating the presence of a Ru-NO bond.

EXAMPLE 4: K[Ru(dipic)₂]H₂O

20 A pressure decrease indicated binding of NO to the metal compound. This is illustrated in Figure 1.

The IR spectrum showed a peak at 1915cm⁻¹, indicating the presence of a Ru-NO bond.

EXAMPLE 5: (H₂pic)[RuCl₂(pic)₂](Hpic)H₂O

25 The IR spectrum showed a peak at 1888cm⁻¹, indicating the presence of a Ru-NO bond.

EXAMPLE 6: K[Ru(H₂edta)Cl₂]H₂O

30 A pressure decrease indicated binding of NO to the metal compound. This is illustrated in Figure 1.

The IR spectrum showed a peak at 1896cm⁻¹, indicating the presence of a Ru-NO bond.

EXAMPLE 7: K[Ru(H₂nta)₂]½H₂O

A pressure decrease indicated binding of NO to the metal compound. This is illustrated in Figure 1.

5 The IR spectrum showed a peak at 1889cm⁻¹, indicating the presence of a Ru-NO bond.

EXAMPLE 8: K[Ru(H₂dtpa)Cl]H₂O

A pressure decrease indicated binding of NO to the metal compound. This is illustrated in Figure 1.

10 The IR spectrum showed a peak at 1905cm⁻¹, indicating the presence of a Ru-NO bond.

EXAMPLE 9: [Ru₃O(lac)₆](lac)

15 The IR spectrum showed a peak at 1884cm⁻¹, indicating the presence of a Ru-NO bond.

EXAMPLE 10: [Ru₃O(OAc)₆](OAc)

The IR spectrum showed a peak at 1877cm⁻¹, indicating the presence of a Ru-NO bond.

20 EXAMPLE 11: [Ru₂(OAc)₄]NO₃

The IR spectrum showed a peak at 1891cm⁻¹, indicating the presence of a Ru-NO bond.

25 EXAMPLE 12: [Ru(OCOEt)₄]NO₃

The IR spectrum showed a peak at 1891cm⁻¹, indicating the presence of a Ru-NO bond.

EXAMPLE 13: K₃[Ru(ox)₃]

30 The IR spectrum showed a peak at 1889cm⁻¹, indicating the presence of a Ru-NO bond.

EXAMPLE 14: [Ru₂(OAc)₄]Cl

The IR spectrum showed a peak at 1895cm⁻¹, indicating the presence of a Ru-NO bond.

5 EXAMPLE 15: [Ru(NH₃)₅Cl]Cl₂

The IR spectrum showed two peaks at 1909cm⁻¹ and 1928cm⁻¹, indicating the presence of a Ru-NO bond.

EXAMPLE 16: [Ru(en)₃]I₃

10 The IR spectrum showed a peak at 1906cm⁻¹, indicating the presence of a Ru-NO bond.

EXAMPLE 17: K[RuCl₄(phen)]H₂O

15 The IR spectrum showed a peak at 1904cm⁻¹, indicating the presence of a Ru-NO bond.

EXAMPLE 18: [Ru(cyclam)Cl₂]Cl

The IR spectrum showed a peak at 1895cm⁻¹, indicating the presence of a Ru-NO bond.

20

EXAMPLE 19: K[RuCl₄(bipy)]

The IR spectrum showed a peak at 1885cm⁻¹, indicating the presence of a Ru-NO bond.

25

EXAMPLE 20: [RuCl₃(dmso)₂(NH₃)]

The IR spectrum showed a peak at 1889cm⁻¹, indicating the presence of a Ru-NO bond.

EXAMPLE 21: [Ru(NH₃)₆]Cl₃

30

The IR spectrum showed a peak at 1910cm⁻¹, indicating the presence of a Ru-NO bond.

EXAMPLE 22: cis-[RuCl₂(dmso)₄]

The IR spectrum showed a peak at 1881cm⁻¹, indicating the presence of a Ru-NO bond.

5 EXAMPLE 23: cis-[RuCl₂(dmso)₃(NH₃)]

The IR spectrum showed a peak at 1893cm⁻¹, indicating the presence of a Ru-NO bond.

EXAMPLE 24: [RuCl₃(dmso)₃]

10 The IR spectrum showed a peak at 1880cm⁻¹, indicating the presence of a Ru-NO bond.

EXAMPLE 25: [Ru(mtc)₃]

15 The IR spectrum showed a peak at 1862cm⁻¹, indicating the presence of a Ru-NO bond.

EXAMPLE 26: [Ru(maltol)₃]

The IR spectrum showed a peak at 1866cm⁻¹, indicating the presence of a Ru-NO bond.

20

EXAMPLE 27: [Ru(acac)₂(MeCN)₂](CF₃SO₃)

The IR spectrum showed a peak at 1899cm⁻¹, indicating the presence of a Ru-NO bond.

25

EXAMPLE 28: K₂[RuCl₅(H₂O)]

The IR spectrum showed a peak at 1903cm⁻¹, indicating the presence of a Ru-NO bond.

EXAMPLE 29: [Os(ox)(bipy)₂]H₂O

30 The IR spectrum showed a peak at 1894cm⁻¹, indicating the presence of a Ru-NO bond.

IN VITRO CELL CULTURE TESTS

Results are shown in Table 2 and Figure 2 for the *in vitro* cell culture tests using the compounds of Examples: 1-3, 6 14, 15 and 26, as follows.

5 EXAMPLE 1: K[Ru(Hedta)Cl]2H₂O

Available nitric oxide was reduced in a dose-dependent fashion with a maximum reduction of 75% at a concentration of 100 μ M.

10 EXAMPLE 2: [Ru(H₂edta)(acac)]

Available nitric oxide was reduced by 82% at 100 μ M test compound.

15 EXAMPLE 3: K[Ru(Hedtra)Cl]H₂O

Available nitric oxide was reduced by 42% at 100 μ M.

15 EXAMPLE 6: K[Ru(H₂edta)Cl₂]H₂O

Available nitric oxide was reduced by 77% at 100 μ M test compound.

20 EXAMPLE 14: [Ru₂(OAc)₄]Cl

Available nitric oxide was reduced by 47% at 100 μ M.

20

EXAMPLE 15: [Ru(NH₃)₅Cl]Cl₂

Available nitric oxide was reduced by 86% at 100 μ M test compound.

25

EXAMPLE 26: [Ru(maltol)₃]

Available nitric oxide was reduced by 71% at 100 μ M.

Table 2

% Decrease of Available
Nitric Oxide

Example 1	25 μ M	12
	50 μ M	23
	100 μ M	75
Example 2	100 μ M	82
Example 3	100 μ M	42
Example 6	100 μ M	77
Example 14	100 μ M	47
Example 15	100 μ M	86
Example 26	100 μ M	71

EX VIVO TESTS

Results are shown in Table 3 for the *ex vivo* tests using the compounds of Examples: 2, 3, 14, 15 and 26, as follows.

5

EXAMPLE 2

Application of test compound resulted in a dose-dependent vasoconstriction at 10 μ M and 100 μ M. This effect was reversible by washout with Krebs solution.

10

EXAMPLE 14

Application of test compound resulted in a dose-dependent vasoconstriction at 10 μ M and 100 μ M. This effect was reversible by washout with Krebs solution.

EXAMPLE 15

15

Application of test compound resulted in a dose-dependent vasoconstriction at 10 μ M and 100 μ M. This effect was reversible by washout with Krebs solution.

EXAMPLE 26

20

Application of test compound resulted in a dose-dependent vasoconstriction at 10 μ M and 100 μ M and 1000 μ M. This effect was reversible by washout with Krebs solution.

Table 3

	% Vasoconstriction	
Example 2	10 μ M	20
	100 μ M	69
Example 3	10 μ M	17
	100 μ M	59
Example 14	10 μ M	11
	100 μ M	40
Example 15	10 μ M	77
	100 μ M	86
Example 26	10 μ M	10
	100 μ M	18
	1000 μ M	25

Experimental

EXAMPLE 33

AMD7040: Synthesis of the Ru(III) complex of N,N'-[2,6-pyridylbis(methylene)]bis-iminodiacetic acid (pbbida)

N,N'-[2,6-pyridylbis(methylene)]bis-iminodiacetic acid (Na₃Hpbbida)

An aqueous solution of sodium hydroxide (30 mL, 0.01M), 2,6-dibromomethylpyridine HBr (1.0 g, 2.9 mmol), iminodiacetic acid dimethyl ester (0.934 g, 5.8 mmol), and cetyltrimethylammonium bromide (0.21 g, 0.58 mmol) was stirred at room temperature for 3 days. A white precipitate formed which was removed by filtration and the filtrate was evaporated to give a white solid. This solid was purified by re-crystallisation from water and ethanol to give the desired compound as the tri-sodium salt (0.9 g, 71%). ¹H NMR (D₂O) δ 3.27 (s, 8H), 3.93 (s, 4H), 7.30 (d, 2H, *J*=7.5 Hz), 7.80 (t, 1H, *J*=7.8 Hz).

Preparation of [Ru(H₂pbida)Cl]·2.5H₂O.

[Dihydrogen chloro[[2,6-(pyridinyl- κ N)methyl]bis[N-(carboxymethyl)glycinato- κ N, κ O]] ruthenium (III)]

5

Na₃Hpbida (0.78 g, 1.8 mmol) was dissolved in HCl (20 mL, 1 mM) and the pH was adjusted to pH 4 with 1N HCl. K₂[RuCl₅(OH₂)] (0.67 g, 1.8 mmol) dissolved in a minimum amount of aqueous HCl (1 mM) was added to the ligand solution and the resulting mixture was heated to reflux for 1.5 hours. A yellow precipitate formed 10 throughout the course of the reaction. The reaction mixture was cooled in an ice bath and the yellow solid was collected via filtration, washed with ice cold water, ethanol and diethyl ether and then dried *in vacuo* at 70 °C for 2 hours (0.55 g, 56%). IR (CSI) ν (cm⁻¹) 1734(CO₂) 1649(CO₂) coordinated). Anal. Calcd. for C₁₅H₁₇ClN₃O₈Ru·2.5H₂O: C, 32.82; H, 4.04; N, 7.66; Cl, 6.47. Found: C, 32.82; H, 15 3.95; N 7.66; Cl, 6.47.

EXAMPLE 34

AMD7043: Synthesis of the Ru(III) complex of N,N'-bis[2-pyridyl(methylene)]ethylenediamine-N,N'-diacetic acid (H₂bped)

20 The ligand, H₂bped, was prepared according to literature procedures: See P. Caravan, S. J. Rettig, C. Orvig. *Inorg. Chem.* 1997, 36, 1306.

Preparation of [Ru(H₂bped)Cl₂]Cl.

[Dihydrogen dichloro[[N,N'-1,2-ethanediyl]bis[(2-pyridinyl- κ N)methylglycinato- κ N] 25 ruthenium (III) chloride]

H₂bped·2HCl (1.0 g, 2.5 mmol) was dissolved in HCl (25 mL, 1 mM) and the pH was adjusted to pH 4 with 1N NaOH. A solution of K₂[RuCl₅(OH₂)] in HCl (minimum volume, 1 mM) was added to the ligand solution and the reaction mixture 30 was heated to reflux for 1.5 hours. The dark green solution was reduced to approximately one half the original volume and on slow evaporation a yellow-orange solid precipitated from the reaction mixture. This was collected by filtration and re-

crystallised from H₂O/EtOH to yield an orange micro-crystalline solid (0.37 g, 26%). IR (CSI) ν (cm⁻¹) 1726 (CO₂). Anal. Calcd. for C₁₈H₂₂Cl₃N₄O₄Ru: C, 38.21; H, 3.92; N, 9.90; Cl, 18.80. Found: C, 38.21; H, 3.96; N 9.90; Cl, 18.79.

5 EXAMPLE 35

AMD7056: Synthesis of the Ru(III) complex of N-[2-(2-pyridylcarboxamido)ethyl]iminodiacetic (pceida).

10 To a stirred solution of N-BOCethylenediamine (0.462 g) in dioxane (10 mL) was added picolinic acid hydroxysuccinimyl ester (0.635 g) and the mixture was allowed to stir overnight. The reaction mixture was filtered and the filtrate was diluted with dichloromethane and washed with saturated aqueous sodium carbonate and then brine. The organic layer was dried (Na₂SO₄) and then evaporated to give a white solid (0.691 g, 90%). This was used without further purification.

15 The solid from above (0.691 g) was dissolved in pre-cooled (0 °C) trifluoroacetic acid (5 mL). The mixture was stirred for 2 hours at 0 °C and then room temperature for 15 minutes. The mixture was evaporated to dryness to give the pyridyl amine intermediate (~quantitative). The residue was dissolved in DMF (20 mL) with stirring and K₂CO₃ (1.8 g, 5.0 equiv.) followed by *t*-butyl bromoacetate (0.84 mL, 2.1 equiv.) were added and the reaction mixture was allowed to stir at room temperature for six days. The reaction mixture was diluted with water and extracted with ethyl acetate. The combined organic phases were then washed with brine and water, dried (MgSO₄) and evaporated to give the desired bis-*t*-butyl ester (1.02 g, 100%) as a light yellow oil. ¹H NMR (CDCl₃) δ 1.42 (s, 9H), 1.45 (s, 9H), 3.00 (t, 2H, *J*=6.1 Hz), 3.48 (s, 2H), 3.50-3.60 (m, 2H), 7.40 (m, 2H), 7.82 (dt, 1H, *J*=7.8, 1.6 Hz), 8.19 (d, 1H, *J*=7.8 Hz), 8.59 (d, 1H, *J*=4.6 Hz), 8.70 (br. m, 1H).

N-[2-(2-pyridylcarboxamido)ethyl]iminodiacetic-TFA salt (H₂pceida-TFA).

30 The di-*t*-butyl ester (1.02 g) from above was dissolved in dichloromethane (1 mL) and cooled to 0 °C. Pre-cooled trifluoroacetic acid was added (7 mL) and the solution was allowed to stir overnight at room temperature. The reaction mixture was then evaporated and the residue was dissolved in water (10 mL) and lyophilised to give the desired ligand (pceida) as a light yellow solid (0.71 g, 69%). ¹H NMR (D₂O)

δ 3.53 (t, 2H, *J*=5.7 Hz), 3.85 (t, 2H, *J*=5.7 Hz), 3.90 (s, 2H), 7.65 (m, 1H), 7.95-8.10 (m, 2H), 8.65 (s, 1H, *J*=4.8 Hz). Anal. Calcd. for C₁₂H₁₅N₃O₅·TFA·H₂O: C, 40.69; H, 4.39; N, 10.17. Found: C, 40.84; H, 4.32; N, 9.99.

5 Preparation of [Ru(pceida)(OH₂)Cl·1.5H₂O.

[Aquachloro[[*N*-2-[(2-pyridinyl-κ*N*)oxo-methyl]aminoethyl][((2-carboxy-κ*O*)methyl)glycinato-κ*N*,κ*O*]] ruthenium (III)]

H₂pceida·TFA (0.4 g, 1 mmol) and K₂[RuCl₅(OH₂)] (0.38 g, 1 mmol) were dissolved in de-ionised water (10 mL) and the pH adjusted to pH 5 with 1N NaOH. KCl (0.075 g, 1 mmol) was added to the reaction mixture and the solution was heated to reflux for 3 hours. The solution was cooled to room temperature and subsequently in an ice bath. Upon cooling a dark red-orange precipitate formed which was collected by filtration, washed with ice cold water and dried *in vacuo* at 40 °C overnight. Yield: 0.13 g, 29%. IR (CSI) ν (cm⁻¹) 1649(CO₂). Anal. Calcd. for C₁₂H₁₅ClN₃O₆Ru·1.5H₂O: C, 31.28; H, 3.94; N, 9.12; Cl, 7.69. Found: C, 31.43; H, 3.92; N, 9.05; Cl, 7.80.

EXAMPLE 36

20 **AMD7046:** Synthesis of the Ru(III) complex of N-[2-pyridyl(methylene)]ethylenediamine-N,N',N'-triacetic acid (pedta).

To a solution of 2-pyridinecarboxaldehyde (3.2 g, 0.03 mol) in benzene (50 mL) was added N-BOC ethylenediamine (5.26 g, 1.1 equiv.) and the mixture was heated to reflux with stirring in a Dean-Stark apparatus for 1.5 hours. The reaction mixture was evaporated to dryness, dissolved in methanol (50 mL) and 5% palladium on carbon was added (0.5 g). The mixture was hydrogenated at 50 psi on a Parr apparatus overnight. The mixture was filtered through celite, and the filtrate was evaporated to give the pyridine intermediate (~ quantitative). ¹H NMR (CDCl₃) δ 1.40 (s, 9H), 2.75-2.85 (m, 2H), 3.20-3.35 (m, 2H), 3.90 (s, 2H), 5.30 (br. S, 1H), 7.10-7.20 (m, 1H), 7.30-7.36 (m, 1H), 7.60-7.70 (m, 1H), 8.50-8.60 (m, 1H).

To a stirred solution of the pyridine intermediate from above (5.08 g) in dichloromethane (30 mL) was added trifluoroacetic acid (30 mL) and the mixture was allowed to continue stirring overnight at room temperature. The mixture was evaporated to give a dark oil. ^1H NMR ($\text{d}_6\text{-DMSO}/\text{D}_2\text{O}$) δ 3.10-3.20 (m, 2H), 3.20-5 3.30 (m, 2H), 4.48 (s, 2H), 7.40-7.45 (m, 2H), 7.80-7.90 (m, 1H), 8.60 (m, 1H). This intermediate was used without further purification in the next step.

N-[2-pyridyl(methylene)]ethylenediamine-N,N',N'-triacetic acid tri-*t*-butyl ester.

To a solution of the oil from above in DMF (~80 mL) was added K_2CO_3 (27.9 g, 10.0 equiv.) followed by *t*-butylbromoacetate (8.95 mL, 3.0 equiv.) and the mixture 10 was allowed to stir at room temperature for 48 hours. The reaction mixture was filtered through celite and the filtrate was evaporated to give a dark oil. Purification by column chromatography on silica gel (5% MeOH/ CH_2Cl_2) gave the tri-*t*-butyl ester (4.14 g, 42% for two steps) as a light yellow oil. ^1H NMR (CDCl_3) δ 1.35-1.50 (m, 27H), 2.83-2.86 (m, 4H), 3.37 (s, 2H), 3.43 (s, 4H), 3.95 (s, 2H), 7.10-7.20 (m, 15 1H), 7.52 (d, 1H, $J=7.5$ Hz), 7.64 (dt, 1H, $J=7.5, 1.7$ Hz), 8.51 (d, 1H, $J=4.7$ Hz).

N-[2-pyridyl(methylene)]ethylenediamine-N,N',N'-triacetic acid-TFA salt (pedta)

The tri-*t*-butyl ester from above (4.14 g) was dissolved in CH_2Cl_2 (20 mL) with stirring and trifluoroacetic acid (30 mL) was added in one portion. The mixture was allowed to stir at room temperature overnight and was then evaporated. The 20 residue was dissolved in water (~40 mL) and charcoal (550 mg) was added. The mixture was heated to 70 °C and filtered through celite and the combined filtrates were then evaporated to small volume and lyophilised to give the desired ligand (pedta) as a yellow solid (3.24 g, 73%). ^1H NMR (D_2O) δ 3.00-3.15 (m, 2H), 3.20-3.30 (m, 2H), 3.59 (s, 4H), 4.04 (s, 2H), 4.51 (s, 2H), 7.50 (m, 1H), 7.61 (d, 1H, $J=7.7$ 25 Hz), 7.98 (dt, 1H, $J=7.7, 1.6$ Hz), 8.63 (d, 1H, $J=5.0$ Hz). Anal. Calcd. for $\text{C}_{14}\text{H}_{19}\text{N}_3\text{O}_6 \cdot 1.8\text{TFA}$: C, 39.83; H, 3.95; N, 7.92. Found: C, 38.85; H, 4.19; N, 8.06.

Preparation of [Ru(Hpedta)Cl]·0.5H₂O

[Hydrogen chloro[N-[bis((2-(carboxy- κ O)methyl)imino- κ N)ethyl]-(2-pyridinyl-30 κ N)methylglycinato- κ N] ruthenium (III)].

5 $\text{H}_3\text{pedta}\cdot\text{TFA}$ (0.75 g, 1.3 mmol) was dissolved in HCl (1.5 mL, 1 mM). A solution of $\text{K}_2[\text{RuCl}_5(\text{OH}_2)]$ (0.5 g, 1.3 mmol) in HCl (2 mL, 1 mM) was added to the ligand solution. The reaction mixture was heated to reflux for 2 hours and subsequently cooled to room temperature. An orange solid precipitated from the solution, which was collected by filtration, washed with ethanol and diethyl ether, and dried *in vacuo* at 40 °C overnight (0.26 g, 43%). IR (CSI) $\nu(\text{cm}^{-1})$ 1730(CO_2H); 1688, 1618 (CO_2) coordinated). Anal. Calcd. for $\text{C}_{14}\text{H}_{17}\text{ClN}_3\text{O}_6\text{Ru}\cdot 0.5\text{H}_2\text{O}$: C 35.87; H 3.87; N 8.96; Cl 7.56. Found: C, 35.86; H, 3.79; N, 8.98; Cl, 7.58.

10 EXAMPLE 37

AMD7087: Synthesis of the Ru(III) complex of phenylenediamine-N,N,N',N'-tetraacetic acid (H_4pdta).

15 Phenylenediamine-N,N,N',N'-tetraacetic acid tetramethyl ester

15 1,2-phenylenediamine (1.4 g, 1.3 mmol), methyl bromoacetate (12.3 mL, 13 mmol) and K_2CO_3 (17.9 g, 13 mmol) were heated at 85 °C in DMF (130 mL) under an inert atmosphere for 3 days. The DMF was removed under reduced pressure and the residue was dissolved in CH_2Cl_2 . The solution was washed with an aqueous solution of saturated NH_4Cl and then H_2O . The organic layer was dried (MgSO_4) and evaporated to give a brown oil. This brown oil was triturated with MeOH to yield a white solid, which was removed by filtration and washed with methanol (0.3 g, 5.8%). ^1H NMR (CDCl_3) δ 3.65 (s, 12H), 4.30 (s, 8H), 6.92-7.04 (m, 4H). FAB (+ve) m/z 397 [$\text{M}+\text{H}]^+$. Anal. Calcd. for $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_8$: C, 54.54; H, 6.10; N, 7.07. Found: C, 54.57; H, 6.21; N, 7.19.

25 Phenylenediamine-N,N,N',N'-tetraacetic acid (H_4pdta)

30 The tetramethyl ester (0.1 g, 0.25mmol) was suspended in $\text{MeOH}/\text{H}_2\text{O}$ (25 mL, 3/1) and cooled to 0 °C. Lithium hydroxide monohydrate (0.106 g, 2.5 mmol) was added to the suspension and the reaction mixture was stirred in the dark overnight (during which time it was allowed to warm to room temperature). The clear solution was acidified with HCl (2N) and the solvent was removed under reduced pressure to leave a white solid. ^1H NMR ($\text{D}_2\text{O}/\text{K}_2\text{CO}_3$) δ 4.27 (s, 8H), 7.25-7.4 (m, 4H). The white solid was used without further purification to prepare the ruthenium complex.

Preparation of [Ru(Hpdta)(OH₂)·3H₂O

[Hydrogen aqua[N-bis((2-carboxy- κ O)methyl)imino- κ N]-1,2-phenediyl(2-(carboxy- κ O)methyl)glycinato- κ N] ruthenium (III)]

5 H₄pdta·xLiCl (0.25 mmol) was heated in HCl (3 mL, 1 mM) until completely dissolved. K₂[RuCl₅(OH₂)] (0.095 g, 0.25 mmol) was added to the ligand solution and the reaction mixture was heated to reflux for 1.5 hours. The solution was allowed to cool to room temperature and the yellow-green precipitate which formed was collected by filtration and washed with H₂O, EtOH and Et₂O (15 mg, 12%). Anal.
10 Calcd. for C₁₄H₁₅N₂O₉Ru·3H₂O: C, 32.95; H, 4.15; N, 5.49. Found: C, 32.65; H, 3.91; N, 5.58.

EXAMPLE 38.

15 **AMD7459:** Ruthenium (III) complex of N'-benzyldiethylenetriamine-N,N,N",N"-tetraacetic acid (bdtta).

N-(hydroxyethyl)iminodiacetic acid di-t-butyl ester

20 Ethanolamine (1.84 g, 0.03 mol) was dissolved in dry THF (300 mL) and triethylamine (12.3 g, 0.12 mol) was added. To this stirring solution *t*-butylbromoacetate (23.5 g, 0.12 mol) was added and the reaction mixture was stirred for 16 hours. The solvent was removed *in vacuo* and the residue partitioned between Et₂O (100 mL) and H₂O (100 mL). The aqueous layer was extracted with Et₂O (3 x 100 mL), and the combined organic portions were dried over MgSO₄. The suspension was filtered and the solvent was removed *in vacuo* to afford the product (7.75 g, 89%)
25 as a white solid. ¹H NMR (CDCl₃) δ 1.46 (6, 18H), 2.89 (t, 2H, *J* = 6.0 Hz), 3.45 (s, 4H), 3.53 (t, 2H, *J* = 6.0 Hz), 3.75 (bs, 1H). ¹³C NMR (CDCl₃) δ 28.15, 56.68, 57.11, 59.37, 81.48, 171.48. ES-MS *m/z* 290 [M+H]⁺.

N-[Methanesulfonyl]ethyl]iminodiacetic acid di-t-butyl ester

30 N-(hydroxyethyl)iminodiacetic acid di-*t*-butyl ester (7.50 g, 0.03 mol) was dissolved in dry CH₂Cl₂ (250 mL) and triethylamine (14.8 g, 0.15 mol) was added. The solution was cooled in an ice bath and methanesulfonylchloride (3.55 g, 0.03 mol) was added dropwise with stirring. The reaction mixture was slowly warmed to

room temperature and stirred for a further 16 hours. The reaction was then quenched with *saturated* NaHCO₃ (150 mL) and the aqueous layer was extracted with CH₂Cl₂ (2 x 150 mL). The combined organic extracts were dried (MgSO₄), filtered, and the solvent was removed *in vacuo* to afford the product (9.5 g, 99%) as an oil. ¹H NMR (CDCl₃) δ 1.46 (s, 18H), 3.08 (m, 5H), 3.48 (s, 4H), 4.34 (t, 2H, *J* = 6.0 Hz).

N'-benzyldiethylenetriamine-N,N,N",N"-tetraAcetic acid tetra-*t*-butyl ester

General Procedure A:

N-[(Methanesulfonyl)ethyl]iminodiacetic acid di-*t*-butyl ester (4.86 g, 13 mmol) was dissolved in dry acetonitrile (50 mL) and benzylamine (0.47 g, 4.4 mmol) was added with stirring. K₂CO₃ (2.4 g, 0.45 mol) was added and the suspension was stirred for 16 hours at 45°C. The solvent was removed *in vacuo* and the residue partitioned between CHCl₃ (100 mL) and *saturated* NaHCO₃ (100 mL). The aqueous portion was extracted with CHCl₃ (3 x 75 mL), and the combined organic extracts were dried (MgSO₄), filtered and the solvent was removed *in vacuo* to afford the crude product as a brown oil. The product was purified by column chromatography on silica gel (2% MeOH, 1% NEt₃, CH₂Cl₂) to afford the product (1.35 g, 37%) as a colorless oil. ¹H NMR (CDCl₃) δ 1.43 (s, 36H), 2.59 (t, 4H, *J*=6.0 Hz), 2.82 (t, 4H, *J*=6.0 Hz), 3.40 (s, 8H), 7.24 (m, 5H). ¹³C NMR (CDCl₃) δ 28.19, 52.08, 52.86, 56.16, 59.17, 80.75, 126.78, 128.14, 128.85, 139.62, 170.74. ES-MS *m/z* 650 [M+H]⁺.

N'-benzyldiethylenetriamine-N,N,N",N"-tetraacetic acid-*t*TFA (bdta)

General Procedure B:

N'-Benzylideneetriamine-N,N,N",N"-tetracetic acid tetra-*t*-butyl ester (1.0 g, 1.5 mmol) was dissolved in trifluoroacetic acid (14.8 g, 130 mmol) and the solution was left stirring for 16 hours. The solvent was removed *in vacuo* and the residue was lyophilized to afford the product (1.19 g, 100%) as a white solid: ¹H NMR (D₂O) δ 3.38 (t, 4H, *J* = 6.0 Hz), 3.48 (t, 4H, *J* = 6.0 Hz), 3.73 (s, 8H), 4.43 (s, 4H), 7.51 (bs, 5H). ¹³C NMR (D₂O) δ 50.22, 50.85, 55.43, 59.04, 129.50, 130.05, 130.90, 131.39, 172.64.

Preparation of [Ru(H₂bdta)Cl]·4.5H₂O
 [Dihydrogen chloro[[N,N'-[[{(phenylmethyl)imino-κN]-2,1-ethanediyl}bis[N-(carboxymethyl)glycinato-κN,κO]] ruthenium (III)]

5 **General Procedure C:**

N'-Benzyldiethylenetriamine-N,N,N'',N'''-tetraacetic acid (bdta) (0.256 g, 0.33 mmol) was dissolved in 1mM HCl (5 mL). K₂[RuCl₅(H₂O)] (0.124 g, 0.33 mmol) was added and the reaction mixture was heated to 100 °C for 1.5 hours. The solution was then cooled and a yellow/green powder was collected. The powder was washed with 10 the mother liquor, H₂O (2 x 10 mL), and Et₂O (3 x 5 mL) to afford the product (0.078 g, 24%) as a light yellow powder. Anal. Calcd. for C₁₉H₂₅N₃O₈RuCl·4.5 H₂O: C, 35.60; H, 5.35; N, 6.56; Cl, 5.53. Found: C, 35.62; H, 5.22; N, 6.47; Cl, 5.33. IR (CsI) ν (cm⁻¹) 1736 (CO₂H); 1657 (CO₂-).

15 **EXAMPLE 39**

AMD7460: Ruthenium (III) complex of N'-[2-pyridyl(methylene)]diethylenetriamine-N,N,N'',N'''-tetraacetic acid (pdtta).

Using General Procedure A:

20 N-[(Methanesulfonyl)ethyl]iminodiacetic acid di-*t*-butyl ester (3.14 g, 8.5 mmol) was reacted with aminomethylpyridine (0.23 g, 2.0 mmol) and the crude reaction mixture was purified by silica gel chromatography (5% MeOH/ CH₂Cl₂). The product fractions were combined and partitioned between Et₂O (30 mL) and NaOH (15 mL 0.1M). The aqueous layer was extracted with Et₂O (3 x 20 mL), and the 25 combined organic extracts were dried (MgSO₄), filtered and the solvent removed *in vacuo* to afford the product (0.38 g, 30%) as an oil. ¹H NMR (CDCl₃) δ 1.40 (s, 36H), 2.64 (t, 4H, *J* = 6.0 Hz), 2.81 (t, 4H, *J* = 6.0 Hz), 3.38 (s, 8H), 3.76 (s, 2H), 7.08 (t, 1H, *J* = 6.0 Hz), 7.45 (d, 1H, *J* = 6.0 Hz), 7.57 (t, 1H, *J* = 6.0 Hz), 8.46 (d, 1H, 6.0 Hz). ¹³C NMR (CDCl₃) δ 28.28, 52.17, 53.31, 56.14, 60.94, 121.74, 122.90, 136.32, 30 148.86, 160.25, 170.69. ES-MS *m/z* 651 [M+H]⁺.

N'-[2-pyridyl(methylene)]diethylenetriamine-N,N,N'',N'''-tetraacetic acid·xHCl (pdtta)

Using General Procedure B:

The oil from above (0.381 g, 0.59 mmol) was treated with TFA (7.4 g, 65 mmol). The crude material was purified on Dowex cation exchange resin (H⁺ form,

50W-200 mesh) to afford the product (0.225 g, 44%) as a white solid. ^1H NMR (D_2O) δ 3.09 (t, 4H, J = 6.6 Hz), 3.61 (t, 4H, J = 6.6 Hz), 3.86 (s, 2H), 4.20 (s, 8H), 7.97 (t, 1H, J = 6.9 Hz), 8.03 (d, 1H, J = 8.1 Hz), 8.53, (t, 1H, J = 8.1 Hz), 8.70 (d, 1H, J = 6.9 Hz).

5

Preparation of $[\text{Ru}(\text{H},\text{pdta})\text{Cl}] \cdot 2\text{H}_2\text{O}$

[Dihydrogen chloro[[N,N'-[[((2-pyridinylmethyl)imino- κN)di-2,1-ethanediyl]bis[N-(carboxymethyl)glycinato- $\kappa\text{N},\kappa\text{O}]]] ruthenium (III)].$

10 **Using General Procedure C:**

Pdta (0.225 g, 0.27 mmol) was reacted with $\text{K}_2[\text{RuCl}_5(\text{H}_2\text{O})]$ (0.095 g, 0.25 mmol). Anal. Calcd. for $\text{C}_{18}\text{H}_{24}\text{O}_8\text{N}_4\text{RuCl}_2\text{H}_2\text{O} \cdot 1.0 \text{ KCl} \cdot 0.75\text{HCl}$: C, 30.94; H, 4.15; N, 8.02; Cl, 13.95. Found: C, 30.85; H, 4.30; N, 8.01; Cl, 13.54. IR (CsI) $\nu(\text{cm}^{-1})$ 1740 (CO_2H); 1657 (CO_2); 311(Ru-Cl).

15

EXAMPLE 40.

AMD8676: Ruthenium (III) complex of N'-butyldiethylenetriamine-N,N,N",N"-tetraacetic acid (budta).

20 N' -butyldiethylenetriamine-N,N,N",N"-tetraacetic acid tetra-*t*-butyl ester

Using General Procedure A:

25 N-[(Methanesulfonyl)ethyl]iminodiacetic acid di-*t*-butyl ester (2.97 g, 8.1 mmol) was reacted with butylamine (0.20 g, 3.0 mmol) and the crude reaction mixture was purified by silica gel chromatography (5% MeOH/CH₂Cl₂) to afford the product (0.439 g, 27%) as a colorless oil. ^1H NMR (CDCl₃) δ 0.81 (t, 3H, J = 6.0 Hz), 1.20 (m, 4H), 1.38 (s, 36H), 2.38 (t, 2H, J = 7.5 Hz), 2.54 (t, 4H, J = 6.0 Hz), 2.71 (t, 4H, J = 6.0 Hz), 3.37 (s, 8H). ^{13}C NMR (CDCl₃) δ 14.36, 20.91, 28.49, 52.43, 53.61, 53.76, 54.92, 56.83, 81.31, 171.02. ES-MS m/z 616 [M+H]⁺.

N' -butyldiethylenetriamine-N,N,N",N"-tetraacetic acid-*x*TFA (budta).

30 **Using General Procedure B:**

The oil from above (0.425 g, 0.69 mmol) was treated with TFA (14.8 g, 100 mmol) to afford the product (0.442 g, 87%) as an off-white solid. ^1H NMR (D₂O) δ 0.672 (bs, 3H), 0.81 (bs, 2H), 1.15 (bs, 2H), 2.71 (bs, 2H), 3.12 (bs, 8H), 3.56 (s, 8H). ES-MS m/z 448 [M+H]⁺.

Preparation of [Ru(H₂budta)Cl]·4H₂O
[Dihydrogen [[N,N'-[(butylimino-κN)di-2,1-ethanediyl]bis[N-(carboxymethyl)glycinato-κN,κO]]]chloro ruthenium (III)].

5 **Using General Procedure C:**

Budta (0.243 g, 0.33mmol) was reacted with K₂[RuCl₅(H₂O)] (0.123 g, 0.33 mmol) to afford the product (0.083 g, 42%): Anal. Calcd. for C₁₆H₂₇N₃O₈RuCl·4H₂O: C, 32.14; H, 5.90; N, 7.03; Cl, 5.93. Found: C, 32.23; H, 5.60; N, 6.94; Cl, 6.02. IR (CsI) ν (cm⁻¹) 1736 (CO₂H); 1657 (CO₂); 411(Ru-Cl).

10

EXAMPLE 41

AMD8679: Ruthenium (III) complex of N'-ethyldiethylenetriamine-N,N,N",N"-tetraacetic acid (edtta).

15 N'-ethyldiethylenetriamine-N,N,N",N"-tetraacetic acid tetra-*t*-butyl ester

Using General Procedure A:

20 N-[(Methanesulfonyl)ethyl]iminodiacetic acid di-*t*-butyl ester (3.169 g, 8.6 mmol) was reacted with ethylamine (0.13 g, 2.9 mmol) to afford, after purification by column chromatography on silica gel (2% MeOH, 1%NEt₃, CH₂Cl₂), the product (0.7 g, 55%) as a colorless oil. ¹H NMR (CDCl₃) δ 1.00 (t, 3H, *J* = 6.0 Hz), 1.46 (s, 36H), 2.56 (m, 6H), 2.80 (t, 4H, *J* = 7.5 Hz), 3.45 (s, 8H). ¹³C NMR (CDCl₃) δ 28.17, 48.16, 52.10, 52.61, 53.44, 56.30, 80.77, 170.70. ES-MS *m/z* 588 [M+H]⁺.

N'-ethyldiethylenetriamine-N,N,N",N"-tetraacetic acid·xTFA (edtta)

Using General Procedure B:

25 The oil from above (0.591 g, 1.01 mmol) was treated with TFA (14.8 g, 100 mmol) to afford the product (0.699 g, 98%) as an off-white solid. ¹H NMR (D₂O) δ 0.92 (t, 3H, *J* = 6.9 Hz), 2.96 (d, 2H, *J* = 6.9 Hz), 3.24 (s, 8H), 3.69 (s, 8H). ¹³C NMR (D₂O) δ 29.59, 49.19, 49.35, 49.95, 55.39, 170.68. ES-MS *m/z* 420 [M+H]⁺.

30 Preparation of [Ru(H₂edta)Cl]·H₂O

[Dihydrogen chloro[[N,N'-[(ethylimino-κN)di-2,1-ethanediyl]bis[N-(carboxymethyl)glycinato-κN,κO]]] ruthenium (III)].

Using General Procedure C:

Reaction of edtta (0.241 g, 0.34 mmol) with $K_2[RuCl_5(H_2O)]$ (0.128 g, 0.34 mmol) afforded the product (0.0373 g, 21%). Anal. Calcd. for $C_{14}H_{23}N_3O_8RuCl \cdot 1H_2O \cdot 0.1KCl$: C, 32.13; H, 4.81; N, 8.03; Cl, 7.45. Found: C, 5 32.43; H, 4.80; N, 8.02; Cl, 7.81. IR (CsI) 1719 (CO_2H); 1678, 1601(CO_2); 415(Ru-Cl).

EXAMPLE 42.

10 **AMD8684:** Ruthenium (III) complex of N'-phenyldiethylenetriamine-N,N,N",N"-tetraacetic acid (phdtta)

*N'-phenyldiethylenetriamine-N,N,N",N"-tetraacetic acid tetra-t-butyl ester***Using General Procedure A:**

15 Reaction of N-[(methanesulfonyl)ethyl]iminodiacetic acid di-t-butyl ester (3.358 g, 9.1 mmol) with aniline (0.28 g, 3.0 mmol) afforded, after purification by column chromatography on silica gel (4:1 Hexane: ethylacetate), the product (0.402 g, 21%) as a colorless oil. 1H NMR ($CDCl_3$) δ 1.46 (s, 36H), 2.86 (t, 4H, J = 7.5 Hz), 3.47 (bs, 12H), 6.62 (t, 1H, J = 7.5 Hz), 6.70 (d, 1H, J = 9.0), 7.17 (t, 1H, J = 9.0 Hz).

*N'-phenyldiethylenetriamine-N,N,N",N"-tetraacetic acid-xTFA (phdtta)*20 **Using General Procedure B:**

The oil from above (0.281 g, 0.44 mmol) was reacted with TFA (7.4 g, 50 mmol) affording the product (0.272 g, 81%) as an off-white solid. 1H NMR (D_2O) δ 3.21 (m, 4H), 3.67 (t, 4H, J = 6.6 Hz), 3.93 (s, 8H), 7.07 (t, 1H, J = 7.8 Hz), 7.08 (t, 1H, J = 7.8 Hz), 7.29 (t, 1H, J = 7.5 Hz).

25 **Preparation of $[Ru(H_2phdtta)Cl] \cdot 1.25H_2O$**
[Dihydrogen chloro/[N,N'-[(phenylimino- κ N)di-2,1-ethanediyl]bis[N-(carboxymethyl)glycinato- κ N, κ O]] ruthenium (III)).

Using General Procedure C:

30 Reaction of phdtta (0.146 g, 0.18 mmol) with $K_2[RuCl_5(H_2O)]$ (0.085 g, 0.23 mmol) afforded the product (0.0194 g, 16%). Anal. Calcd. for $C_{18}H_{23}N_3O_8RuCl \cdot 1.25H_2O \cdot 0.8KCl \cdot 0.8EtOH$: C, 35.40; H, 4.59; N, 6.32; Cl, 9.60. Found: C, 35.73; H, 4.47; N, 5.93; Cl, 9.79. IR (CsI) $\nu(cm^{-1})$ 1730 (CO_2H); 1611 (CO_2); 403(Ru-Cl)

EXAMPLE 43.

AMD7436: Ruthenium (III) complex of N,N''-bis-[2-pyridyl(methylene)]diethylenetriamine-N,N',N''-triacetic acid (bpdtta).

5 N,N',N''-Titosyldiethylenetriamine

To a solution of tosyl chloride (21.18 g, 0.11 mol) in Et₂O (120 mL) was added diethylenetriamine (3.82 g, 0.04 mol). To this solution, an aqueous solution of NaOH (4.44 g, 0.11 mol) in de-ionized water (40 mL) was added dropwise. The resulting suspension was stirred for two hours and the white solid was collected by 10 filtration and washed with H₂O and then Et₂O. The crude product was recrystallized from hot MeOH to afford the product (12.63 g, 60.4%) as a white crystalline solid. ¹H NMR (CDCl₃) δ 2.43 (bs, 9H), 3.06 (dt, 4H, *J* = 5.5, 6.9 Hz), 3.17 (t, 4H, *J* = 6.9 Hz), 6.55 (t, 2H, *J* = 5.5 Hz), 7.40 (m, 6H), 7.63 (d, 2H, *J* = 8.1 Hz), 7.74 (d, 4H, *J* = 8.1 Hz). ¹³C NMR (acetone-d₆) δ 21.79, 43.51, 50.60, 128.26, 128.50, 130.92, 131.07, 15 137.27, 139.25, 144.38, 144.95. ES-MS *m/z* 588 [M+H]⁺.

2-[Methanesulfonyl(methyl)]pyridine

2-Pyridinemethanol (3.39 g, 31.1 mmol) and triethylamine (9.44 g, 93 mmol) were dissolved in dry CH₂Cl₂ (250 mL) and the resulting solution was cooled to 0°C in an ice bath. Methanesulfonylchloride (4.27 g, 37.3 mmol) was added dropwise and 20 the reaction mixture was stirred for 50 minutes. The reaction was then quenched with *saturated* NaHCO₃ (115 mL). The aqueous layer was washed with CH₂Cl₂ (2 x 50 mL), and the organic portions were combined and dried over MgSO₄. After filtering, the solvent was removed *in vacuo* to afford the product (6.5 g, 100%) as a red oil. ¹H NMR (CDCl₃) δ 3.11 (s, 3H), 5.33 (s, 2H), 7.30 (m, 1H), 7.48 (d, 1H, *J* = 7.8 Hz), 25 7.77 (dd, 1H, *J* = 1.7, 7.7 Hz), 8.59 (m, 1H).

N,N''-bis-[2-pyridyl(methylene)]-N,N',N''-tritosyldiethylenetriamine

To a solution of N,N',N''-tritosyldiethylenetriamine (8.8 g, 15.6 mmol) in DMF (75 mL) under a nitrogen atmosphere was added NaH (60% in oil, 1.24 g, 31.1 mmol) and the mixture was stirred for 45 minutes. 2-[Methanesulfonyl(methyl)]pyridine (6.5 g, 34.7 mmol) dissolved in 10 mL CH₂Cl₂ was then added and the reaction was heated to 80°C for 20 hours. Ethanol was then added and the DMF was removed *in vacuo*. The residue was dissolved in CH₂Cl₂ and washed with brine (3 x 100 mL), saturated NH₄Cl solution (3 x 100 mL), and finally a

saturated aqueous solution of K_2CO_3 (3 x 100 mL). The organic layer was dried over Na_2SO_4 , filtered and the solvent was removed *in vacuo* to afford the crude product (9.0 g) as an off-white solid. 1H NMR δ 2.42 (bs, 12H), 3.04 (m, 4H), 3.30 (m, 4H), 4.41 (s, 4H), 7.39 (m, 10H), 7.71 (m, 8H), 8.48 (m, 2H). ES-MS m/z 748 [M+H]⁺.

5 This product was used without further purification.

N,N'' -bis-[2-pyridyl(methylene)]diethylenetriamine

The solid from above (3.79 g, 5.1 mmol) was added to 13 mL concentrated H_2SO_4 maintained at a temperature of 120°C. After 5 minutes the reaction mixture was cooled and EtOH (90 mL) was added resulting in the precipitation of a brown 10 solid. The solid was collected by filtration, dissolved in H_2O (100 mL) and heated in the presence of activated charcoal. The mixture was filtered through celite and the volume of the filtrate was reduced to approximately 20 mL and then concentrated HCl (20 mL) was added. Most of the solvent was removed *in vacuo* and cold EtOH was added to precipitate a white solid. The white solid was then dissolved in H_2O and the 15 pH was adjusted to 12 with 3M NaOH. The aqueous solution was extracted with $CHCl_3$ (3 x 50 mL), and the combined organic extracts were dried ($MgSO_4$). Evaporation of the solvent afforded the product (0.785 g, 54%) as a colorless oil. 1H NMR δ 2.43 (s, 3H), 2.80 (s, 8H), 3.92 (s, 4H), 7.14 (t, 2H, J = 6.0 Hz), 7.30 (d, 2H, J = 6.0 Hz), 7.62 (dd, 2H, J = 3.0, 6.0 Hz), 8.53 (d, 2H, J = 3.0 Hz).

20 N,N'' -bis-[2-pyridyl(methylene)]diethylenetriamine-N,N',N''-triacetic acid tri-*t*-butyl ester

The oil from above (0.737 g, 2.59 mmol) was dissolved in dry toluene (20 mL), containing *t*-butylbromoacetate (3.02 g, 15.50 mmol) and triethylamine (5.20 g, 51.0 mmol) and the reaction mixture was stirred overnight. After 16 hours the solvent 25 was removed *in vacuo* and the residue was partitioned between Et_2O (40 mL) and H_2O (40 mL). The aqueous portion was extracted with Et_2O (2 x 40 mL) and the organic portions were combined, and dried over $MgSO_4$. Removal of the solvent *in vacuo* afforded the desired product (1.00 g, 62%) as an oil. 1H NMR ($CDCl_3$) δ 1.40 (s, 9H), 1.45 (s, 18H), 2.75 (s, 8H), 3.27 (s, 2H), 3.32 (s, 4H), 3.91 (s, 4H), 7.12 (t, 30 2H, 6.0 Hz), 7.50 (d, 2H, 6.0 Hz), 7.62 (dd, 2H, J = 3.0, 6.0 Hz), 8.50 (d, 2H, J = 3 Hz). ES-MS m/z 628 [M+H]⁺.

N,N''-bis[2-pyridyl(methylene)]diethylenetriamine-N,N',N''-triaceticacid·5TFA
(bpdtta)

The oil from above (1.45 g, 2.30 mmol) was dissolved in trifluoroacetic acid (8.8 g, 78 mmol) and left stirring for 16 hours. The solvent was removed *in vacuo* and 5 the resulting oil was lyophilized. An off-white powder was obtained (2.05 g, 86%). ¹H NMR (acetone-d₆) δ 3.50 (t, 4H, *J* = 5.7 Hz), 3.69 (s, 4H), 3.79 (t, 4H, *J* = 5.7 Hz), 4.41 (s, 2H), 4.53 (s, 4H), 8.04 (t, 2H, *J* = 6.4 Hz), 8.13 (d, 2H, *J* = 6.4 Hz), 8.59 (t, 2H, *J* = 7.9 Hz), 8.92 (d, 2H, *J*=7.9 Hz). ES-MS *m/z* 461 [M+H]⁺. Anal. Calcd. for 10 C₂₂H₂₉N₅O₆·5TFA·2.5H₂O: C, 35.77; H, 3.66; N, 6.34. Found: C, 35.54; H, 3.30; N, 6.18.

Preparation of [Ru(H₂bpdtta)][CF₃CO₂]₂·3H₂O

[*N*-[2-[[*[(*carboxy-κ*O*)methyl][(2-pyridinyl-κ*N*)methyl]amino-κ*N*]ethyl-*N*-[2-*[(*carboxymethyl)[(2-pyridinyl-κ*N*)methyl]amino-κ*N*]ethyl]glycinato-κ*N*] ruthenium 15 (III) bis(trifluoroacetate).

Bpdta (0.37g, 0.35 mmol) was dissolved in 1mM HCl (3 mL) and the pH was adjusted to 4 with 1M NaOH. K₂[RuCl₅(H₂O)] (0.13 g, 0.35 mmol), dissolved in a minimum amount of 1mM HCl was added to the reaction mixture. The solution was 20 refluxed for 1.5 hours and then cooled in an ice bath. The residue was passed through Sephadex gel (G-10) and a yellow band was collected and lyophilized (0.11 g, 37%). Anal. Calcd. for C₂₂H₂₈N₅O₆Ru·2TFA·3H₂O: C, 37.19; H, 4.08; N, 8.34. Found: C, 37.16; H, 4.00; N, 8.62. IR (CsI) *v*(cm⁻¹) 1688 (Co₂H); 1630(CO₂).

25 EXAMPLE 44.

AMD8701: Ruthenium (III) complex of 1,3-Propanediamine-N,N,N',N'-tetraacetic acid (pdta).

1,3-Propanediamine-N,N,N',N'-tetraacetic acid tetra-*t*-butyl ester
30 1,3-propanediamine (0.528 g, 7.1 mmol) was dissolved in a mixture of dry THF (50 mL), triethylamine (5.76 g, 57 mmol) and *t*-butylbromoacetate (8.34 g, 43 mmol) and the reaction mixture was stirred under a nitrogen atmosphere for 24 hours.

The solvent was then removed *in vacuo* and the residue partitioned between CHCl_3 (40 mL) and *saturated* NaHCO_3 (30 mL). The aqueous portion was extracted with CHCl_3 (3 x 30 mL), and the combined organic portions were dried over MgSO_4 , filtered, and the solvent removed *in vacuo*. The crude material was purified by silica 5 gel chromatography (4:1 Hexanes: EtOAc) afforded the product (3.00 g, 80%) as a colorless oil. ^1H NMR (CDCl_3) δ 1.45 (s, 36H), 1.63-1.68 (m, 2H), 2.73 (dd, 4H, J = 6.0, 9.0 Hz), 3.42 (s, 8H). ^{13}C NMR δ 28.18, 51.93, 55.76, 80.80, 170.74. ES-MS m/z 531 $[\text{M}+\text{H}]^+$.

1,3-Propanediamine-N,N,N',N'-tetraacetic acid·xTFA (pdta)

10 **Using General Procedure B:**

Reaction of the oil from above (0.866 g, 1.63 mmol) with TFA (8.88 g, 78 mmol) afforded the product (0.8405 g, 96%). ^1H NMR (CD_3OD) δ 2.15-2.19 (m, 2H), 3.43 (t, 4H, J = 6.0 Hz), 4.16 (s, 8H). ES-MS m/z 307 $[\text{M}+\text{H}]^+$.

15 $\text{Preparation of K}[\text{Ru}(\text{H}_2\text{pdta})\text{Cl}_3]\cdot 3\text{H}_2\text{O}$
[Potassium dihydrogen dichloro[[N,N' -1,3-propanediylbis[N -(carboxymethyl)glycinato- $\kappa N,\kappa O$]]] ruthenium (III)]

Using General Procedure C:

20 Reaction of pdta (0.291 g, 0.54 mmol) with $\text{K}_2[\text{RuCl}_5(\text{H}_2\text{O})]$ (0.203 g, 0.54 mmol) afforded the product (0.075 g, 24%) as a yellow solid. Anal. Calcd. for $\text{C}_{11}\text{H}_{16}\text{N}_2\text{O}_8\text{Cl}_2\text{RuK}\cdot 3.0\text{H}_2\text{O}$: C, 23.20; H, 3.89; N, 4.92; Cl, 12.45. Found: C, 22.97; H, 3.67; N, 4.80; Cl, 12.15. IR (CsI) ν (cm^{-1}) 1738 (CO_2H); 1642 (CO_2); 316(Ru-Cl).

25 **EXAMPLE 45.**

AMD7494: Ruthenium (III) complex of N-[2-(carboxy)-6-pyridyl(methylene)]iminodiacetic acid (cpida).

Methyl 2-(hydroxymethyl)pyridinecarboxylate

30 Dimethyl-2,6-pyridinedicarboxylate (1.057 g, 5.4 mmol) was dissolved in dry CH_2Cl_2 (45 mL) and the solution was cooled to -78°C . DIBAL-H (11 mL, 10.8 mmol) was added dropwise with stirring and the solution was stirred at -78°C for 0.5

hours and then slowly warmed to room temperature over a period of 1 hour. The reaction was quenched with H₂O (15 mL) /sodium potassium tartrate (15 mL) and extracted with CH₂Cl₂ (3 x 80 mL). The combined organic extracts were dried (MgSO₄) and evaporated *in vacuo* to afford the crude product. Purification by column chromatography on silica gel (4:1 Hexanes : Ethyl acetate to 10% MeOH/ CH₂Cl₂) afforded the desired product (0.220 g, 26%) as a colorless oil. ¹H NMR (CDCl₃) δ 3.33 (t, 1H, *J* = 4.5 Hz), 4.00 (s, 3H), 4.87 (d, 2H, *J* = 4.5 Hz), 7.54 (d, 1H, *J* = 6.0), 7.83 (dd, 1H, *J* = 6.0, 9.0), 8.00 (d, 1H, *J* = 9.0 Hz).

Methyl 2-(methanesulfonylmethyl)pyridinecarboxylate
10 To a stirred solution of methyl 2-(hydroxymethyl)pyridinecarboxylate (0.220 g, 1.3 mmol) dissolved in dry CH₂Cl₂ (13 mL) and triethylamine (0.40 g, 4.0 mmol) cooled in an ice bath was added dropwise, methanesulfonylchloride (0.18 g, 1.6 mmol). After 30 minutes the reaction was quenched with *saturated* NaHCO₃ (15 mL) and the aqueous phase was separated and extracted with CH₂Cl₂ (3 x 15 mL). The combined organic extracts were dried (MgSO₄) and the solvent was evaporated *in vacuo* to afford the product (0.347g, 100%) as a yellow orange oil. ¹H NMR (CDCl₃) δ 3.15 (s, 3H), 4.01 (s, 3H), 5.44 (s, 2H), 7.70 (d, 1H, *J* = 6.0 Hz), 7.92 (dd, 1H, *J* = 6.0, 9.0 Hz), 8.12 (d, 1H, *J* = 9.0 Hz).

N-[2-(carboxymethyl)-6-pyridyl(methylene)]iminodiacetic acid dimethyl ester
20 *General Procedure D:*
The oil from above (0.323 g, 1.3 mmol) was dissolved in dry DMF (13 mL) and iminodiacetic acid dimethyl ester (0.191 g, 1.2 mmol) was added. Once the reagents had dissolved, K₂CO₃ (0.36 g, 2.6 mmol) was added and the reaction mixture was stirred at 35 °C for 16 hours. The solvent was removed *in vacuo* and partitioned between H₂O (10 mL) and CH₂Cl₂ (15 mL) . The aqueous portion was extracted with CH₂Cl₂ (3 x 15 mL), and the combined organic extracts were dried (MgSO₄) and evaporated *in vacuo* . The crude material was purified by silica gel chromatography (75% EtOAc/hexanes) to afford the product (0.200 g, 49%) as a colorless oil. ¹H NMR (CDCl₃) δ 3.70 (s, 6H), 3.97 (s, 3H), 4.16 (s, 4H), 5.36 (s, 2H), 7.51 (d, 1H, *J* = 9.0), 7.84 (dd, 1H, *J* = 6.0, 9.0), 8.02 (d, 1H, *J* = 6.0 Hz). ¹³C NMR δ 49.48, 52.63, 53.32, 68.46, 124.46, 124.79, 138.25, 155.93, 157.31, 165.88, 170.09.

N-[2-(carboxy)-6-pyridyl(methylene)]iminodiacetic acid·xHCl (cpida)

The oil from above (0.200 g, 0.65 mmol) was dissolved in MeOH (19 mL) and H₂O (6 mL) and the solution was cooled to 0 °C using an ice bath. Lithium hydroxide monohydrate (0.270 g, 6.4 mmol) was added and the mixture was stirred for 17 hours at room temperature in the absence of light. The solution was acidified with 2N HCl and the solvent was removed *in vacuo*. The crude material was purified on Dowex cation exchange resin (H⁺ form, 50W-200 mesh) to afford the product (0.172 g, 78%).
5 ¹H NMR (D₂O) δ 4.02 (s, 2H), 4.15 (s, 2H), 5.39 (s, 2H), 7.95 (d, 1H, *J* = 7.5 Hz), 8.25 (d, 1H, *J* = 7.2 Hz), 8.46 (dd, 1H, *J* = 7.2, 7.5 Hz). ¹³C NMR (D₂O) δ 50.27, 50.56, 127.02, 128.74, 147.29, 152.83, 156.73, 173.22, 173.46. ES-MS *m/z* 313
10 [M+H]⁺.

Preparation of [Ru(Hcpida)(OH₂)(Cl)]·1.5H₂O

[Hydrogen aqua[6-[[[(carboxy-κO)methyl](carboxymethyl)amino-κN]methyl]-2-pyridinecarboxylato-κN¹,κO²]chloro ruthenium (III)].

15

Using General Procedure C:

Reaction of cpida (0.157 g, 0.48 mmol) with K₂[RuCl₅(H₂O)] (0.172 g, 0.46 mmol) afforded the product. Anal. Calcd. for C₁₁H₁₂N₂O₇RuCl·1.5H₂O·0.9KCl: C, 25.66; H, 2.94; N, 5.44; Cl, 13.08. Found: C, 25.56; H, 2.64; N, 5.06; Cl, 12.97. IR (CsI): ν (cm⁻¹) 1709 (CO₂H); 1632, 607(CO₂); 341(Ru-Cl).
20

EXAMPLE 46.

AMD7493: Ruthenium (III) complex of N-[2-(Hydroxymethyl)-6-pyridyl(methylene)]iminodiacetic acid (hpida).

25

2-[Methanesulfonyl(methylene)]-6-pyridinecarboxaldehyde

2-(Hydroxymethyl)-6-pyridinecarboxaldehyde (2.30 g, 0.017 mol) was dissolved in dry CH₂Cl₂ (160 mL) containing triethylamine (5.08 g, 0.05 mol). The solution was cooled to 0 °C in an ice bath and methanesulfonylchloride (2.12 g, 0.018 mol) was added dropwise. Stirring was continued for 0.5 hours and the reaction was 30 quenched with saturated NaHCO₃ (160 mL). The aqueous portion was extracted with CH₂Cl₂ (3 x 150 mL), and the combined organic extracts were dried (Na₂SO₄) and the solvent was removed *in vacuo* to afford the product (3.61 g, 100%) as a brown oil. ¹H

NMR (CDCl₃) δ 3.15 (s, 3H), 5.43 (s, 2H), 7.70 (m, 1H), 7.97 (m, 2H), 10.05 (s, 1H).

This was used without further purification.

Using General Procedure D.

Reaction of the oil from above (3.61 g, 0.017 mol) with iminodiacetic acid di-*t*-

5 butyl ester (3.706 g, 0.015 mmol) afforded, after column chromatography on silica (4:1 hexanes: EtOAc), the product (2.136 g, 40%) as a colorless oil. ¹H NMR (CDCl₃) δ 1.46 (s, 18H), 3.50 (s, 4H), 4.14 (s, 2H), 7.85 (m, 1H), 7.94 (m, 1H), 10.05 (s, 1H).

N-[2-(Hydroxymethyl)-6-pyridyl(methylene)]iminodiacetic acid di-*t*-butyl ester.

10 The oil from above (2.25 g, 6.2 mmol) was dissolved in dry MeOH (60 mL) under a nitrogen atmosphere. Sodium borohydride (0.235 g, 6.2 mmol) was added in one portion and the reaction was heated to 60 °C with stirring. After 1 hour the solvent was removed *in vacuo* and the residue was partitioned between H₂O (30 mL) and CH₂Cl₂ (30 mL). The aqueous phase was separated and extracted with CH₂Cl₂ (3 x 40 mL) and the combined organic extracts were dried (MgSO₄) and evaporated *in vacuo* to afford the product (2.16 g, 95%) as a colorless oil. ¹H NMR (CDCl₃) δ 1.46 (s, 18H), 3.48 (s, 4H), 3.98 (t, 1H, *J* = 4.5 Hz), 4.05 (s, 2H), 4.72 (d, 2H, *J* = 4.5 Hz), 7.08 (d, 1H, *J* = 6.0 Hz), 7.53 (d, 1H, *J* = 9.0 Hz), 7.66 (dd, 1H, *J* = 6.0, 9.0 Hz). ¹³C NMR (CDCl₃) δ 28.57, 56.22, 59.88, 64.13, 81.47, 119.04, 122.02, 137.64, 158.25, 158.65, 170.90. ES-MS *m/z* 367 [M+H]⁺.

N-[2-(Hydroxymethyl)-6-pyridyl(methylene)]iminodiacetic acid.xTFA (hpida)

Using General Procedure B:

Reaction of N-[2-(Hydroxymethyl)-6-pyridyl(methylene)]iminodiacetic acid di-*t*-butyl ester with TFA (4.44 g, 40 mmol) afforded the product (0.492 g, 100%) as a white solid. ¹H NMR (D₂O) δ 3.64 (s, 4H), 4.28 (s, 2H), 4.85 (s, 2H), 7.69 (bs, 2H), 8.27 (t, 1H, *J* = 8.0 Hz). ¹³C NMR (D₂O) δ 55.98, 60.07, 123.75, 125.19, 147.02, 152.72, 155.65, 174.85. ES-MS *m/z* 255 [M+H]⁺.

Preparation of [Ru(Hhpida)(OH₂)Cl₂]·H₂O

30 [Hydrogen aqua[N-(carboxymethyl)-N-[[6-(hydroxymethyl)-2-pyridinyl-
κ*N*]methyl]glycinato-κ*N*,κ*O*]dichloro ruthenium (III)].

Following General Procedure C:

Reaction of hpida (0.152 g, 0.32 mmol) with $K_2[RuCl_5(H_2O)]$ (0.118 g, 0.32 mmol) afforded the product (0.0352 g, 24%). Anal. Calcd. for $C_{11}H_{15}N_2O_6Cl_2Ru \cdot H_2O$: C, 28.64; H, 3.71; N, 6.07; Cl, 15.37. Found: C, 28.44; H, 5 3.67; N, 6.02; Cl, 15.36. IR (CsI) $\nu(cm^{-1})$ 1657, 1630(CO₂); 316(Ru-Cl).

EXAMPLE 47.

AMD8699: Ruthenium (III) complex of N-[2-(benzyloxymethyl)-6-pyridyl(methylene)iminodiacetic acid (bpida).

10

2-(Benzylloxymethyl)-6-(hydroxymethyl)pyridine

2,6-Pyridinedimethanol (1.523 g, 0.011 mol) was dissolved in DMSO (5 mL) and powdered KOH (0.63 g, 0.011 mol) was added. After 10 minutes benzylbromide (1.87 g, 0.011 mol) was added and the reaction was heated to 80 °C for 17 hours. The 15 reaction mixture was quenched with H₂O (9 mL) and extracted with Et₂O (3 x 25 mL). The combined organic extracts were dried (MgSO₄) and the solvent was evaporated *in vacuo*. The crude product was purified by column chromatography on silica (1:1 hexanes: EtOAc and then EtOAc) to afford the product (0.971g, 39%) as a colorless oil. ¹H NMR (CDCl₃) δ 3.79 (bs, 1H), 4.66 (s, 2H), 4.70 (s, 2H), 7.48 (d, 2H, *J* = 3.6 Hz), 7.13 (d, 1H, *J* = 7.5 Hz), 7.32-7.43 (m, 6H), 7.70 (dd, 1H, *J* = 7.2, 20 7.8 Hz). ¹³C NMR (CDCl₃) δ 60.40, 63.89, 72.96, 119.01, 119.91, 127.80, 128.48, 137.31, 137.94, 157.57, 158.16.

2-(Benzylloxymethyl)-6-(methanesulfonylmethyl)pyridine

The oil from above (0.971 g, 4.24 mmol) was dissolved in dry CH₂Cl₂ (40 mL) containing triethylamine (1.29 g, 12.7 mmol) under a nitrogen atmosphere and the solution was cooled to 0°C with stirring in an ice bath. Methanesulfonylchloride (0.577 g, 5.0 mmol) was then added dropwise and the mixture was stirred for 45 minutes and then quenched with *saturated* NaHCO₃ (30 mL). The separated aqueous phase was extracted with CH₂Cl₂ (2 x 20 mL) and the combined organic extracts were 30 dried (MgSO₄) and evaporated *in vacuo* to afford the product (1.18g, 91%) as a brown

oil. ^1H NMR (CDCl_3) δ 3.07 (s, 3H), 4.65 (s, 2H), 4.67 (s, 2H), 5.29 (s, 2H), 7.27-7.38 (m, 6H), 7.50 (d, 1H, J = 9.0 Hz), 7.77 (dd, 1H, J = 6.0, 9.0 Hz).

N-[2-(benzyloxymethyl)-6-pyridyl(methylene)]iminodiacetic acid di-*t*-butyl ester

Using General Procedure D:

5 Reaction of the oil from above (1.18 g, 3.84 mmol) with iminodiacetic acid di-*t*-butyl ester (0.85 g, 3.47 mmol) afforded, after silica gel chromatography (4:1 Hexanes: EtOAc), the product (0.772 g, 45%) as a colorless oil. ^1H NMR (CDCl_3) δ 1.45 (s, 18H), 3.48 (s, 4H), 4.03 (s, 2H), 4.65 (s, 2H), 4.67 (s, 2H), 7.27-7.38 (m, 6H), 7.54 (d, 1H, J = 7.5 Hz), 7.68 (dd, 1H, J = 7.5, 7.8 Hz). ^{13}C NMR (CDCl_3) δ 28.19, 10 55.78, 59.83, 72.92, 73.26, 80.98, 119.58, 121.46, 127.71, 127.83, 128.42, 137.16, 138.09, 157.82, 158.86, 170.53. ES-MS m/z 457 [M+H] $^+$.

N-[2-(benzyloxymethyl)-6-pyridyl(methylene)]iminodiacetic acid·xTFA (bpida).

Using General Procedure B:

Reaction of the product from above (0.7 g, 1.53 mmol) with TFA (10.36 g, 90 mmol) afforded the product (0.876 g, 100%) as a yellow viscous oil. ^1H NMR (D_2O) δ 3.77 (s, 4H), 4.44 (s, 2H), 4.75 (s, 2H), 4.92 (s, 2H), 7.33-7.41 (m, 5H), 7.76 (d, 1H, J = 9.0 Hz), 7.83 (d, 1H, J = 6.0 Hz), 8.33 (dd, 1H, J = 6.0, 9.0 Hz). ^{13}C NMR (D_2O) δ 55.73, 56.51, 67.68, 68.27, 73.62, 123.45, 124.33, 128.18, 128.58, 137.52, 144.88, 154.30, 172.94. ES-MS m/z 345 [M+H] $^+$.

20

Preparation of [Ru(bpida)Cl(OH₂)]

[Aqua[N-[(carboxy- κO)methyl]-N-[[6-[(phenylmethoxy)methyl]-2-pyridinyl- κN]methyl]glycinato- $\kappa N,\kappa O$]chloro ruthenium (III)]

25 Using General Procedure C:

Reaction of bpida (0.376 g, 0.66 mmol) with $\text{K}_2[\text{RuCl}_5(\text{H}_2\text{O})]$ (0.247 g, 0.66 mmol) afforded the product (0.0910 g, 26%) as a yellow solid. Anal. Calcd. for $\text{C}_{18}\text{H}_{20}\text{N}_2\text{O}_6\text{RuCl}\cdot 0.4\text{KCl}$: C, 41.05; H, 3.83; N, 5.32; Cl, 9.42. Found: C, 41.30; H, 3.95; N, 5.27; Cl, 9.83. IR (CsI) $\nu(\text{cm}^{-1})$ 1657(CO₂); 391(Ru-Cl).

30

EXAMPLE 48.

AMD8677: Ruthenium (III) complex of N-[(3-carboxymethyl)benzyl]ethylenediamine-N,N',N'-triacetic acid (cmbedta).

5 Ethylenediamine-N,N',N'-triacetic acid tri-t-butyl ester

To a stirred solution of ethylenediamine (0.50 g, 8.3 mmol) in dry THF (70 mL) and triethylamine (3.34 g, 33 mmol) was added *t*-butylbromoacetate (4.9 g, 25 mmol) and the reaction mixture was stirred for 16 hours at room temperature. The solvent was removed *in vacuo* and the residue was partitioned between CH₂Cl₂ (80 mL) and H₂O (50 mL). The separated aqueous phase was extracted with CH₂Cl₂ (2 x 80 mL) and the combined organic extracts were dried (MgSO₄) and evaporated *in vacuo*. The crude material was purified by column chromatography on silica gel (5% MeOH / CH₂Cl₂) to afford the product (0.887g, 27%) as an oil. ¹H NMR (CDCl₃) δ 1.43 (s, 27H), 2.63 (t, 2H, *J* = 6.0 Hz), 2.84 (t, 2H, *J* = 6.0 Hz), 3.28 (s, 2H), 3.42 (s, 4H). ¹³C NMR (CDCl₃) δ 28.46, 28.51, 47.42, 51.84, 54.15, 56.41, 81.31, 81.36, 171.22, 171.68.

N-[(3-carboxymethyl)benzyl]ethylenediamine-N,N',N'-triacetic acid tri-*t*-butyl ester

General Procedure E:

To a stirred solution of the oil from above (0.165 g, 0.41 mmol) in dry THF (5 mL) and triethylamine (0.087 g, 0.86 mmol) was added 3-bromomethylbenzoate (0.094 g, 0.41 mmol) and the reaction was stirred at 35 °C for 22 hours. The solvent was removed *in vacuo* and the residue was partitioned between CH₂Cl₂ (10 mL) and saturated NaHCO₃ (10 mL). The separated aqueous phase was extracted with CH₂Cl₂ (2 x 10 mL), and the combined organic extracts were dried (MgSO₄) and evaporated *in vacuo*. The crude material was purified by radial chromatography on silica gel (7:1 Hexanes:EtOAc) to afford the product (0.115 g, 51%) as a colorless oil. ¹H NMR (CDCl₃) δ 1.40 (s, 18H), 1.43 (s, 9H), 2.79-2.86 (m, 4H), 3.25 (s, 2H), 3.40 (s, 4H), 3.83 (s, 2H), 3.87 (s, 3H), 7.35 (dd, 1H, *J* = 6.0, 9.0 Hz), 7.55 (d, 1H, *J* = 9.0 Hz), 7.89 (d, 1H, *J* = 6.0 Hz), 7.95 (s, 1H).

30 N-[(3-carboxymethyl)benzyl]ethylenediamine-N,N',N'-triacetic acid·xTFA (cmbedta)

Using General Procedure B:

Reaction of the oil from above (0.115 g, 0.21 mmol) with TFA (7.4 g, 65 mmol) afforded the product (0.094 g, 74%) as a light brown solid. ¹H NMR (D₂O) δ

3.16 (bs, 2H), 3.43-3.48 (m, 6H), 3.90 (s, 3H), 4.09 (s, 2H), 4.63 (s, 2H), 7.58 (t, 1H, *J* = 7.8 Hz), 7.83 (d, 1H, *J* = 7.8 Hz), 8.10 (d, 1H, *J* = 7.8 Hz), 8.23 (s, 1H). ^{13}C NMR (D_2O) δ 50.93, 53.38, 54.09, 54.53, 56.27, 60.46, 131.15, 132.48, 132.59, 132.78, 133.58, 137.21, 168.28, 169.47, 175.47.

5

Preparation of $\text{K}[\text{Ru}(\text{cembedta})\text{Cl}] \cdot \text{H}_2\text{O}$

[Potassium chloro[methyl 3-[[2-[bis[(carboxy- κO)methyl]amino- κN]ethyl][(carboxy- κO)methyl]amino- κN]methyl]benzoato ruthenium (III)].

10 **Using General Procedure C:**

Reaction of cembedta (0.094 g, 0.16 mmol) with $\text{K}_2[\text{RuCl}_5(\text{H}_2\text{O})]$ (0.058 g, 0.16 mmol) afforded the product (0.0334 g, 36%) as a yellow solid. Anal. Calcd. for $\text{C}_{17}\text{H}_{19}\text{N}_2\text{O}_8\text{RuClK} \cdot 0.15\text{KCl} \cdot \text{H}_2\text{O}$: C, 34.95; H, 3.62; N, 4.80; Cl, 6.98. Found: C, 35.19; H, 3.92; N, 4.80; Cl, 7.28. IR (CsI) ν (cm^{-1}) 1728 (CO_2Me); 1686($\text{CO}_2\text{-}$); 15 386(Ru-Cl).

EXAMPLE 49.

AMD8893: Ruthenium (III) Complex of N-[2-(N-acetylpyrrolidine)]ethylenediamine-N,N',N'-triacetic acid (apedta).

20

Chloroacetylpyrrolidine

A solution of chloroacetyl chloride (3.6 mL, 45.0 mmol) in anhydrous THF (10 mL) was added dropwise to a stirred mixture of pyrrolidine (2.56 g, 36.0 mmol) and potassium carbonate (7.46 g, 54.0 mmol) in anhydrous THF (50 mL) cooled to 0 25 $^{\circ}\text{C}$. The reaction mixture was stirred at 0 $^{\circ}\text{C}$ for 30 minutes and the reaction mixture was then evaporated to give a white solid. The solid was partitioned between CH_2Cl_2 and H_2O and the aqueous layer was extracted twice with CH_2Cl_2 . The combined organic phases were washed twice with H_2O , twice with NH_4Cl (1 N) then dried (MgSO_4) and evaporated to give a yellow oil (2.97 g, 55.9%). ^1H NMR (CDCl_3) δ 30 1.84 (m, 2H), 2.02 (m, 2H), 3.52 (q, 4H, *J*=6.0 Hz), 4.02 (s, 2H).

N-[2-(N-acetylpyrrolidine)]ethylenediamine-N,N',N'-triacetic acid tri-*t*-butyl ester

*Potassium carbonate (0.69 g, 4.98 mmol) was added to a solution of ethylenediamine-N,N',N'-triacetic acid tri-*t*-butyl ester (0.80 g, 1.99 mmol) and chloroacetylpyrrolidine (0.59 g, 3.98 mmol) in anhydrous acetonitrile (20 mL). The mixture was heated to reflux for 60 hours under N_2 and then evaporated. The orange residue was dissolved in a mixture of CH_2Cl_2 and K_2CO_3 (saturated).*

The aqueous layer was then separated and extracted twice with CH_2Cl_2 . The combined organic phases were washed twice with saturated aqueous K_2CO_3 , dried (MgSO_4) and evaporated. The resulting orange oil was purified twice on silica gel using centrifugal chromatography (using CH_2Cl_2 as the eluent) to afford the desired compound as a yellow oil (0.48 g, 47%). ^1H NMR (CDCl_3) δ 1.44 (s, 27H), 1.86 (m, 2H), 1.94 (m, 2H), 2.87 (s, 4H), 3.45 (s, br, 6H), 3.50 (s, 4H), 3.55 (s, 2H). ES-MS m/z 514 [$\text{M}+\text{H}]^+$.

5 N-[2-(N-acetylpyrrolidine)]ethylenediamine-N,N',N'-triacetic acid·xTFA (apedta)

Trifluoroacetic acid (1.0 mL, 0.49 mmol) was added to a solution of the product from above (0.25 g, 12.98 mmol) in anhydrous CH_2Cl_2 (5 mL) and the 10 mixture was stirred overnight at room temperature under nitrogen. The reaction mixture was evaporated and then lyophilized to afford the desired compound as a pale yellow solid (0.21 g, 74.7%). ^1H NMR (D_2O) δ 1.88 (m, 4H), 3.38 (m, 6H), 3.53 (t, 2H, $J=4.8$ Hz), 3.82 (s, 4H), 4.15 (s, 2H), 4.27 (s, 2H). ^{13}C NMR (D_2O) δ 24.03, 25.66, 46.41, 46.94, 50.28, 53.32, 55.32, 56.00, 56.46, 164.36, 169.51, 172.94. ES-15 MS m/z 346 [$\text{M}+\text{H}]^+$, 368 [$\text{M}+\text{Na}]^+$, 384 [$\text{M}+\text{K}]^+$.

Preparation of [Ru(apedta)(OH₂)]·1.2H₂O

[Aqua[N-[2-[bis[(carboxy- κ O)methyl]amino- κ N]ethyl]-N-[2-oxo-2-(1-pyrrolidinyl)ethyl]glycinato- κ N, κ O] ruthenium (III)].

20

Apedta (0.37 g, 0.65 mmol) was heated in HCl (1 mM, 6 mL) until completely dissolved. The pH of the solution was then adjusted to pH 3.0 with KOH (1 N). K_2 -[RuCl₅(OH₂)] (0.24 g, 0.65 mmol) was added to the solution and the reaction mixture was heated to 100 °C for 2 hours. The solution was evaporated and purified by size 25 exclusion column chromatography on Sephadex G-10 resin (H_2O) and the resulting solid was dried overnight *in vacuo* at 40 °C to afford a brown crystalline solid (0.062 g, 18.1%). ES-MS m/z 467 [$\text{M}-\text{OH}_2+\text{Na}]^+$. IR (CsI) ν (cm⁻¹) 1646 (C=O). Anal. Calcd. for $\text{C}_{14}\text{H}_{22}\text{N}_3\text{O}_8\text{Ru} \cdot 1.2 \text{ H}_2\text{O} \cdot 0.6 \text{ KCl}$: C, 31.86; H, 4.66; N, 7.96; Cl, 4.03. Found: C, 31.75; H, 4.54; N, 7.68; Cl, 4.05.

30

EXAMPLE 50.

AMD8894: Ruthenium (III) complex of N-[2-(N-acetyl-(L)-isoleucyl)]ethylenediamine-N,N',N'-triacetic acid (aiedta).

N-chloroacetyl-(L)-isoleucine t-butyl ester

At 0 °C under nitrogen, a solution of chloroacetyl chloride (0.64 mL, 8.01 mmol) in anhydrous THF (10 mL) was added dropwise to a suspension of (L)-isoleucine *t*-butyl ester (1.2 g, 6.41 mmol) and potassium carbonate (1.33 g, 9.62 mmol) in anhydrous THF (10 mL). The reaction mixture was stirred at 0 °C for 30 minutes and then the mixture was evaporated to give a white residue, which was dissolved in a mixture of CH₂Cl₂ and H₂O. The aqueous layer was washed twice with CH₂Cl₂ and then the organic layer was washed twice with H₂O and twice with NH₄Cl (1 N). The combined organic layers were dried (MgSO₄) and evaporated to afford a yellow oil. The crude product was purified by column chromatography on silica gel (5% MeOH/CH₂Cl₂) to afford the desired compound as a yellow oil (0.66 g, 40.9%).
¹H NMR (CDCl₃) δ 0.94 (m, 6H), 1.24 (m, 1H), 1.48 (m, 10H), 1.93 (m, 1H), 4.07 (s, 2H), 4.48 (dd, 1H, *J*=6.0 Hz, 3.0 Hz), 7.09 (br d, 1H, *J*=6.0 Hz).

A stirred suspension of N-chloroacetyl-(L)-isoleucine *t*-butyl ester (0.66 g, 2.62 mmol), potassium carbonate (0.46 g, 3.30 mmol) and ethylenediamine-N,N',N'-triacetic acid tri-*t*-butyl ester (0.53 g, 1.31 mmol) in anhydrous acetonitrile (15 mL) was heated to reflux for 60 hours under nitrogen and then evaporated. The light brown residue was partitioned between CH₂Cl₂ and saturated aqueous K₂CO₃. The separated aqueous layer was extracted twice with CH₂Cl₂ and then the combined organic phases were washed twice with K₂CO₃ (saturated) then dried (MgSO₄) and evaporated to give an orange oil. The crude product was purified by centrifugal chromatography on silica gel (CH₂Cl₂ treated with 1% NH₄OH) to afford the desired compound as a yellow oil (0.51 g, 63.4%). ¹H NMR (CDCl₃) δ 0.89 (m, 6H), 1.20 (m, 1H), 1.45 (m, 10H), 1.86 (m, 1H), 2.81 (m, 4H), 3.29 (s, 2H), 3.34 (s, 2H), 3.39 (s, 4H), 4.40 (dd, 1H, *J*=4.8 Hz), 7.88 (d, 1H, *J*=9.0 Hz). ¹³C NMR (CDCl₃) δ 12.15, 15.94, 25.63, 28.45, 28.53, 38.18, 53.00, 53.45, 56.48, 56.95, 57.22, 58.89, 81.35, 81.70, 81.80, 170.78, 170.90, 171.04, 171.55.

N-[2-(N-acetyl-(L)-isoleucyl)]ethylenediamine-N,N',N'-triacetic acid.xTFA (aiedta).

30 Trifluoroacetic acid (4.0 mL, 51.9 mmol) was added to a solution of the intermediate from above (0.51 g, 0.83 mmol) in anhydrous CH₂Cl₂ (8 mL) and the mixture was stirred overnight at room temperature under nitrogen. The solvent was

evaporated and the residue lyophilized to afford a pale yellow solid (0.45 mg, 86%). ^1H NMR (D_2O) δ 0.89 (m, 6H), 1.20 (m, 1H), 1.45 (m, 1H), 1.93 (m, 1H), 3.32 (t, 2H, J =6.0 Hz), 3.40 (t, 2H, J =6.0 Hz), 3.82 (s, 2H), 3.88 (s, 2H), 3.96 (s, 4H), 4.33 (d, 1H, J =6.0 Hz). ^{13}C NMR (D_2O) δ 11.08, 15.39, 25.05, 36.60, 51.76, 52.03, 55.54, 55.84, 5 56.64, 58.04, 169.77, 171.49, 172.30, 175.52. ES-MS m/z 406 [M+H] $^+$, 428 [M+Na] $^+$, 444 [M+K] $^+$.

Preparation of [Ru(aiedtaK)(OH₂)]1.6H₂O
[Potassium aqua[N-[2-[bis[(carboxy- κ O)methyl]amino- κ N]ethyl]-N-[(carboxy-
10 κ O)methyl]glycyl- κ N-L-isoleucinato ruthenium (III)].

Aiedta (0.35 g, 0.55 mmol) was heated in aqueous HCl (1 mM, 5.5 mL) until completely dissolved and the pH of the solution was then adjusted to pH=3.0 with KOH (1N). K₂[RuCl₅(OH₂)] (0.21 g, 0.55 mmol) was added to the solution and the 15 reaction mixture was heated at 100 °C for 2 hours. The solution was evaporated and the residue was purified by size exclusion column chromatography on Sephadex G-10 resin (H₂O). The resulting solid was dried overnight *in vacuo* at 40 °C to afford the desired complex as a brown crystalline solid (0.030 g, 8.6%). ES-MS m/z 527[M-OH₂-K+Na+H] $^+$, 549[M-OH₂-K+2Na] $^+$. IR (CsI) ν (cm⁻¹) 1626 (C=O). Anal. Calcd. 20 for C₁₆H₂₅N₃O₁₀RuK·1.6 H₂O·0.6 KCl: C, 30.35; H, 4.49; N, 6.64; Cl, 3.36. Found: C, 30.48; H, 4.64; N, 6.67; Cl, 3.26.

EXAMPLE 51.

AMD8711: Ruthenium (III) complex of N-benzylethylenediamine-N,N',N'-triacetic acid (bedta).

25

N-Benzylethylenediamine-N,N',N'-triacetic acid tri-t-butyl ester
Following General Procedure E:

Reaction of ethylenediamine-N,N',N'-triacetic acid tri-*t*-butyl ester (0.734 g, 1.8 mmol) with benzylbromide (0.316 g, 1.8 mmol) afforded, after column 30 chromatography on silica gel (7:1 hexanes: EtOAc), the product (0.496 g, 55%) as a colorless oil. ^1H NMR (CDCl_3) δ 1.40 (s, 18H), 1.42 (s, 9H), 2.80-2.88 (m, 4H), 3.24 (s, 2H), 3.44, (s, 4H), 3.80 (s, 2H), 7.21-7.34 (m, 5H).

N-benzylethylenediamine-N,N',N'-triacetic acid·xTFA (bedta)

Following General Procedure B:

Reaction of the intermediate from above (0.496 g, 1.0 mmol) with TFA (12.6 g, 100 mmol) afforded the product (0.454 g, 82%) as a white solid. ¹H NMR (MeOD) δ 3.10 (t, 2H, *J* = 6.0 Hz), 3.39-3.45 (bs, 6H), 4.09 (s, 2H), 4.59 (s, 2H), 7.47-7.50 (m, 5 3H), 7.57-7.60 (m, 2H). ¹³C NMR (MeOD) δ 50.59, 53.04, 56.26, 60.90, 130.66, 131.42, 132.01, 132.78, 169.39, 175.74.

Preparation of K[Ru(Hbedta)Cl₂]·1.6H₂O

10 *[Potassium Hydrogen aqua[N-{2-[[carboxy-κO)methyl](carboxymethyl)amino-κN]ethyl]-N-(phenylmethyl)glycinato-κN,κO]dichloro ruthenium (III)]*

Following General Procedure C:

Reaction of bedta (0.210 g, 0.38 mmol) with K₂[RuCl₅(H₂O)] (0.142 g, 0.38 mmol) afforded the product (0.0460 g, 21%) as a yellow solid. Anal. Calcd. for 15 C₁₅H₁₈N₂O₆Cl₂RuK·1.6H₂O·0.1KCl: C, 31.63; H, 3.75; N, 4.92; Cl, 13.07. Found: C, 31.63; H, 3.96; N, 4.77; Cl, 13.03. IR (CsI) ν (cm⁻¹) 1726 (CO₂H); 1641(CO₂-); 391 (Ru-Cl).

EXAMPLE 52.

20 **AMD8702:** Ruthenium (III) complex of N-[(3-carboxy)benzyl]ethylenediamine-N,N',N'-triacetic acid (cbedta).

N-[(3-carboxy)benzyl]ethylenediamine-N,N',N'-triacetic acid-xTFA (cbedta)

To a stirred solution of N-[(3-carboxymethyl)benzyl]ethylenediamine-25 N,N',N'-triacetic acid tri-*t*-butyl ester (0.771 g, 1.4 mmol) in MeOH (19 mL) and H₂O (6 mL) was added lithium hydroxide (0.236 g, 5.6 mmol) and the reaction was stirred for 16 hours at room temperature (in the absence of light) and then the solvent was evaporated *in vacuo*. This intermediate was used directly in the next step without further purification.

30 The residue was dissolved in TFA (8.3 g, 73 mmol) and stirred for 16 hours then evaporated *in vacuo*. EtOH was added to the residue, the resulting suspension was filtered, and the product lyophilized to afford a white solid (1.04 g, 100%). ¹H NMR (MeOD) δ 3.15 (t, 2H, *J* = 6 Hz), 3.43-3.48 (bs, 6H), 4.09 (s, 2H), 4.64 (s, 2H), 7.59 (dd, 1H, *J* = 6.0, 9.0 Hz), 7.85 (d, 1H, *J* = 6.0 Hz), 8.12 (d, 1H, *J* = 9.0 Hz), 8.26

(s, 1H). ^{13}C NMR (MeOD) δ 50.47, 53.65, 54.16, 60.01, 65.74, 130.65, 132.05, 132.30, 133.13, 133.48, 136.67, 168.93, 169.07, 175.12. ES-MS m/z 369 [M+H] $^+$.

Preparation of $\text{K}[\text{Ru}(\text{H},\text{cbelta})\text{Cl}_2]\cdot 4.5\text{H}_2\text{O}$

5 [Potassium Dihydrogen [3-[[[(carboxy- κO)methyl]/[2-[[[(carboxy- κO)methyl](carboxymethyl) amino- κN]ethyl]amino- κN]methyl]benzoato]dichloro ruthenium (III)].

Following General Reaction C:

Reaction of cbelta (0.377 g, 0.60 mmol) with $\text{K}_2[\text{RuCl}_5(\text{H}_2\text{O})]$ (0.236 g, 0.60 mmol) afforded the product (51.0 mg, 12%) as a yellow solid. Anal. Calcd. for $\text{C}_{16}\text{H}_{18}\text{N}_2\text{O}_8\text{Cl}_2\text{RuK}\cdot 4.5\text{H}_2\text{O}\cdot 0.1\text{KCl}$: C, 28.86; H, 4.09; N, 4.21; Cl, 11.18. Found: C, 28.63; H, 3.69; N, 4.29; Cl, 11.08. IR (CsI) ν (cm $^{-1}$) 1709 (CO $_2$ H); 389 (Ru-Cl).

EXAMPLE 53.

15 **AMD8849:** Ruthenium (III) complex $\text{N,N}'\text{-bis}[2\text{-(N-acetylpyrrolidine)}]$ ethylenediamine-N,N'-diacetic acid (bpedda).

$\text{N,N}'\text{-bis}[2\text{-(N-acetylpyrrolidine)}]$ ethylenediamine-N,N'-diacetic acid (bpedda)

A solution of pyrrolidine (0.56 g, 3.90 mmol) in anhydrous THF (20 mL) was 20 added dropwise to a stirred solution of ethylenediamine-N,N,N',N'-tetraacetic acid dianhydride (1.0 g, 7.81 mmol) in anhydrous THF (20 mL) under nitrogen and the mixture was stirred for 15.5 hours. The precipitate which formed was collected by filtration and dried *in vacuo* overnight to give the product as a white solid (1.59 g, ~ 100%). ^1H NMR (D_2O) δ 1.90 (m, 8H), 3.40 (q, 8H, J =7.2 Hz), 3.52 (s, 4H), 3.83 (s, 4H), 4.13 (s, 4H). ES-MS m/z 399 [M+H] $^+$, 421 [M+Na] $^+$. Anal. Calcd. for $\text{C}_{18}\text{H}_{30}\text{N}_4\text{O}_6\cdot 0.2\text{H}_2\text{O}$: C, 53.77; H, 7.62; N, 13.93. Found: C, 53.68; H, 7.54; N, 13.71.

Preparation of $[\text{Ru}(\text{bpedda})\text{Cl}(\text{OH}_2)]\cdot 3\text{H}_2\text{O}$

[Aquachloro[[N,N'-1,2-ethanediylbis[N-[2-oxo-2-(1-pyrrolidinyl)ethyl]glycinato- $\kappa\text{N},\kappa\text{O}]]] ruthenium (III)].$

Bpedda (0.50 g, 1.26 mmol) was heated in aqueous HCl (1 mM, 10 mL) until completely dissolved. $\text{K}_2[\text{RuCl}_5(\text{OH}_2)]$ (0.47, 1.26 mmol) was added to the solution and the reaction mixture was heated at 100 °C for 2 hours. The solution was filtered 35 and the filtrate was evaporated. The residue was purified by size exclusion column

chromatography on Sephadex G-10 resin (H₂O) to afford the desired complex as a red solid (0.039 g, 5.2%). ES-MS *m/z* 498 [M-Cl-H₂O]⁺. IR (KBr) ν (cm⁻¹) 1626 (C=O). Anal. Calcd. for C₁₈H₃₀N₄O₇ClRu·3H₂O: C, 35.73; H, 6.00; N, 9.26; Cl, 5.86. Found: C, 35.48; H, 5.50; N, 9.19; Cl, 6.01.

5

EXAMPLE 54.

AMD7461: Ruthenium (III) complex of 2-Hydroxy-1,3-propanediamine-N,N,N',N'-tetraacetic acid (hppta).

10 Preparation of [Ru(H₂hppta)(OH₂)(O₃SCF₃)]·EtOH
[Dihydrogen aqua[[N,N'-(2-hydroxy-1,3-propanediyl)bis[N-(carboxymethyl)glycinato- κ N,O]]] (trifluoromethanesulfonato- κ O) ruthenium (III)].

15 2-Hydroxy-1,3-propanediamine-N,N,N',N'-tetraacetic acid (0.082 g, 0.25 mmol) was dissolved in EtOH (20 mL) and [Ru(DMF)₆](OTf)₃ (0.26 g, 0.25 mmol) was added. The reaction was heated to 69 °C for 3 days with stirring, cooled to room temperature and the resulting precipitate was collected by filtration. The solid was washed with EtOH (10 mL) and Et₂O (2 x 10 mL) to afford the desired product (0.0420 mg, 26%). Anal. Calcd. for C₁₂H₁₈N₂O₁₃RuF₃S·1.0EtOH: C, 26.50; H, 3.81; N, 4.42. Found: C, 26.60; H, 3.89; N, 4.76. IR (CsI) ν (cm⁻¹) 1744 (CO₂H); 1647 (CO₂).

EXAMPLE 55.

25 **AMD7462:** Ruthenium (III) complex of 1,2-Ethylenediamine-N,N'-diacetic acid (edda).

Preparation of K[Ru(edda)Cl₂]·2.5H₂O

[Potassium dichloro[[N,N'-1,2-ethanediyl]bis[glycinato- κ N, κ O]] ruthenium (III)].

30 1,2-Ethylenediamine-N,N'-diacetic acid (0.130 g, 0.74 mmol) was dissolved in EtOH (20 mL) and RuCl₃·H₂O (0.155 g, 0.74 mmol) added. The mixture was heated

to 60 °C during which time a precipitate formed. The solid was collected by filtration and washed with Et₂O to afford the desired product (0.0620 g, 22%) as a brown solid. Anal. Calcd. for C₆H₁₀N₂O₄Cl₂RuK·2.1H₂O: C, 17.03; H, 3.38; N, 6.62; Cl, 16.76. Found: C, 17.40; H, 3.76; N, 6.80; Cl, 17.20. IR (CsI) ν (cm⁻¹) 1640 (CO₂); 318 (Ru-Cl).

EXAMPLE 56.**Synthesis of dithiocarbamate ligands****General Procedure F:**

10 Carbon disulfide (1.5-2 equivalents) was dissolved in anhydrous diethyl ether and cooled to 0 °C in an ice bath. The appropriate amine (1 equivalent) and KOH (1-2 equivalents) were dissolved in anhydrous methanol and added dropwise to the carbon disulfide solution. The reaction mixture was stirred for 3 hours at 0 °C. The solvent was removed and the resulting residue was triturated with diethyl ether. The 15 white solid was filtered and washed with diethyl ether and dried *in vacuo*.

The following ligands were prepared using general procedure F:

Pyrrolidinedithiocarbamic acid potassium salt [KS₂CNC₄H₈]

20 Carbon disulfide (2.16 mL, 36 mmol) was reacted with pyrrolidine (2 mL, 24 mmol) and KOH (1.34 g, 24 mmol) to yield 3.8 g (85%) product. ¹H NMR (D₂O) δ 1.94-1.99 (m, 4H), 3.71-3.76 (m, 4H).

L-Prolinedithiocarbamic acid dipotassium salt [KS₂CNProK]

25 Carbon disulfide (1.04 mL, 17.4 mmol) was reacted with L-proline (1.0 g, 8.7 mmol) and KOH (0.97 g, 17.4 mmol) to yield 1.37 g (59%) product. ¹H NMR (D₂O) δ 1.950-2.05 (m, 3H), 2.25-2.35 (m, 1H), 3.78-3.96 (m, 2H), 4.84 (m, 1H). ¹³C NMR (D₂O) δ 24.78, 31.62, 55.77, 69.58, 180.32, 205.71.

30 L-Prolinemethyl ester dithiocarbamic acid potassium salt [KS₂CNProOMe]

Carbon disulfide (0.53 mL, 8.8 mmol) was reacted with L-proline methyl ester (0.57 g, 4.4 mmol) and KOH (0.49 g, 8.8 mmol) to yield 0.66 g (62%) product. This

product contained some residual starting material and was used without further purification in the preparation of the ruthenium complexes. ^1H NMR (D_2O) δ 2.03-2.17 (m, 3H), 2.41-2.44 (m, 1H), 3.78 (m, 1H), 3.91-3.99 (m, 1H), 4.03 (s, 3H), 4.81-4.85 (m, 0.5H), 5.01 (m, 0.5H). ^{13}C NMR (D_2O) δ 24.71, 31.02, 53.30, 60.83, 66.79, 5 175.43, 208.26.

N-Methyl-L-isoleucinedithiocarbamic acid dipotassium salt [KS₂CNMeIleK]

Carbon disulfide (0.83 mL, 13.8 mmol) was reacted with N-methyl-L-isoleucine (1.0 g, 6.89 mmol) and KOH (0.77 g, 13.8 mmol) to yield 0.73 g (37%) 10 product. This product contained some starting material and was used without further purification in the preparation of the ruthenium complexes. ^1H NMR (D_2O) δ 0.91 (t, 3H, $J=7.5$ Hz), 1.00 (d, 3H, $J=6.6$ Hz), 1.14-1.23 (m, 1H), 1.30-1.35 (m, 1H), 1.98 (br m, 1H), 3.38 (br s, 3H), 6.01 (d, 1H, $J=10.2$ Hz).

15 EXAMPLE 57.

AMD8672: Preparation of Chloro(1,4,7-triazacyclononane)bis-(dimethylsufoxide) ruthenium(II) chloride, [Ru(tacn)(DMSO)₂Cl]Cl.

[Chloro[octahydro-1*H*-1,4,7-triazonine- $\kappa\text{N}^1,\kappa\text{N}^4,\kappa\text{N}^7$]bis[(sulfinyl- κS)bis[methane] ruthenium (II) chloride].

20

Prepared according to literature procedures: A. Geilenkirchen, P. Neubold, R. Schneider, K. Wieghardt, U. Florke, H-J. Haupt, B. Nuber *J. Chem. Soc., Dalton Trans.* 1994, 457.

25 EXAMPLE 58.

AMD8641: Preparation of Trichloro(1,4,7-triazacyclononane) Ruthenium(III): [Ru(tacn)Cl₃].

[Trichloro[octahydro-1*H*-1,4,7-triazonine- $\kappa\text{N}^1,\kappa\text{N}^4,\kappa\text{N}^7$] ruthenium (III)].

Prepared according to literature procedures: A. Geilenkirchen, P. Neubold, R. Schneider, K. Wieghardt, U. Florke, H-J. Haupt, B. Nuber *J. Chem. Soc., Dalton Trans.* 1994, 457.

5 EXAMPLE 59.

AMD8671: Preparation of Trichloro (1,4,7-trimethyl-1,4,7-triazacyclononane) Ruthenium (III):
[Ru(Me₃tacn)Cl₃].
[Trichloro[hexahydro-1,4,7-trimethyl-1,4,7-triazone-κN¹,κN⁴,κN⁷] ruthenium (III)].

10 Prepared according to literature procedures: P. Neubold, K. Wieghardt, B. Nuber, *J. Weiss Inorg. Chem.* 1989, 28, 459.

EXAMPLE 60.

AMD8670: Preparation of [Ru(tacn)(S₂CNMe₂)₃][PF₆]
15 *[(Dimethylcarbamodithioato-κS)(dimethylcarbamodithioato-κS,κS') [octahydro-1H-1,4,7-triazone-κN¹,κN⁴,κN⁷] ruthenium (III) hexafluorophosphate].*

General Procedure G

20 RuLCl₃, where L represents either 1,4,7-triazacyclononane (tacn) or 1,4,7-trimethyl-1,4,7-triazacyclononane (Me₃tacn), was suspended in deionized water and heated to 40 °C. Two equivalents of the dithiocarbamic acid salt was added and the reaction continued for 1-1.5 hours during which time the reaction mixture turned a dark blue or purple colour. The reaction mixture was removed from heat and filtered while hot. Saturated NH₄PF₆ was added to the filtrate, which produced a dark 25 precipitate. The solid was filtered and washed with deionized water and diethyl ether and dried *in vacuo*.

Using General Procedure G:

30 Ru(tacn)Cl₃ (0.30 g, 0.89 mmol) was reacted with N,N-dimethyldithiocarbamic acid sodium salt (NaS₂CNMe₂·2H₂O) (Aldrich, 0.32 g, 1.78 mmol) to yield 0.448 g product (80%). Anal. Calcd. for C₁₂H₂₆N₅S₄RuPF₆: C, 23.45; H, 4.26; N, 11.39; S, 20.86. Found: C, 23.23; H, 4.34; N, 11.18; S, 20.61. ES-MS *m/z* 471 [M-PF₆]⁺.

EXAMPLE 61.

AMD8803: Preparation of [Ru(tacn)(S₂CNEt₂)₂][PF₆].[(Diethylcarbamodithioato- κ S)(diethylcarbamodithioato- κ S, κ S') [octahydro-1*H*-1,4,7-triazonine- κ N¹, κ N⁴, κ N⁷] ruthenium (III) hexafluorophosphate].

5

Using General Procedure G:

Ru(tacn)Cl₃ (0.10 g, 0.29 mmol) was reacted with N,N-diethyldithiocarbamic acid sodium salt (NaS₂CNEt₂·3H₂O) (Aldrich, 0.134 g, 0.6 mmol) to yield 0.163 g product (81%). Anal. Calcd. for C₁₆H₃₅N₅S₄RuPF₆: C, 28.61; H, 5.25; N, 10.43; S, 10.09. Found: C, 28.44; H, 5.12; N, 10.31; S, 19.30. ES-MS *m/z* 527 [M-PF₆]⁺.

EXAMPLE 62.

AMD8842: Preparation of [Ru(tacn)(S₂CNC₄H₈)₂][PF₆].[(1,4-butanediylcarbamodithioato- κ S)(1,4-butanediylcarbamodithioato- κ S, κ S') [octahydro-1*H*-1,4,7-triazonine- κ N¹, κ N⁴, κ N⁷] ruthenium (III) hexafluorophosphate].

Using General Procedure G:

Ru(tacn)Cl₃ (0.10 g, 0.29 mmol) was reacted with pyrrolidinedithiocarbamic acid potassium salt (0.109 g, 0.59 mmol) to yield 0.11 g of crude product. This crude product was purified by column chromatography on silica gel (MeCN/sat. KNO₃/H₂O 7/1/0.5). The solvent was removed from the combined fractions containing the desired product and the residue was triturated with acetonitrile. The excess KNO₃ was removed by filtration and saturated solution of NH₄PF₆ in methanol was added to the filtrate. The resulting precipitate was collected by filtration and washed with deionized water then diethyl ether and dried *in vacuo* to give the title compound (0.069 g, 36%). Anal. Calcd. for C₁₆H₃₁N₅S₄RuPF₆·0.2H₂O·0.2NH₄PF₆: C, 27.30; H, 4.61; N, 10.35; S, 18.22. Found: C, 27.06; H, 4.50; N, 10.23; S, 18.24. ES-MS *m/z* 523 [M-PF₆]⁺.

30

EXAMPLE 63.

AMD8731: Preparation of [Ru(tacn)(S₂CNPro)₂]₂[PF₆]₂

[Dihydrogen ((1-carboxy)-1,4-butanediylcarbamodithioato- κ S)((1-carboxy)-1,4-butanediylcarbamodithioato- κ S, κ S') [octahydro-1H-1,4,7-triazone- κ N¹, κ N⁴, κ N⁷] ruthenium (III) hexafluorophosphate].

5

Using General Procedure G:

Ru(tacn)Cl₃ (0.30 g, 0.90 mmol) was reacted with L-prolinedithiocarbamic acid dipotassium salt (0.48 g, 1.8 mmol) to yield 0.273 g (38%) product. Anal. Calcd. for C₁₈H₃₁N₅O₄S₄RuPF₆·1.8H₂O: C, 27.43; H, 4.42; N, 8.89; S, 16.27. Found: C, 27.36; H, 4.38; N, 9.07; S, 16.33. ES-MS *m/z* 611 [M-PF₆]⁺. IR (CsI) ν (cm⁻¹) 1723 (CO₂H).

EXAMPLE 64.

AMD8802: Preparation of [Ru(tacn)(S₂CNProOMe)₂]₂[PF₆]₂

((1-carboxymethyl)-1,4-butanediylcarbamodithioato- κ S)((1-carboxymethyl)-1,4-butanediylcarbamodithioato- κ S, κ S') [octahydro-1H-1,4,7-triazone- κ N¹, κ N⁴, κ N⁷] ruthenium (III) hexafluorophosphate.

Using General Procedure G:

Ru(tacn)Cl₃ (0.136 g, 0.40 mmol) was reacted with L-proline methyl ester dithiocarbamic acid potassium salt (0.20 g, 0.80 mmol) to yield 0.078 g (25%) product. Anal. Calcd. for C₂₀H₃₅N₅O₄S₄RuPF₆: C, 30.65; H, 4.50; N, 8.94; S, 16.35. Found: C, 30.54; H, 4.47; N, 8.81; S, 16.52. ES-MS *m/z* 639 [M-PF₆]⁺. IR (CsI) ν (cm⁻¹) 1742 (CO₂Me).

25 EXAMPLE 65.

AMD8801: Preparation of [Ru(tacn)(S₂CNMelle)₂]₂[PF₆]₂

[Dihydrogen (N-methyl-N-sec-butylcarboxycarbamodithioato- κ S)(N-methyl-N-sec-butylcarboxycarbamodithioato- κ S, κ S') [octahydro-1H-1,4,7-triazone- κ N¹, κ N⁴, κ N⁷] ruthenium (III) hexafluorophosphate].

30

Using General Procedure G:

Ru(tacn)Cl₃ (0.10 g, 0.30 mmol) was reacted with N-methyl-L-isoleucinedithiocarbamic acid dipotassium salt (0.178 g, 0.60 mmol) to yield 0.068 g

(28%) product. Anal. Calcd. for $C_{22}H_{43}N_5O_4S_4RuPF_6$: C, 32.39; H, 5.31; N, 8.58; S, 15.72. Found: C, 32.41; H, 5.46; N, 8.85; S, 15.58. ES-MS m/z 671 $[M-PF_6]^+$. IR (CsI) ν (cm^{-1}) 1726 (CO₂H).

5 EXAMPLE 66.

AMD8682: Preparation of $[Ru(Me_3tacn)(S_2CNMe_2)_2]/[PF_6]$.
[(Dimethylcarbamodithioato- κS)(dimethylcarbamodithioato- $\kappa S, \kappa S'$) [hexahydro-1,4,7-trimethyl-1,4,7-triazonine- $\kappa N^1, \kappa N^4, \kappa N^7$] ruthenium (III) hexafluorophosphate].

10 Using General Procedure G:

Ru(Me₃tacn)Cl₃ (0.10 g, 0.264 mmol) was reacted with N,N-dimethyldithiocarbamic acid sodium salt (Aldrich, 0.094 g, 0.528 mmol) to yield 0.10 g crude product. This crude product (0.05 g) was purified by column chromatography on silica gel (MeCN/sat. KNO₃/H₂O 7/1/0.5). The solvent was removed from the 15 combined fractions containing the desired product and the residue was triturated with acetonitrile. The KNO₃ was removed by filtration and a saturated solution of NH₄PF₆ in methanol was added to the filtrate. The resulting precipitate was collected, washed with deionized water and diethyl ether and then dried *in vacuo* to give the title compound (0.030 g, 35%). Anal. Calcd. for $C_{15}H_{33}N_5S_4RuPF_6$: C, 27.39; H, 5.06; N, 10.65; S, 19.50; Cl, 0.00. Found: C, 27.51; H, 5.01; N, 10.58; S, 19.28; Cl, 0.00. ES-MS m/z 513 $[M-PF_6]^+$.

EXAMPLE 67.

AMD8800: Preparation of $[Ru(tacn)(mida)]/[PF_6]$.
[(N -(carboxy- κO)-methyl)- N -methylglycinato- $\kappa N, \kappa O$][octahydro-1*H*-1,4,7-triazonine- $\kappa N^1, \kappa N^4, \kappa N^7$] ruthenium (III) hexafluorophosphate].

Ru(tacn)Cl₃ (0.10 g, 0.30 mmol) and N-methyliminodiacetic acid (mida) (0.044 g, 0.30 mmol) were refluxed in deionized water (30 mL) for 3 hours. The 30 reaction mixture was filtered hot to remove any unreacted starting material. Saturated aqueous NH₄PF₆ was added to the filtrate and crystallization was induced by the addition of ethanol. The pale yellow precipitate was collected by filtration, washed with diethyl ether and dried *in vacuo* to yield 0.041 g (26%) product. Anal. Calcd. for

$C_{11}H_{22}N_4O_4RuPF_6$: C, 25.39; H, 4.26; N, 10.77. Found: C, 25.37; H, 4.24; N, 10.59.
ES-MS m/z 376 [$M-PF_6$]⁺. IR (CsI) ν (cm⁻¹) 1642 (CO₂-).

EXAMPLE 68.

5 *AMD8811: Preparation of [Ru(H₂nota)Cl].*
[Hydrogen chloro[hexahydro-1,4,7-(tricarboxy- κO , $\kappa O'$ -methyl)-1,4,7-triaxonine- κN^1 , κN^4 , κN^7] ruthenium (III)].

10 1,4,7-Triazacyclononane-1,4,7-triacetic acid (nota) (0.50 g, 1 mmol) was dissolved in deionized water (5 mL) and the pH adjusted to pH 3-4 with KOH (1 M). An aqueous solution of K₂[RuCl₅(OH₂)] (0.40 g, 1 mmol) was added to the solution and the reaction mixture was heated to reflux for 2 hours. The solution was cooled and an insoluble material was removed by filtration. Addition of ethanol to the filtrate resulted in the precipitation of [Ru(H₂nota)Cl₂] (0.1 g) which was removed by 15 filtration. Upon allowing the filtrate to stand, a second precipitate was obtained which was collected and washed with diethyl ether to give the title compound (0.040 g, 8.5%). Anal. Calcd. for C₁₂H₁₉N₃O₆RuCl·H₂O·0.2KCl: C, 30.62; H, 4.50; N, 8.93; Cl, 9.04. Found: C, 30.48; H, 4.64; N, 8.84; Cl, 9.12. ES-MS m/z 403 [$M-Cl$]⁺. IR (CsI) ν (cm⁻¹) 1728, (CO₂H); 1678 (CO₂).

20 EXAMPLE 69.

AMD7044: Preparation of [Ru(terpy)(bpy)Cl][PF₆].

[Chloro(2,2'-bipyridine- κN^1 , κN^1 ')(2,2':6':2''-terpyridine- κN^1 , κN^2 , κN^1 ')] ruthenium (II) hexafluorophosphate].

25 General Procedure H:

Terpyridylruthenium trichloride (Ru(terpy)Cl₃) (E. C. Constable *et al. New J. Chem.* 1992, 16, 855) (0.50 g, 1.13 mmol), bidentate ligand, L (one equivalent) and 4-ethylmorpholine (4 drops) were heated to reflux in methanol (100 mL) for 2 hours. The hot solution was filtered through celite and a saturated solution of NH₄PF₆ in 30 methanol was added to the filtrate. The volume was reduced to approximately one third the original volume at which time a precipitate formed. The crude product was

collected by filtration and purified either by re-crystallization from an MeCN/MeOH solution or by column chromatography on silica gel (7/1/0.5: MeCN/sat. $\text{KNO}_3/\text{H}_2\text{O}$).

Using General Procedure H:

Reaction of $\text{Ru}(\text{terpy})\text{Cl}_3$ (0.50 g, 1.13 mmol) and 2,2'-dipyridyl (0.18 g, 1.13 mmol) gave the desired product 0.27 g (35%) following purification by column chromatography on silica gel. ^1H NMR (CD_3CN) δ 6.94 (m, 1H), 7.26 (m, 3H), 7.66 (m, 3H), 7.86 (m, 2H), 7.94 (m, 1H), 8.06 (t, 1H, $J=7.8$ Hz), 8.26 (m, 2H), 8.36 (d, 2H, $J=8.1$ Hz), 8.47 (d, 2H, $J=7.8$ Hz), 8.59 (d, 1H, $J=8.2$ Hz), 10.20 (d, 1H, $J=5.8$ Hz). ^{13}C NMR (CD_3CN) δ 123.4, 124.23, 124.49, 124.57, 127.09, 127.90, 128.25, 134.73, 136.55, 137.54, 138.05, 153.13, 153.25, 153.49, 157.25, 159.01, 159.70, 159.75. Anal. Calcd. for $\text{C}_{25}\text{H}_{19}\text{N}_5\text{ClRuPF}_6 \cdot 0.2\text{NH}_4\text{PF}_6$: C, 42.68; H, 2.84; N, 10.35; Cl, 5.04. Found: C, 42.83; H, 2.61; N, 10.54; Cl, 4.91.

EXAMPLE 70.

15 AMD7054: Preparation of $[\text{Ru}(\text{terpy})(2\text{-pyridinethione})_2\text{Cl}][\text{PF}_6]$.
[Chlorobis(2(1*H*)-pyridinethione- κS^2)(2,2':6':2"-terpyridine- $\kappa\text{N}^1, \kappa\text{N}^2, \kappa\text{N}^1''$)
ruthenium (II) hexafluorophosphate].

Using General Procedure H:

20 Reaction of $\text{Ru}(\text{terpy})\text{Cl}_3$ (0.50 g, 1.13 mmol) and 2-mercaptopyridine (0.25 g, 2.27 mmol) gave the desired product (0.263g, 32%) after re-crystallization from MeCN/MeOH. ^1H NMR (CD_3CN) δ 6.94 (m, 2H), 7.11 (d, 1H, $J=7.8$ Hz), 7.26 (d, 1H, 5.5 Hz), 7.41 (m, 1H), 7.56 (m, 2H), 7.74 (m, 1H), 7.83 (m, 1H), 8.04-8.21 (m, 5H), 8.28-8.37 (m, 2H), 8.44-8.48 (m, 2H), 9.88 (d, 1H, $J=5.5$ Hz). ^{13}C NMR (CD_3CN) δ 122.04, 123.55, 123.79, 124.03, 124.13, 124.36, 124.60, 125.05, 128.12, 128.41, 137.08, 137.79, 138.29, 139.32, 139.40, 151.45, 152.90, 154.77, 155.61, 156.84, 158.80, 159.12, 159.16, 159.90, 163.65. Anal. Calcd. for $\text{C}_{25}\text{H}_{21}\text{N}_5\text{S}_2\text{ClRuPF}_6$: C, 40.74; H, 2.87; N, 9.50; S, 8.70; Cl, 4.81. Found: C, 40.82; H, 2.80; N, 9.39; S, 8.66; Cl, 4.88.

EXAMPLE 71.

AMD7055: Preparation of [Ru(terpy)(2-pyrimidinethione)₂Cl][PF₆].

[Chlorobis(2(1*H*)-pyrimidinethione- κS^2)(2,2':6':2"-terpyridine- $\kappa N^1, \kappa N^2, \kappa N^3$)ruthenium (II) hexafluorophosphate].

5

Using General Procedure H:

Reaction of Ru(terpy)Cl₃ (0.50 g, 1.13 mmol) and 2-mercaptopyrimidine (0.25 g, 2.28 mmol) gave the desired product (0.073g, 8.6%) following purification by column chromatography on silica gel.

10 ¹H NMR (CD₃CN) δ 6.99-7.05 (m, 2H), 7.43 (m, 1H), 7.55-7.60 (M, 2H), 7.81 (m, 1H), 8.10-8.23 (m, 5H), 8.35-8.39 (m, 2H), 8.47-8.50 (m, 2H), 8.87 (dd, 1H, *J*=4.7, 4.7 Hz), 9.95 (dd, 1H, *J*=5.9, 2.3 Hz). Anal. Calcd. for C₂₃H₁₉N₇S₂ClRuPF₆: C, 37.38; H, 2.59; N, 13.27; S, 8.68. Found: C, 38.27; H, 2.39; N, 13.75; S, 8.45.

15 EXAMPLE 72.

AMD7086: Preparation of [Ru(terpy)(S₂CNMe₂)Cl][PF₆].

[Chloro(dimethylcarbamodithioato- $\kappa S, \kappa S'$)(2,2':6':2"-terpyridine- $\kappa N^1, \kappa N^2, \kappa N^3$)ruthenium (III) hexafluorophosphate].

20 Ru(terpy)Cl₃ (0.50 g, 1.14 mmol) and N,N-dimethyldithiocarbamic acid sodium salt (Aldrich, 0.204 g, 1.14 mmol) were heated to reflux in methanol (100 mL) for 2 hours. The hot solution was filtered through celite and the volume of the filtrate was reduced to approximately one half the original volume. Addition of a saturated solution of NH₄PF₆ in methanol to the filtrate resulted in the formation of a precipitate, which was collected by filtration and purified by column chromatography on silica gel (MeCN/sat. KNO₃/H₂O: 7/1/0.5) to give the title compound (0.20g, 28%). Anal. Calcd. for C₁₈H₁₇N₄S₂ClRuPF₆: C, 34.05; H, 2.70; N, 8.82; S, 10.10. Found: C, 33.76; H, 2.80; N, 9.62; S, 9.95.

30 EXAMPLE 73.

AMD7036: Preparation of [Ru(bpy)₂Cl₂]²⁺·2H₂O

[Dichlorobis(2,2'-bipyridine- $\kappa N^1, \kappa N^1$) ruthenium (II) dihydrate].

Prepared according to literature procedures: B. Bosnich, F. P. Dwyer *Aust. J. Chem.* 1966, 19, 2229.

EXAMPLE 74.

5 AMD7037: Preparation of $[\text{Ru}(\text{phen})_2\text{Cl}_2]\cdot 2\text{H}_2\text{O}$
[Dichlorobis(1,10-phenanthroline- $\kappa N^1, \kappa N^{10}$) ruthenium (II) dihydrate].

Prepared according to literature procedures: B. Bosnich, F. P. Dwyer *Aust. J. Chem.* 1966, 19, 2229.

10

EXAMPLE 75.

AMD7039: Preparation of $[\text{Ru}(\text{bpy})_2(2\text{-mercaptopypyridine})][\text{ClO}_4]$.
[Bis(2,2'-bipyridine- $\kappa N^1, \kappa N^{1'}$)(2(1H)-pyridinethionato- $\kappa N^1, \kappa S^2$) ruthenium (II)].
Perchlorate.

15

Prepared according to literature procedures: B. Kumar Santra, M. Menon, C. Kumar Pal, G. Kumar Lahiri *J. Chem. Soc., Dalton Trans.* 1997, 1387.

EXAMPLE 76.

AMD7045: Preparation of $[\text{Ru}(\text{bpy})_2(2\text{-mercaptopypyridine})][\text{PF}_6]$.
20 [Bis(2,2'-bipyridine- $\kappa N^1, \kappa N^{1'}$)(2(1H)-pyridinethionato- $\kappa N^1, \kappa S^2$) ruthenium (II)
hexafluorophosphate].

[$[\text{Ru}(\text{bpy})_2\text{Cl}_2]\cdot 2\text{H}_2\text{O}$ (1.0 g, 1.9 mmol) was dissolved in a 1:1 mixture of methanol water (100 mL). 2-Mercaptopyridine was added to the solution and the reaction mixture was heated to reflux for 1.5 hours. The solution was cooled to room temperature and a saturated solution of NH_4PF_6 in methanol was added. Upon standing a dark purple precipitate formed which was removed by filtration and washed with water. This crude product was purified by column chromatography on silica gel (2:1 w CHCl_3MeCN) to give the title compound (0.92 g, 72%). ^1H NMR (CD₃CN) δ 6.58-6.27 (m, 1H), 6.76 (d, 1H, $J=8.16\text{Hz}$), 7.00-7.02 (m, 1H), 7.13-7.17 (m, 1H), 7.19-7.23 (m, 1H), 7.29-7.34 (m, 1H), 7.55-7.60 (m, 1H), 7.67-7.89 (m, 5H), 8.04 (t, 2H, $J=7.9\text{ Hz}$), 8.25 (d, 1H, $J=5.2\text{ Hz}$), 8.36 (t, 2H, $J=8.2\text{ Hz}$), 8.46 (t, 2H,

J=7.3 Hz), 9.84-9.86 (m, 1H). Anal. Calcd. for C₂₅H₂₀N₅SRuPF₆: C, 44.91; H, 3.02; N, 10.48; S, 4.80. Found: C, 44.88; H, 3.02; N, 10.58; S, 4.71.

EXAMPLE 77.

5 **AMD8657:** Synthesis of [Ru(acac)₂(MeCN)₂][CF₃SO₃].
[Bis(acetonitrile)bis(2,4-pentanedionato- κ O, κ O') ruthenium (III)
trifluoromethanesulfonate].

General Procedure I:

10 This synthesis was adapted from a literature procedure: Oomura, K.; Ooyama, D.; Satoh, Y.; Nagao, N.; Nagao, H.; Howell, M.; Mukaida, M. *Inorg. Chim. Acta* 1998, 269, 342. In a schlenk tube, Ru(β -diketonato)₃ was dissolved in acetonitrile (~ 1 g/50 mL) and the mixture was stirred for 5 min at 65 °C to yield a orange/red/purple solution; Trifluoromethanesulfonic acid (1.1-4 equivalents) was then added dropwise.

15 Instantly, the solution became brown/green; a reflux condenser was then attached and the mixture was heated to reflux for 0.5-4 h. The final navy blue (Ru(III)) and/or orange/red/brown (Ru(II)) mixture was concentrated and purified by crystallization or column chromatography.

20 tris-(2,4-pentanedionato) ruthenium(III) [Ru(acac)₃] was Prepared according to procedure adapted from the literature: Johnson, A.; Everett, Jr., G. W. *J. Am. Chem. Soc.* 1972, 94, 1419.

Preparation of [Ru(acac)₂(MeCN)₂][CF₃SO₃]

Using General Procedure I:

25 Ru(acac)₃ (1.07 g, 2.68 mmol) was dissolved in acetonitrile (50 mL). Addition of Trifluoromethanesulfonic acid (300 μ L, 3.39 mmol) yielded the title complex after stirring for 1 h at reflux; crystallization from a 40:1 mixture of Et₂O:CH₂Cl₂ at 5 °C overnight yielded a dark blue, crystalline solid (1.42 g, 96 %). Anal. Calcd. for C₁₅H₂₀N₂O₇SF₃Ru·H₂O: C, 31.85; H, 3.91; N, 3.98. Found: C, 32.13; H, 3.87; N, 3.96. ES-MS *m/z* 382 [M-CF₃SO₃]⁺. IR (KBr) ν (cm⁻¹) 2326, 2296 (C≡N); 1524 (C=O).

EXAMPLE 78.

AMD8660: Synthesis of Ru(acac)₂(MeCN)₂.[Bis(acetonitrile)bis(2,4-pentanedionato- $\kappa O,\kappa O'$) ruthenium (II)].5 Preparation of Ru(acac)₂(MeCN)₂

[Ru(acac)₂(MeCN)₂][CF₃SO₃] (0.201 g, 0.378 mmol) was dissolved in EtOH (10 mL) to give a blue solution. Addition of Me₂NCS₂Na·2H₂O (0.076 g, 0.426 mmol) afforded an orange/brown solution immediately. The mixture was stirred at room temperature for 5 min and then the solvent was removed under reduced pressure. The orange/brown residue was purified by column chromatography on silica gel; 20:1 CH₂Cl₂:MeOH). The major orange band was collected in several fractions and the solvent removed under reduced pressure to yield a yellow/orange solid (0.094 g, 65 %). Anal. Calcd. for C₁₄H₂₀N₂O₄Ru·0.5C₂H₆O: C, 37.89; H, 5.18; N, 3.19. Found: C, 38.01; H, 4.99; N, 3.26. ES-MS *m/z* 382 [M+H]⁺. IR (KBr) ν (cm⁻¹) 2333, 1566 (C≡N); 1566 (C=O).

EXAMPLE 79.

AMD8892: Synthesis of [Ru(3Meacac)₃(MeCN)₂][CF₃SO₃].[Bis(acetonitrile)bis(3-methyl-2,4-pentanedionato- $\kappa O,\kappa O'$) ruthenium (III) trifluoromethanesulfonate].

tris-(3-methyl-2,4-pentanedionato) ruthenium(III) [Ru(3Meacac)₃] was prepared according to literature procedures: Endo, A.; Shimizu, K.; Satō, G. P. *Chem. Lett.* 1985, 581.

25 Preparation of [Ru(3Meacac)₃(MeCN)₂][CF₃SO₃]

Using General Procedure I:

Ru(3Meacac)₃ (0.522 g, 1.19 mmol) was dissolved in acetonitrile. Addition of Trifluoromethanesulfonic acid (115 μ L, 1.31 mmol) yielded the title complex after 1 h at reflux; crystallization from a 40:1 mixture of Et₂O:CH₂Cl₂ at 5 °C overnight 30 yielded a dark blue, crystalline solid (0.608 g, 92 %). Anal. Calcd. for C₁₇H₂₄N₂O₇SF₃Ru: C, 36.56; H, 4.33; N, 5.02; S, 5.74. Found: C, 36.29; H, 4.34; N, 5.04; S, 5.86. ES-MS *m/z* 410 [M-CF₃SO₃]⁺. IR (KBr) ν (cm⁻¹) 2316, 2296 (C≡N); 1535 (C=O).

EXAMPLE 80.

AMD8901: Synthesis of Ru(3Meacac)₂(MeCN)₂ [Bis(acetonitrile)bis(3-methyl-2,4-pentanedionato- κ O, κ O') ruthenium (II)].

5 *Preparation of Ru(3Meacac)₂(MeCN)₂*

[Ru(3Meacac)₂(MeCN)₂]*[CF₃SO₃]* (0.105 g, 0.188 mmol) was dissolved in acetonitrile (25 mL) to give a blue solution. Addition of zinc shavings (~ 12 g) followed by rapid stirring for 4 h at room temperature led to the formation of a bright orange solution. The zinc was removed by filtration, the solvent concentrated in vacuo and then the mixture was purified by column chromatography on silica gel; 20:1 CH₂Cl₂:MeOH). The major orange band was collected in several fractions and the solvent removed under reduced pressure to yield a bright orange solid (0.025 g, 32 %). Anal. Calcd. for C₁₆H₂₄N₂O₄Ru·0.1CH₂Cl₂: C, 46.27; H, 5.84; N, 6.70. Found: C, 46.00; H, 5.81; N, 6.43. ES-MS m/z 410 [M+H]⁺. IR (KBr) ν (cm⁻¹) 2336, 2248 (C≡N); 1555 (C=O).

15 EXAMPLE 81.

AMD8883 and AMD8884: Synthesis of Ru(3Clacac)₂(MeCN)₂ and [Ru(3Clacac)₂(MeCN)₂][CF₃SO₃]* [Bis(acetonitrile)bis(3-chloro-2,4-pentanedionato- κ O, κ O') ruthenium (II)] and [Bis(acetonitrile)bis(3-chloro-2,4-pentanedionato- κ O, κ O') ruthenium (III) trifluoromethanesulfonate].*

20

tris-(3-chloro-2,4-pentanedionato) ruthenium(III) [Ru(3Clacac)₃] was prepared according to literature procedure: Endo, A.; Shimizu, K.; Satō, G. P. *Chem. Lett.* 1985, 581.

25 *Preparation of Ru(3Clacac)₂(MeCN)₂ and [Ru(3Clacac)₂(MeCN)₂]*[CF₃SO₃]**
Using General Procedure I:

Ru(3Clacac)₃ (0.375 g, 0.745 mmol) was dissolved in acetonitrile (25 mL). Trifluoromethanesulfonic acid (220 μ L, 2.48 mmol) was added and the mixture was heated to reflux for 1 h; purification by column chromatography on silica gel (20:1 CH₂Cl₂:MeOH) resulted in the isolation of two major bands (orange and blue). The fractions containing the orange band were concentrated to ~ 5 mL and hexanes were added to give a bright orange precipitate of Ru(II)(3Clacac)₂(MeCN)₂ which was isolated via suction filtration (0.085 g, 25 %). Anal. Calcd. for C₁₄H₁₈N₂O₄Cl₂Ru·0.4CH₂Cl₂: C, 35.64; H, 3.91; N, 5.76; Cl, 20.72. Found: C, 35.91; H, 4.07; N, 5.61; Cl, 21.00. ES-MS m/z 452 [M+H]⁺. IR (KBr) ν (cm⁻¹) 2335, 2261 (C≡N); 1543 (C=O).

The fractions containing the blue band were concentrated and the dark blue product was crystallized from a 40:1 mixture of Et₂O:CH₂Cl₂ at 5 °C overnight to

give $[\text{Ru(III)}(\text{3Clacac})_2(\text{MeCN})_2][\text{CF}_3\text{SO}_3]$ (0.155 g, 35%). Anal. Calcd. for $\text{C}_{15}\text{H}_{18}\text{N}_2\text{O}_7\text{Cl}_2\text{SF}_3\text{Ru}\cdot 0.1\text{C}_4\text{H}_{10}\text{O}$: C, 30.48; H, 3.16; N, 4.62; S, 5.28; Cl, 11.69. Found: C, 30.56; H, 3.28; N, 4.77; S, 5.29; Cl, 11.70. ES-MS m/z 451 $[\text{M}-\text{CF}_3\text{SO}_3]^+$. IR (KBr) ν (cm^{-1}) 2326, 2298 (C≡N); 1532 (C=O).

5

EXAMPLE 82.

AMD8881: *Synthesis of $[\text{Ru}(\text{3Bracac})_2(\text{MeCN})_2][\text{CF}_3\text{SO}_3]$.*
[Bis(acetonitrile)bis(3-bromo-2,4-pentanedionato- $\kappa O,\kappa O'$) ruthenium (III) trifluoromethanesulfonate].

10

tris-(3-bromo-2,4-pentanedionato) ruthenium(III) $[\text{Ru}(\text{3Bracac})_3]$ was prepared according to literature procedures: Endo, A.; Shimizu, K.; Satô, G. P. *Chem. Lett.* 1985, 581.

Preparation of $[\text{Ru}(\text{3Bracac})_2(\text{MeCN})_2][\text{CF}_3\text{SO}_3]$

15 Using General Procedure I:

Ru(3Bracac)₃ (0.638 g, 1.00 mmol) was dissolved in acetonitrile (25 mL). Addition of Trifluoromethanesulfonic acid (265 μL , 2.99 mmol) yielded the title complex after 1 h at reflux; the mixture was purified by column chromatography on silica gel (20:1 $\text{CH}_2\text{Cl}_2:\text{MeOH}$) followed by crystallization from a 40:1 mixture of Et₂O:CH₂Cl₂ at 5 °C overnight, to give a dark blue crystalline solid (0.315 g, 46 %). Anal. Calcd. for $\text{C}_{15}\text{H}_{18}\text{N}_2\text{O}_7\text{Br}_2\text{SF}_3\text{Ru}\cdot 0.3\text{C}_4\text{H}_{10}\text{O}$: C, 27.39; H, 2.98; N, 3.94; S, 4.51. Found: C, 27.62; H, 2.69; N, 4.25; S, 4.70. ES-MS m/z 539 $[\text{M}-\text{CF}_3\text{SO}_3]^+$. IR (KBr) ν (cm^{-1}) 2326, 2299 (C≡N_{sym.}); 1522 (C=O).

25 EXAMPLE 83.

AMD8900: *Synthesis of $[\text{Ru}(\text{3Bracac})_2(\text{MeCN})_2]$.*
[Bis(acetonitrile)bis(3-bromo-2,4-pentanedionato- $\kappa O,\kappa O'$) ruthenium (II)].

Preparation of $[\text{Ru}(\text{3Bracac})_2(\text{MeCN})_2]$

30 [Ru(3Bracac)₂(MeCN)₂][CF₃SO₃] (0.350 g, 0.508 mmol) was dissolved in acetonitrile (50 mL) to give a blue solution. Addition of basic alumina (~ 15 g) followed by rapid stirring for 2 h at room temperature resulted in the formation of an orange/brown solution. The alumina was removed by filtration, the solvent concentrated under reduced pressure and the residue was purified by column chromatography on silica gel (20:1 $\text{CH}_2\text{Cl}_2:\text{MeOH}$). The major orange band was collected in several fractions and the solvent was removed under reduced pressure.

The orange residue was recrystallized from acetone:hexanes to yield a bright orange solid (0.115 g, 42 %). Anal. Calcd. for $C_{14}H_{18}N_2O_4Br_2Ru\cdot 0.3C_3H_6O$: C, 32.76; H, 3.72; N, 4.93; Br, 28.12. Found: C, 32.74; H, 3.74; N, 4.96; Br, 28.23. ES-MS m/z 540 $[M+H]^+$. IR (KBr) ν (cm^{-1}) 2340, 2263 (C≡N); 1530 (C=O).

5

EXAMPLE 84.

AMD8910 and AMD8896: Synthesis of $[Ru(3Iacac)(acac)(MeCN)_2][CF_3SO_3]$ and $[Ru(3Iacac)(MeCN)_4][CF_3SO_3]$.

[Bis(acetonitrile)(2,4-pentanedionato- $\kappa O,\kappa O'$)(3-iodo-2,4-pentanedionato- $\kappa O,\kappa O'$)
 10 ruthenium (III) trifluoromethanesulfonate] and
 [Tetrakis(acetonitrile)(3-iodo-2,4-pentanedionato- $\kappa O,\kappa O'$) ruthenium (II)
 trifluoromethanesulfonate].

tris-(3-iodo-2,4-pentanedionato) ruthenium(III) $[Ru(3Iacac)_3]$ was prepared according to literature
 15 procedures: Endo, A.; Shimizu, K.; Satō, G. P. *Chem. Lett.* 1985, 581.

Preparation of $[Ru(3Iacac)_2(MeCN)_2][CF_3SO_3]$ and $[Ru(3Iacac)(MeCN)_4][CF_3SO_3]$.

Using General Procedure I:

Ru(3Iacac)₃ (0.460 g, 0.593 mmol) was dissolved in acetonitrile (25 mL).
 20 Trifluoromethanesulfonic acid (60 μ L, 0.678 mmol) was added and the reaction was heated to reflux for 1 hour; the reaction mixture was purified by column chromatography on silica gel (15:1 $CH_2Cl_2:MeCN$) to give $[Ru(3Iacac)(acac)(MeCN)_2][CF_3SO_3]$ as a dark blue crystalline solid (0.089 g, 30 %). Anal. Calcd. for $C_{15}H_{19}N_2O_7ISF_3Ru$: C, 27.45; H, 2.92; N, 4.27; S, 4.88; I, 19.33. Found: C, 27.35; H, 3.00; N, 4.21; S, 4.91; I, 19.46. ES-MS m/z 508 $[M-CF_3SO_3]^+$. IR (KBr) ν (cm^{-1}) 2326, 2297, 2249 (C≡N), 1523 (C=O).

Repeating the above procedure with 4 equivalents of Trifluoromethanesulfonic acid followed by silica gel column purification and recrystallization of the product from acetone:hexanes gave $[Ru(3Iacac)(MeCN)_4][CF_3SO_3]$ as a grey/purple
 30 crystalline solid (0.125 g, 33 %). Anal. Calcd. for $C_{14}H_{18}N_4O_5ISF_3Ru\cdot 0.7 C_3H_6O$: C, 28.44; H, 3.29; N, 8.24; S, 4.71. Found: C, 28.12; H, 3.20; N, 8.02; S, 4.39. ES-MS m/z 491 $[M-CF_3SO_3]^+$. IR (KBr) ν (cm^{-1}) 2339, 2284 (C≡N), 1537 (C=O).

EXAMPLE 85.

AMD8691: Synthesis of [Ru(dpac)₂(MeCN)₂][CF₃SO₃].

[Bis(acetonitrile)bis(1,3-diphenyl-1,3-propanedionato- $\kappa O,\kappa O'$) ruthenium (III) trifluoromethanesulfonate].

5

tris-(1,3-diphenyl-1,3-propanedionato) ruthenium(III) [Ru(dpac)₃] was prepared according to procedures adapted from the literature: Endo, A.; Shimizu, K.; Satō, G. P.; Mukaida, M. *Chem. Lett.* 1984, 437.

10 Preparation of [Ru(dpac)₂(MeCN)₂][CF₃SO₃]

Using General Procedure I:

Ru(dpac)₃ (8.103 g, 10.5 mmol) was dissolved in acetonitrile (250 mL). Trifluoromethanesulfonic acid (2.5 mL, 28.2 mmol) was added and the reaction mixture was heated to reflux for 20 mins. The mixture was evaporated to dryness and 15 the residue was purified by column chromatography on silica gel (CH₂Cl₂ \rightarrow 20:1 CH₂Cl₂:MeOH). The fractions containing the dark green band were combined and evaporated to give a dark green crystalline solid (5.75 g, 70 %). Anal. Calcd. for C₃₅H₂₈N₂O₇SF₃Ru·0.4H₂O: C, 53.49; H, 3.69; N, 3.56; S, 4.08. Found: C, 53.45; H, 3.74; N, 3.43; S, 3.97. ES-MS *m/z* 630 [M-CF₃SO₃]⁺. IR (KBr) ν (cm⁻¹) 2363, 2337 20 (C≡N); 1523 (C=O).

EXAMPLE 86.

AMD8692: Synthesis of Ru(dpac)₂(MeCN)₂

[Bis(acetonitrile)bis(1,3-diphenyl-1,3-propanedionato- $\kappa O,\kappa O'$) ruthenium (II)].

25

Preparation of Ru(dpac)₂(MeCN)₂

[Ru(dpac)₂(MeCN)₂][CF₃SO₃] (0.225 g, 0.289 mmol) was dissolved in CH₂Cl₂ (25 mL) to give a green solution. Addition of basic alumina (~ 10 g) resulted in an instant colour change to orange. The mixture was stirred for 30 min at room 30 temperature, the alumina was removed by filtration and the filtrate was evaporated to dryness to yield a bright orange solid (0.045 g, 25 %). Anal. Calcd. for C₃₀H₂₈N₂O₄Ru·0.5H₂O: C, 64.01; H, 4.57; N, 4.39. Found: C, 64.02; H, 4.58; N, 4.19. ES-MS *m/z* 630 [M+H]⁺. IR (KBr) ν (cm⁻¹) 2339, 2258 (C≡N), 1516 (C=O).

EXAMPLE 87.

AMD8707: Synthesis of [Ru(hmac)₂(MeCN)₂][CF₃SO₃].

[Bis(acetonitrile)bis(2,2,6,6-tetramethyl-3,5-heptanedionato- κ O, κ O') ruthenium (III) trifluoromethanesulfonate].

5

tris-(2,2,6,6-tetramethyl-3,5-heptanedionato) ruthenium(III) [Ru(hmac)₃] was prepared according to literature procedures: Endo, A.; Katjitan, M.; Mukaida, M.; Shimizu, K.; Satô, G. P. *Inorg. Chim. Acta* 1988, 150, 25.

10 Preparation of [Ru(hmac)₂(MeCN)₂][CF₃SO₃]

Using General Procedure I:

Ru(hmac)₃ (0.145 g, 0.207 mmol) was dissolved in acetonitrile (10 mL). Trifluoromethanesulfonic acid (40 μ L, 0.452 mmol) was added and the mixture was heated to reflux for 30 mins. The mixture was evaporated to dryness and the residue 15 was purified by column chromatography on silica gel (CH₂Cl₂: hexanes 1:1 followed by 20:1 CH₂Cl₂:MeOH). The fractions containing the blue band were combined and evaporated to give a dark blue crystalline solid (0.104 g, 67 %). Anal. Calcd. for C₂₇H₄₄N₂O₇SF₃Ru·1.6CH₄O: C, 45.79; H, 6.78; N, 3.73. Found: C, 45.86; H, 6.62; N, 3.34. ES-MS *m/z* 550 [M-CF₃SO₃]⁺. IR (KBr) ν (cm⁻¹) 2326, 2297 (C≡N); 1529 20 (C=O).

EXAMPLE 88.

AMD8658: Synthesis of Ru(hfac)₂(MeCN)₂

[Bis(acetonitrile)bis(1,1,1,5,5-hexafluoro-2,4-pentanedionato- κ O, κ O') ruthenium (II)].

tris-(1,1,1,5,5-hexafluoro-2,4-pentanedionato) ruthenium(III) [Ru(hfac)₃]. The ruthenate complex, K[Ru(hfac)₃], was isolated and then oxidized to Ru(hfac)₃ according to a literature procedure: Endo, A.; Katjitan, M.; Mukaida, M.; Shimizu, 30 K.; Satô, G. P. *Inorg. Chim. Acta* 1988, 150, 25.

Preparation of Ru(hfac)₂(MeCN)₂

Using General Procedure I:

Ru(hfac)₃ (4.00 g, 5.54 mmol) was dissolved in acetonitrile (200 mL). Trifluoromethanesulfonic acid (865 μ L, 6.06 mmol) was added and the mixture was heated to reflux for 1 hour. The solvent was evaporated and the residue was purified by column chromatography on silica gel (CH₂Cl₂) to give a brown/black crystalline 5 solid (2.71 g, 95 %). Anal. Calcd. for C₁₄H₈N₂O₄F₁₂Ru: C, 28.15; H, 1.35; N, 4.69. Found: C, 28.35; H, 1.33; N, 4.62. ES-MS *m/z* 598 [M+H]⁺. IR (KBr) ν (cm⁻¹) 2357, 2285 (C≡N), 1546 (C=O).

EXAMPLE 89.

10 *AMD8693 and AMD8694: Synthesis of sym and asym-Ru(tfac)₂(MeCN)₂ [sym-Bis(acetonitrile)bis(1,1,1-trifluoro-2,4-pentanedionato- κ O, κ O') ruthenium (II)] and [asym-Bis(acetonitrile)bis(1,1,1-trifluoro-2,4-pentanedionato- κ O, κ O') ruthenium (II)].*

15 tris-(1,1,1-trifluoro-2,4-pentanedionato) ruthenium(III) [Ru(tfac)₃] was prepared according to literature procedures (a mixture of Δ and Λ -isomers isolated): Endo, A.; Katjitan, M.; Mukaida, M.; Shimizu, K.; Satô, G. P. *Inorg. Chim. Acta* 1988, 150, 25.

Synthesis of sym and asym-Ru(tfac)₂(MeCN)₂

20 Following General Procedure I:

A mixture of Δ and Λ -Ru(tfac)₃ (1.57 g, 2.80 mmol) in acetonitrile (100 mL). Trifluoromethanesulfonic acid (500 μ L, 3.50 mmol) was added and the mixture was heated to reflux for 4 hours during which time the solution turned purple/blue. Addition of basic alumina (~ 50 g) afforded an orange solution containing a mixture 25 of the title complexes. The alumina was removed via filtration and the filtrate was purified by column chromatography on silica gel (20:1 CH₂Cl₂:MeOH) to give three bands which eluted in the following order: *sym*-Ru(tfac)₂(MeCN)₂, *sym/asym*-Ru(tfac)₂(MeCN)₂ mixture and *asym*-Ru(tfac)₂(MeCN)₂. Each fraction was evaporated to dryness to give orange solids; the yields of each compound after 30 recrystallization from acetone/ hexanes were: 0.121 g, 0.319 g and 0.244 g, respectively, affording an overall yield of 48%. Both pure isomers have essentially identical analytical data. Anal. Calcd. for C₁₄H₁₄N₂O₄F₆Ru·1.3C₃H₆O: C, 38.11; H,

3.90; N, 4.95. Found: C, 38.29; H, 3.24; N, 4.97. ES-MS m/z 490 [M+H]⁺. IR (KBr) ν (cm⁻¹) 2345, 2270 (C≡N); 1591 (C=O).

EXAMPLE 90.

5 *AMD8730 and AMD8710: Synthesis of sym and asym-Ru(tftmac)₂(MeCN)₂ [sym-Bis(acetonitrile)bis(1,1,1-trifluoro-5,5-dimethyl-2,4-hexanedionato- κ O, κ O') ruthenium (II)] and [asym-Bis(acetonitrile)bis(1,1,1-trifluoro-5,5-dimethyl-2,4-hexanedionato- κ O, κ O') ruthenium (II)].*

10 tris-(1,1,1-trifluoro-5,5-dimethyl-2,4-hexanedionato) ruthenium(III) [Ru(tftmac)₃] was prepared according to literature procedure (a mixture of Δ and Λ -isomers isolated): Endo, A.; Katjitan, M.; Mukaida, M.; Shimizu, K.; Satô, G. P. *Inorg. Chim. Acta* **1988**, *150*, 25.

15 Preparation of sym and asym-Ru(tftmac)₂(MeCN)₂
Using General Procedure I:
A mixture of Δ and Λ -Ru(tftmac)₃ (1.30 g, 1.89 mmol) was dissolved in acetonitrile (100 mL). Trifluoromethanesulfonic acid (425 μ L, 2.97 mmol) was added 20 and the reaction mixture was heated to reflux for 3 hours during which time the solution turned purple. Addition of basic alumina (\sim 35 g) afforded an orange solution containing a mixture of the title complexes after stirring for 1.5 h at room temperature. The alumina was removed by filtration and the filtrate was purified by column chromatography on silica gel (CH₂Cl₂). Two compounds were isolated which eluted 25 in the order: *sym*-Ru(tftmac)₂(MeCN)₂ followed by *asym*-Ru(tftmac)₂(MeCN)₂. The fractions collected were evaporated to yield orange solids, which were recrystallized from acetone/ hexanes to give 0.098 g and 0.461 g, respectively, affording an overall yield of 64%. Both pure isomers have essentially identical analytical data. Anal. Calcd. for C₂₀H₂₆N₂O₄F₆Ru·0.5C₃H₆O: C, 42.86; H, 4.85; N, 4.65. Found: C, 42.93; H, 4.60; N, 4.77. ES-MS m/z 574 [M+H]⁺. IR (KBr) ν (cm⁻¹) 2330, 2268 (C≡N); 1591 (C=O).

EXAMPLE 91.

AMD8757: Synthesis of [Ru(maltol)₂(MeCN)₂][CF₃SO₃].
 [Bis(acetonitrile)bis[(3-hydroxy-κO)-2-methyl-4-pyronato-κO'] ruthenium (III)
 trifluoromethanesulfonate].

5

Preparation of [Ru(maltol)₂(MeCN)₂][CF₃SO₃]

Following General Procedure I:

Ru(maltol)₃ (0.210 g, 0.441 mmol) was dissolved in acetonitrile (20 mL).
 Trifluoromethanesulfonic acid (50 μL, 0.565 mmol) was added and the reaction
 10 mixture was heated to reflux for 3 hours. The mixture was evaporated and the residue
 was purified by column chromatography on silica gel (10:1 CH₂Cl₂: MeOH). The
 fractions containing the dark green band were combined and evaporated and the
 residue was then recrystallized from acetone/ hexanes to give a dark green crystalline
 solid (0.085 g, 35 %). Anal. Calcd. for C₁₇H₁₆N₂O₉SF₃Ru·0.4C₃H₆O: C, 36.09; H,
 15 3.06; N, 4.63. Found: C, 36.06; H, 3.09; N, 4.44. ES-MS *m/z* 434 [M-CF₃SO₃]⁺. IR
 (KBr) ν (cm⁻¹) 2322, 2289 (C≡N), 1602, 1548 (C=O).

EXAMPLE 92.

AMD8695 and AMD8696: Synthesis of [Ru(acac)₂(MeCN)₂(tmpd)][CF₃SO₃] and
[Ru(acac)₂(MeCN)₂(tmpd)][CF₃SO₃].
 [Bis(acetonitrile)bis[4-(hydroxy-κO)-3-penten-2-onato](N,N,N',N'-tetramethyl-1,3-
 propanediamine-κN,κN') ruthenium (III) trifluoromethanesulfonate] and
 [Bis(acetonitrile)bis[4-(hydroxy-κO)-3-penten-2-onato]bis(N,N,N',N'-tetramethyl-
 1,3-propanediamine-κN) ruthenium (III) trifluoromethanesulfonate].

25

General Procedure J

In a schlenk tube, [Ru(acac)₂(MeCN)₂][CF₃SO₃] was dissolved in CH₂Cl₂ to
 give a blue solution. Dropwise addition of an amine ligand, resulted in an immediate
 colour change to red/orange. The mixture was stirred at 40 °C for 0.5-3 h before the
 30 solvent was removed under reduced pressure and the red/brown residue was purified
 by column chromatography on silica gel. The amine ligands used included:
 N,N,N',N'-tetramethyl-1,3-propanediamine (tmpd), diethylenetriamine (dien), 2-(2-
 aminoethylamino)ethanol (aeae), N-(2-aminoethyl)-1,3-propanediamine (aepd), N-(3-
 aminopropyl)-1,3-propanediamine (appd), and L1.

35

Preparation of [Ru(acac)₂(MeCN)₂(tmpd)][CF₃SO₃] and [Ru(acac)₂(MeCN)₂(tmpd)₂][CF₃SO₃]

Using General Procedure J:

Addition of tmpd (135 μ L, 0.807 mmol) to a CH₂Cl₂ solution of [Ru(acac)₂(MeCN)₂][CF₃SO₃] (0.353 g, 0.665 mmol) afforded a red/orange solution after 1.5 hours. The mixture was purified by column chromatography on silica gel (20:1 CH₂Cl₂:MeOH) to give a red product and an orange product. The fractions from the red and orange bands were evaporated to give dark red (0.039 g, 9 %) and bright orange (0.069 g, 13 %) solids, respectively. The red solid was characterized as [Ru(acac)₂(MeCN)₂(tmpd)][CF₃SO₃]. Anal. Calcd. for C₂₂H₃₈N₄O₇·SF₃Ru·1.3CH₂Cl₂: C, 36.25; H, 5.30; N, 7.25. Found: C, 36.18; H, 5.29; N, 7.46. ES-MS *m/z* 512 [M-CF₃SO₃]⁺. IR (KBr) ν (cm⁻¹) 2361, 2340 (C≡N); 1620, 1524 (C=O). The orange solid was characterized as [Ru(acac)₂(MeCN)₂(tmpd)₂][CF₃SO₃]. Anal. Calcd. for C₂₉H₅₆N₆O₇·SF₃Ru·1.8CH₂Cl₂: C, 39.27; H, 6.38; N, 8.93. Found: C, 39.18; H, 6.39; N, 9.17. ES-MS *m/z* 642 [M-CF₃SO₃]⁺. IR (KBr) ν (cm⁻¹) 2300 (C≡N); 1624, 1608, 1548, 1521 (C=O).

EXAMPLE 93.

AMD8704 and AMD8705: Synthesis of *sym* and *asym*-[Ru(acac)₂(MeCN)₂(dien)][CF₃SO₃].

[Bis(acetonitrile)[*N,N'*-bis[2-(amino- κ N)ethyl]amine]bis[4-(hydroxy- κ O)-3-penten-2-onato] ruthenium (III) trifluoromethanesulfonate] and

[Bis(acetonitrile)[*N*-(2-aminoethyl)-1,2-ethanediamine- κ N, κ N']bis[4-(hydroxy- κ O)-3-penten-2-onato] ruthenium (III) trifluoromethanesulfonate].

25

Preparation of *sym* and *asym*-[Ru(acac)₂(MeCN)₂(dien)][CF₃SO₃]

Following General Procedure J:

Addition of dien (70 μ L, 0.613 mmol) to a CH₂Cl₂ solution of [Ru(acac)₂(MeCN)₂][CF₃SO₃] (0.325 g, 0.613 mmol) afforded a red/orange solution after 1 hour. The volume was reduced to 5 mL and Et₂O (~ 50 mL) was added to give an orange/brown precipitate which was removed via filtration. The brilliant orange filtrate was concentrated under reduced pressure and the residue was purified by

column chromatography on silica gel (20:1 → 12:1 CH₂Cl₂: MeOH). The first orange band afforded a bright orange solid (0.048 g, 12 %) whose characterisation data was consistent with the structure *asym*-[Ru(acac)₂(MeCN)₂(dien)][CF₃SO₃]. Anal. Calcd. for C₁₉H₃₃N₅O₇SF₃Ru: C, 36.02; H, 5.25; N, 11.05. Found: C, 35.75; H, 5.18; N, 10.78. ES-MS *m/z* 485 [M-CF₃SO₃]⁺. IR (KBr) ν (cm⁻¹) 1628, 1514 (C=O).

The second orange band afforded an orange solid (0.035 g, 9%) whose characterisation data was consistent with the structure *sym*-[Ru(acac)₂(MeCN)₂(dien)][CF₃SO₃]. Anal. Calcd. for C₁₉H₃₃N₅O₇SF₃Ru·3.6CHCl₃: C, 25.50; H, 3.46; N, 6.58. Found: C, 25.44; H, 3.75; N, 6.61. ES-MS *m/z* 485 [M-CF₃SO₃]⁺. IR (KBr) ν (cm⁻¹) 1624, 1521 (C=O).

EXAMPLE 94.

AMD8874: Synthesis of [Ru(acac)₂(MeCN)₂(aeae)][CF₃SO₃].
 [Bis(acetonitrile)[2-(2-amino- κ N-ethylamino- κ N')ethanol]bis[4-(hydroxy- κ O)-3-penten-2-onato] ruthenium (III) trifluoromethanesulfonate].

Synthesis of [Ru(acac)₂(MeCN)₂(aeae)][CF₃SO₃]

Using General Procedure J:

Addition of aeae (85 μ L, 0.841 mmol) to a CH₂Cl₂ solution of [Ru(acac)₂(MeCN)₂][CF₃SO₃] (0.391 g, 0.737 mmol) afforded a red/orange solution after 5 hours. The mixture was purified by column chromatography on silica gel (15:1 to 10:1 CH₂Cl₂: MeOH) to give a red/brown solid (0.127 g, 27%). Anal. Calcd. for C₁₉H₃₂N₄O₈SF₃Ru·1.2CF₃SO₃H·0.8H₂O: C, 29.26; H, 4.23; N, 6.76; S, 8.51. Found: C, 29.25; H, 4.01; N, 6.41; S, 8.40. ES-MS *m/z* 486 [M-CF₃SO₃]⁺. IR (KBr) ν (cm⁻¹) 2263 (C≡N), 1626, 1550, 1524 (C=O).

EXAMPLE 95.

AMD8878: Synthesis of [Ru(acac)₂(MeCN)₂(appd)][CF₃SO₃].
 [Bis(acetonitrile)[*N*-(3-aminopropyl)-1,3-propanediamine- κ N, κ N']bis[4-(hydroxy- κ O)-3-penten-2-onato] ruthenium (III) trifluoromethanesulfonate].

Preparation of [Ru(acac)₂(MeCN)₂(appd)][CF₃SO₃]

Using General Procedure J:

Addition of appd (110 μ L, 0.774 mmol) to a CH_2Cl_2 solution of $[\text{Ru}(\text{acac})_2(\text{MeCN})_2][\text{CF}_3\text{SO}_3]$ (0.373 g, 0.704 mmol) afforded a red/orange solution after 5 hours. The mixture was purified by column chromatography on silica gel (20:1 to 8:1 CH_2Cl_2 : MeOH) to give an orange solid (0.041 g, 9%). Anal. Calcd. for $\text{C}_{21}\text{H}_{37}\text{N}_5\text{O}_7\text{SF}_3\text{Ru}\cdot 0.4\text{CF}_3\text{SO}_3\text{H}\cdot 0.7\text{CH}_2\text{Cl}_2$: C, 33.98; H, 5.01; N, 8.97; S, 5.75. Found: C, 34.28; H, 4.97; N, 8.33; S, 5.89. ES-MS m/z 513 $[\text{M}-\text{CF}_3\text{SO}_3]^+$. IR (KBr) ν (cm^{-1}) 2335, 2289 (C≡N); 1626, 1551 (C=O).

10 EXAMPLE 96.

AMD8879: *Synthesis of $[\text{Ru}(\text{acac})_2(\text{MeCN})_2(\text{aepd})][\text{CF}_3\text{SO}_3]$.*
[Bis(acetonitrile)][N-(2-aminoethyl)-1,3-propanediamine- $\kappa\text{N},\kappa\text{N}'$]bis[4-(hydroxy- κO)-3-penten-2-onato] ruthenium (III) trifluoromethanesulfonate.

15 Preparation of $[\text{Ru}(\text{acac})_2(\text{MeCN})_2(\text{aepd})][\text{CF}_3\text{SO}_3]$

Following General Procedure J: .

Addition of aepd (100 μ L, 0.782 mmol) to a CH_2Cl_2 solution of $[\text{Ru}(\text{acac})_2(\text{MeCN})_2][\text{CF}_3\text{SO}_3]$ (0.377 g, 0.711 mmol) afforded a red/orange solution after 2 hours. The mixture was purified by column chromatography on silica gel (20:1 to 8:1 CH_2Cl_2 : MeOH) to give an orange solid (0.055 g, 12%). Anal. Calcd. for $\text{C}_{20}\text{H}_{35}\text{N}_5\text{O}_7\text{SF}_3\text{Ru}\cdot 0.4\text{H}_2\text{O}$: C, 36.68; H, 5.51; N, 10.69; S, 4.90. Found: C, 36.96; H, 5.38; N, 10.33; S, 4.85. ES-MS m/z 499 $[\text{M}-\text{CF}_3\text{SO}_3]^+$. IR (KBr) ν (cm^{-1}) 2367, 2334 (C≡N), 1624, 1550 (C=O).

25 EXAMPLE 97.

AMD8813: *Synthesis of $[\text{Ru}(\text{acac})_2(\text{MeCN})_2(\text{L1})][\text{CF}_3\text{SO}_3]$.*
[Bis(acetonitrile)][N,N-bis[2-(amino- κN)ethyl]-L-isoleucyl-L-prolinato]bis[4-(hydroxy- κO)-3-penten-2-onato] ruthenium (III) trifluoromethanesulfonate.

30 Synthesis of N,N-bis(2-aminoethyl)-Ile-Pro (L1)

To a solution of nosyl aziridine (0.744 g, 3.26 mmol) in dry THF (20 mL) was added the dipeptide Ile-Pro (0.372 g, 1.63 mmol). The white slurry was stirred for 16 h at 65 °C under N_2 resulting in a clear, yellow solution. The solvent was removed *in*

vacuo to give a yellow oil which was purified by column chromatography on silica gel (3:2 EtOAc:hexanes and then 25:1 CH₂Cl₂:MeOH) to give the desired intermediate as a pale yellow oil (0.377 g, 34 %). ¹H NMR (CDCl₃) δ 0.79 (t, 3H), 0.91 (d, 4H), 1.04 (m, 1H), 1.55 (m, 2H), 1.94 (m, 2H), 2.29 (dm, 1H), 2.79 (m, 2H), 3.35-3.56 (m, 8H), 5 4.27 (m, 1H), 4.34 (m, 1H), 6.13 (s, 1H), 6.34 (s, 1H), 7.71 (m, 6H), 8.04 (m, 2H); ¹³C NMR (CDCl₃) δ 11.63, 16.13, 24.79, 25.69, 29.26, 38.21, 42.75, 44.20, 47.29, 53.93, 59.69, 64.13, 65.07, 124.74, 125.62, 131.01, 133.47, 133.20, 133.62, 134.03, 134.34, 148.29, 172.31. ES-MS *m/z* 707 [M+Na]⁺, 685 [M+H]⁺.

To a solution of the oil from above (0.377 g, 0.550 mmol) in dry acetonitrile 10 (15 mL) was added K₂CO₃ (0.761 g, 5.50 mmol) and thiophenol (454 μL, 4.41 mmol). The mixture was stirred for 3.5 h at room temperature under nitrogen, during which time, a bright yellow slurry formed. The mixture was filtered and the solid was washed with acetonitrile. The combined filtrates were evaporated and the residue was purified by column chromatography on neutral alumina using 5:1 CH₂Cl₂: MeOH 15 followed by 7:2:1 CH₂Cl₂: MeOH: NH₄OH to give L1 as a pale yellow oil (0.085 g, 49 %). ES-MS *m/z* 337 [M+Na]⁺, 315 [M+H]⁺.

Preparation of [Ru(acac)₂(MeCN)₂(L1)][CF₃SO₃]

Using General Procedure J:

20 Addition of L1 (0.085 g, 0.271 mmol) to a CH₂Cl₂ solution of [Ru(acac)₂(MeCN)₂][CF₃SO₃] (0.126 g, 0.238 mmol) afforded a red/orange solution after the mixture was heated to reflux for 5 hours. The mixture was purified by column chromatography on silica gel (14:1 to 10:1 CH₂Cl₂:MeOH) to give a deep red solid (0.041 g, 25 %). Anal. Calcd. for C₃₀H₅₀N₆O₁₀SF₃Ru·3.6CH₂Cl₂: C, 35.07; H, 5.01; N, 7.30. Found: C, 35.11; H, 4.90; N, 7.05. ES-MS *m/z* 696 [M-CF₃SO₃]⁺. 25

EXAMPLE 98.

AMD8656: Synthesis of [Ru(acac)₂(S₂CNMe₂)].

[(Dimethylcarbamodithioato-κS,κS')bis(2,4-pentanedionato-κO,κO') ruthenium (III)].

30

General Procedure K:

In a schlenk tube, [Ru(β-diketonato)₂(MeCN)₂][CF₃SO₃] (where β-diketonato = acac or dpac) was dissolved in EtOH:H₂O (20:1) to give a blue or green solution.

Addition of a dithiocarbamate salt resulted in an immediate colour change to red/brown. The mixture was stirred at 70 °C for 4-16 h before the solvent was removed under vacuum and the red/brown residue was purified using column chromatography. The dithiocarbamate salts were either purchased from Aldrich 5 (NaS₂CNMe₂·2H₂O) or synthesized according to general procedure F (KS₂CNProK, KS₂CNProOMe, KS₂CNMeIleK).

Preparation of Ru(acac)₂(S₂CNMe₂)

10 Using General Procedure K:

Addition of NaS₂CNMe₂·2H₂O (0.101 g, 0.563 mmol) to a solution of [Ru(acac)₂(MeCN)₂][CF₃SO₃] (0.263 g, 0.496 mmol) in a mixture of ethanol and water gave an immediate colour change from blue to orange. The mixture was stirred at 70 °C for 5 h yielding a red/brown mixture which was purified by column 15 chromatography on silica gel (20:1 CH₂Cl₂: MeOH) to give a dark red solid upon drying *in vacuo* (0.092 g, 44 %). Anal. Calcd. for C₁₃H₂₀NO₄S₂Ru·0.5EtOH: C, 37.89; H, 5.18; N, 3.19. Found: C, 38.01; H, 4.99; N, 3.26. ES-MS *m/z* 443 [M+Na]⁺.

EXAMPLE 99.

20 *AMD8792: Synthesis of [Ru(dpac)₂(S₂CNMe₂)].*
[(Dimethylcarbamodithioato-κS,κS')bis(1,3-diphenyl-1,3-propanedionato-κO,κO')
ruthenium (III)].

Preparation of [Ru(dpac)₂(S₂CNMe₂)]

25 Using General Procedure K:

Addition of NaS₂CNMe₂·2H₂O (0.073 g, 0.409 mmol) to a solution of [Ru(dpac)₂(MeCN)₂][CF₃SO₃] (0.290 g, 0.372 mmol) in a mixture of ethanol and water gave an immediate colour change from green to red/orange. The mixture was stirred at 70 °C for 16 h to give a red/brown mixture which was evaporated and 30 purified by column chromatography on silica gel (5:1 CH₂Cl₂: hexanes) to give a deep red solid (0.025 g, 11 %). Anal. Calcd. for C₃₃H₂₈NO₄S₂Ru·0.3MeCN·0.4hexanes: C,

60.51; H, 4.87; N, 2.55; S, 8.97. Found: C, 60.25; H, 4.90; N, 2.38; S, 8.50. ES-MS *m/z* 650 [M+Na]⁺. IR (KBr) ν (cm⁻¹) 1514 (C=O).

EXAMPLE 100.

5 **AMD8822:** Synthesis of [Ru(acac)₂(S₂CNProOMe)].
 [(1-carboxymethyl)-1,4-butanediylcarbamodithioato- $\kappa S,\kappa S'$]bis(2,4-pentanedionato- $\kappa O,\kappa O'$) ruthenium (III).

10 **Preparation of [Ru(acac)₂(S₂CNProOMe)]**

Using General Procedure K:

Addition of KS₂CNProOMe (0.548 g, 2.24 mmol) to solution of [Ru(acac)₂(MeCN)₂][CF₃SO₃] (1.06 g, 2.00 mmol) in a mixture of ethanol and water gave an immediate colour change from blue to orange. The mixture was stirred at 70 15 °C for 4 h to give a red/orange mixture which was evaporated and the residue purified by column chromatography on silica gel (50:1 CH₂Cl₂: MeOH) to give a deep red solid (0.147 g, 13 %). Anal. Calcd. for C₁₇H₂₄NO₆S₂Ru: C, 40.55; H, 4.80; N, 2.78; S, 12.73. Found: C, 40.68; H, 4.82; N, 2.76; S, 12.60. ES-MS *m/z* 527 [M+Na]⁺, 505 [M+H]⁺. IR (KBr) ν (cm⁻¹) 1746 (CO₂Me), 1549 (C=O).

20 **EXAMPLE 101.**

AMD8823 and AMD8826: Synthesis of Ru(dpac)₂(S₂CNProOMe) and Ru(dpac)₂(Pro).
 [(1-carboxymethyl)-1,4-butanediylcarbamodithioato- $\kappa S,\kappa S'$]bis(1,3-diphenyl-1,3-25 propanedionato- $\kappa O,\kappa O'$) ruthenium (III) and
 [L-prolinato(1-)- $\kappa N,\kappa O$]bis(1,3-diphenyl-1,3-propanedionato- $\kappa O,\kappa O'$) ruthenium (III)

Synthesis of Ru(dpac)₂(S₂CNProOMe) and Ru(dpac)₂(Pro)

Using General Procedure K:

30 Reaction of KS₂CNProOMe (0.382 g, 2.24 mmol) with [Ru(dpac)₂(MeCN)₂][CF₃SO₃] (0.947 g, 1.22 mmol) in ethanol/water solution followed by purification of the reaction mixture by column chromatography on silica gel (50:1 CH₂Cl₂:MeOH) gave two products. A red solid whose characterisation data

was consistent with $[\text{Ru}(\text{dpac})_2(\text{S}_2\text{CNProOMe})]$ (0.065 g, 5%). Anal. Calcd. for $\text{C}_{37}\text{H}_{32}\text{NO}_6\text{S}_2\text{Ru}\cdot 0.3\text{dpac}\cdot 1.0\text{EtOH}$: C, 60.41; H, 4.81; N, 1.62; S, 7.41. Found: C, 60.48; H, 4.91; N, 1.80; S, 7.64. ES-MS m/z 752 $[\text{M}+\text{H}]^+$. IR (KBr) ν (cm^{-1}) 1746 (CO_2Me); 1587 (C=O). An orange/brown solid whose characterisation data were 5 consistent with $[\text{Ru}(\text{dpac})_2(\text{Pro})]$ (0.095 g, 18 %). Anal. Calcd. for $\text{C}_{35}\text{H}_{29}\text{NO}_6\text{Ru}$: C, 63.63; H, 4.42; N, 2.12. Found: C, 63.45; H, 4.43; N, 2.24. ES-MS m/z 661 $[\text{M}+\text{H}]^+$. IR (KBr) ν (cm^{-1}) 1667 (CO_2^-), 1586 (C=O).

EXAMPLE 102.

10 **AMD8736:** Synthesis of $[\text{Ru}(\text{acac})_2(\text{S}_2\text{CNProK})]$.

[Potassium[(1-carboxy)-1,4-butanediylcarbamodithioato- $\kappa\text{S},\kappa\text{S}'$]bis(2,4-pentanedionato- $\kappa\text{O},\kappa\text{O}'$) ruthenium (III)].

Preparation of $[\text{Ru}(\text{acac})_2(\text{S}_2\text{CNProK})]$

15 Using General Procedure K:

Reaction of KS_2CNProK (0.422 g, 1.58 mmol) with $[\text{Ru}(\text{acac})_2(\text{MeCN})_2][\text{CF}_3\text{SO}_3]$ (0.756 g, 1.42 mmol) gave a dark blue slurry. The mixture was stirred at reflux for 1 h giving a red/black mixture, which was evaporated to dryness. Sonication of the residue with CH_2Cl_2 gave a black solid, which was 20 removed via filtration. The filtrate was purified by column chromatography on silica gel (20:1 to 12:1 CH_2Cl_2 : MeOH) to give a deep red solid (0.105 g, 15 %). Anal. Calcd. for $\text{C}_{16}\text{H}_{21}\text{NO}_6\text{S}_2\text{RuK}\cdot 2.1\text{H}_2\text{O}\cdot 0.2\text{KCF}_3\text{SO}_3$: C, 32.26; H, 4.21; N, 2.32; S, 11.69. Found: C, 32.43; H, 4.25; N, 2.25; S, 11.66. ES-MS m/z 490 $[\text{M}+\text{H}]^+$. IR (KBr) ν (cm^{-1}) 1558 (C=O).

25

EXAMPLE 103.

AMD8791: Synthesis of $[\text{Ru}(\text{acac})_2(\text{NMelle})]$.

[N-methyl-L-isoleucinato(1-)- $\kappa\text{N},\kappa\text{O}$]bis(2,4-pentanedionato- $\kappa\text{O},\kappa\text{O}'$) ruthenium (III).

30

Preparation of $[\text{Ru}(\text{acac})_2(\text{NMelle})]$

Using General Procedure K:

Reaction of $\text{KS}_2\text{CNMelleK}$ (0.269 g, 0.903 mmol) with $[\text{Ru}(\text{acac})_2(\text{MeCN})_2][\text{CF}_3\text{SO}_3]$ (0.445 g, 0.839 mmol) in a mixture of ethanol and water gave an immediate colour change from blue to orange/brown. The mixture was stirred at 70 °C for 7 h giving a red/brown solution. The volume of the reaction mixture was reduced to ~3 mL and Et_2O was added to give a brown precipitate, which was separated by filtration. The filtrate was purified by column chromatography on silica gel (20:1 $\text{CH}_2\text{Cl}_2:\text{MeOH}$) to give an orange/brown solid (0.050 g, 12%). Anal. Calcd. for $\text{C}_{17}\text{H}_{27}\text{NO}_6\text{Ru}\cdot 0.2\text{C}_4\text{H}_{10}\text{O}$: C, 46.75; H, 6.39; N, 3.06. Found: C, 47.03; H, 6.16; N, 3.28. ES-MS m/z 465 $[\text{M}+\text{Na}]^+$, 443 $[\text{M}+\text{H}]^+$. IR (KBr) ν (cm^{-1}) 1670, 1560 10 (C=O).

EXAMPLE 104.

AMD8795: Synthesis of $[\text{Ru}(\text{acac})_2(\text{NMelle})]_2$
Bis[μ -[*N*-methyl-L-isoleucinato(1-)- $\kappa N:\kappa O$]]tetrakis(2,4-pentanedionato- $\kappa O,\kappa O'$) 15 diruthenium (III).

Preparation of $[\text{Ru}(\text{acac})_2(\text{NMelle})]_2$

$[\text{Ru}(\text{acac})_2(\text{MeCN})_2][\text{CF}_3\text{SO}_3]$ (0.270 g, 0.508 mmol) was dissolved in EtOH (6 mL) to give a dark blue solution. NMelle (0.084 g, 0.581 mmol) was added and the mixture was stirred at 75 °C for 16 h to give an orange solution. The solvent was removed under reduced pressure and the orange residue was purified by column chromatography on silica gel (20:1 $\text{CH}_2\text{Cl}_2:\text{MeOH}$) to give an orange solid (0.150 g, 67%). Anal. Calcd. for $\text{C}_{34}\text{H}_{56}\text{N}_2\text{O}_{12}\text{Ru}_2\cdot 0.3\text{C}_6\text{H}_{14}$: C, 47.11; H, 6.65; N, 3.07. Found: C, 47.21; H, 6.62; N, 3.08. ES-MS m/z 911 $[\text{M}+\text{Na}]^+$. IR (KBr) ν (cm^{-1}) 1649, 1552 25 (C=O).

EXAMPLE 105.

AMD8845: Synthesis of $[\text{Ru}(\text{dpac})_2(\text{Pro})]_2$
[Bis[μ -[L-prolinato(1-)- $\kappa N:\kappa O$]]tetrakis(1,3-diphenyl-1,3-propanedionato- $\kappa O,\kappa O'$)] 30 diruthenium (III)].

Preparation of $[\text{Ru}(\text{dpac})_2(\text{Pro})]_2$

[Ru(dpac)₂(MeCN)₂][CF₃SO₃] (0.493 g, 0.633 mmol) was dissolved in EtOH (8 mL) to give a dark green solution. (L)-Proline (0.078 g, 0.677 mmol) was added and the mixture was stirred at 75 °C for 16 h to give a brown/orange solution. The solvent was removed under reduced pressure and the brown residue was purified by 5 column chromatography on silica gel (50:1 CH₂Cl₂:MeOH) to give an orange/brown solid (0.035 g, 8%). Anal. Calcd. for C₇₀H₆₀N₂O₁₂Ru·0.4CH₂Cl₂: C, 62.43; H, 4.50; N, 2.06. Found: C, 62.44; H, 4.53; N, 1.98. ES-MS *m/z* 1345 [M+Na]⁺. IR (KBr) ν (cm⁻¹) 1666, 1522 (C=O).

10 EXAMPLE 106.

AMD8856: Synthesis of Ru(acac)₂(2-pyridine thiolato)(2-pyridinethione). [bis(2,4-pentanedionato- $\kappa O,\kappa O'$)[2(1*H*)-pyridinethionato- κS^2][2(1*H*)-pyridinethione- κS^2] ruthenium (III)].

15 Preparation of Ru(acac)₂(2MP).

[Ru(acac)₂(MeCN)₂][CF₃SO₃] (0.399 g, 0.751 mmol) was dissolved in EtOH (10 mL) to give a dark blue solution. 2-Mercaptopyridine (0.340 g, 3.06 mmol) was added and the mixture was stirred and heated at 75 °C for 5 h to give a red/purple solution. The solvent was removed under reduced pressure and the purple residue was 20 purified via preparative TLC on silica gel (20:1 CH₂Cl₂:MeOH) to give a purple solid (0.057 g, 14 %). Anal. Calcd. for C₂₀H₂₃N₂O₄S₂Ru: C, 46.14; H, 4.45; N, 5.38; S, 12.32. Found: C, 46.15; H, 4.48; N, 5.42; S, 12.23. ES-MS *m/z* 522 [M+H]⁺. IR (KBr) ν (cm⁻¹) 1545 (C=O), 1120 (C=S).

25 EXAMPLE 107.

AMD8857: Synthesis of Ru(acac)₂(η^2 -2-pyridinethiolato). [bis(2,4-pentanedionato- $\kappa O,\kappa O'$)[2(1*H*)-pyridinethionato- $\kappa N,\kappa S^2$] ruthenium (III)].

Preparation of [Ru(acac)₂(2MP)].

30 [Ru(acac)₂(MeCN)₂][CF₃SO₃] (0.292 g, 0.550 mmol) was dissolved in EtOH (10 mL) to give a dark blue solution. 2-Mercaptopyridine (0.065 g, 0.588 mmol) and KOH (0.036 g, 0.645 mmol) were added to give an instantaneous orange solution. The mixture was stirred at 80 °C for 4 h to give a turquoise solution. The solvent was

removed under reduced pressure and the blue residue was purified by column chromatography on silica gel (25:1 CH₂Cl₂: MeOH). A turquoise blue band was isolated which was further purified via preparative TLC to afford a blue solid (0.089 g, 40 %). Anal. Calcd. for C₁₅H₁₈NO₄SRu·0.3C₃H₆O: C, 44.74; H, 4.68; N, 3.28; S, 7.51. Found: C, 44.70; H, 4.55; N, 3.37; S, 7.51. ES-MS *m/z* 433 [M+Na]⁺, 411 [M+H]⁺. IR (KBr) ν (cm⁻¹) 1545 (C=O).

EXAMPLE 108.

AMD8865: Synthesis of [Ru(acac)₂(4ImP)₂][CF₃SO₃].
10 [bis(2,4-pentanedionato- κ O, κ O')bis[4-(1H-imidazol-1-yl- κ N³)phenol] ruthenium (III) trifluoromethanesulfonate].

Preparation of [Ru(acac)₂(4ImP)₂][CF₃SO₃]

[Ru(acac)₂(MeCN)₂][CF₃SO₃] (0.405 g, 0.550 mmol) was dissolved in EtOH (10 mL) to give a dark blue solution. 4-(Imidazol-1-yl)phenol (4ImP) (0.538 g, 3.36 mmol) was added and the mixture was stirred at 80 °C for 21 h to give a deep red solution. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel (20:1 CH₂Cl₂: MeOH) to give a red crystalline solid (0.203 g, 34 %). Anal. Calcd. for C₂₉H₃₀N₄O₉SF₃Ru: C, 45.31; H, 3.93; N, 7.29; S, 4.17. Found: C, 45.44; H, 4.11; N, 7.00; S, 3.88. ES-MS *m/z* 620 [M-CF₃SO₃]⁺. IR (KBr) ν (cm⁻¹) 1524 (C=O).

EXAMPLE 109.

AMD8873 and AMD8877: Synthesis of [Ru(dpac)₂(4ImP)(MeCN)][CF₃SO₃]·EtOH and [Ru(dpac)₂(4ImP)₂][CF₃SO₃].
25 [(Acetonitrile)bis(1,3-diphenyl-1,3-propanedionato- κ O, κ O')[4-(1H-imidazol-1-yl- κ N³)phenol] ruthenium (III) trifluoromethanesulfonate] and [bis(1,3-diphenyl-1,3-propanedionato- κ O, κ O')bis[4-(1H-imidazol-1-yl- κ N³)phenol] ruthenium (III) trifluoromethanesulfonate].

30

[Ru(dpac)₂(MeCN)₂][CF₃SO₃] (0.305 g, 0.341 mmol) was dissolved in EtOH (10 mL) to give a dark green solution. 4-(Imidazol-1-yl)phenol (0.327 g, 2.04 mmol)

was added and the mixture was stirred at 80 °C for 24 h to give a brown solution. The solvent was removed under reduced pressure and the brown residue was purified by column chromatography on silica gel (20:1 CH₂Cl₂:MeOH) to give two products: [Ru(dpac)₂(4ImP)₂][CF₃SO₃] as a brown solid (0.080 g, 25 %). Anal. Calcd. for 5 C₄₄H₃₉N₃O₉SF₃Ru: C, 55.99; H, 4.16; N, 4.45; S, 3.40. Found: C, 56.18; H, 4.25; N, 4.46; S, 3.16. ES-MS *m/z* 795 [M-CF₃SO₃]⁺. IR (KBr) ν (cm⁻¹) 2361 (C≡N), 1522 (C=O); and [Ru(dpac)₂(4ImP)(MeCN)][CF₃SO₃]:EtOH as a brown solid (0.085 g, 24 %). Anal. Calcd. for C₄₉H₃₈N₄O₉SF₃Ru·3.4C₉H₈N₂O: C, 61.22; H, 4.21; N, 9.69; S, 2.05. Found: C, 61.51; H, 4.44; N, 9.42; S, 1.87. ES-MS *m/z* 868 [M-CF₃SO₃]⁺. IR 10 (KBr) ν (cm⁻¹) 1522 (C=O).

EXAMPLE 110.

AMD8866: Synthesis of [Ru(acac)₂(ImProOMe)₂][CF₃SO₃].

[Bis[methyl-1-[(1*H*-imidazol-1-yl- κ N³)acetyl]-L-proline]bis(2,4-pentanedionato-15 κ O, κ O') ruthenium (III) trifluoromethanesulfonate].

Synthesis of the ligand: ImProOMe

N-(2-chloro)acetamido-(L)-proline methyl ester

20 Chloroacetic acid (0.674 g, 7.13 mmol) was dissolved in THF (40 mL) at 0 °C under nitrogen. N-Methylmorpholine (784 μ L, 7.18 mmol) was then added and the colourless mixture was stirred for 10 minutes *iso*-butylchloroformate (1.01 mL, 7.84 mmol) was added and the mixture was stirred for 30 min during which a white slurry was formed. The ice-bath was removed, and (L)-proline methyl ester (0.600 g, 4.65 mmol) and N-methylmorpholine (550 μ L, 5.04 mmol) were added. The reaction slurry was stirred at room temperature for 5.5 h and the resulting white precipitate was filtered off and washed with THF (3 x 5 mL). The combined filtrates were evaporated to dryness and the residue was purified by column chromatography on silica gel (22:1 CH₂Cl₂: MeOH) to give the title compound as a pale yellow oil (0.422 g, 44 %). ES-30 MS *m/z* 206 [M+H]⁺. ¹H NMR (CDCl₃) δ 1.96 (m, 2H), 2.14 (m, 2H), 3.56 (m, 2H), 3.63 (s, 3H), 3.96 (d, 2H, *J*=3.3 Hz), 4.42 (dd, 1H, *J*=8.5 Hz); ¹³C NMR (CDCl₃) δ 25.2, 29.5, 42.3, 47.4, 52.7, 59.7, 165.2, 172.5.

Preparation of ImProOMe

N-(2-chloro)acetamido-(L)-proline methyl ester (0.422 g, 2.05 mmol) was added to a suspension of sodium imidazolate (0.281 g, 3.12 mmol) in DMF (5 mL) at room temperature and the mixture was heated to 75 °C for a further 16 hours. The 5 reaction mixture was evaporated and the residue was purified by column chromatography on silica gel (20:1 CH₂Cl₂:MeOH) to give white crystalline solid (0.244 g, 50 %). ES-MS *m/z* 238 [M+H]⁺. ¹H NMR (CDCl₃) δ 1.83-2.11 (m, 4H), 3.34-3.46 (m, 2H), 3.54 (s, 3H), 4.33 (dd, 1H, *J*=8.4 Hz), 3.61 (s, 2H), 6.82 (s, 1H), 6.87 (s, 1H), 7.34 (s, 1H); ¹³C NMR (CDCl₃) δ 25.1, 29.2, 46.6, 48.8, 53.3, 59.5, 10 120.7, 129.3, 138.4, 165.5, 172.5.

Preparation of [Ru(acac)₂(ImProOMe)₂][CF₃SO₃]

[Ru(acac)₂(MeCN)₂][CF₃SO₃] (0.275 g, 0.518 mmol) was dissolved in EtOH (10 mL) to give a dark blue solution. ImProOMe (0.244 g, 1.08 mmol) was added and 15 the mixture was stirred and heated at 80 °C for 20 h to give a red/purple solution. The solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel (20:1 CH₂Cl₂:MeOH) to give a red solid (0.127 g, 32 %). Anal. Calcd. for C₃₃H₄₄N₆O₁₃SF₃Ru: C, 42.95; H, 4.81; N, 9.11; S, 3.47. Found: C, 43.06; H, 4.94; N, 8.83; S, 3.27. ES-MS *m/z* 774 [M-CF₃SO₃]⁺. IR (KBr) ν (cm⁻¹) 20 1670, 1522 (C=O).

EXAMPLE 111.

AMD8891: Synthesis of [Ru(acac)₂(histamine)(MeCN)][CF₃SO₃].
[(Acetonitrile)(4-ethylamino-1*H*-imidazol- κ N³)bis(2,4-pentanedionato- κ O, κ O') 25 ruthenium (III)].

Preparation of [Ru(acac)₂(histamine)(MeCN)][CF₃SO₃]

[Ru(acac)₂(MeCN)₂][CF₃SO₃] (0.338 g, 0.638 mmol) was dissolved in EtOH (10 mL) to give a dark blue solution. Histamine (0.083 g, 0.744 mmol) was added and 30 the mixture was stirred at 80 °C for 1 h and then at room temperature for 18 h to give a red/brown solution. The solvent was removed under reduced pressure and the brown residue was purified by column chromatography on silica gel (20:1 CH₂Cl₂: MeOH)

to give an orange solid (0.066 g, 17%). Anal. Calcd. for $C_{18}H_{26}N_4O_7SF_3Ru \cdot 0.9C_3H_6O$: C, 38.09; H, 4.85; N, 8.58; S, 4.91. Found: C, 38.15; H, 4.61; N, 8.41; S, 4.70. ES-MS m/z 452 [$M-CF_3SO_3$]⁺. IR (KBr) ν (cm⁻¹) 2291 (C≡N), 1670, 1547 (C=O).

5

EXAMPLE 112.

AMD8903: Preparation of [Ru(edtmp)].3H₂O.

A mixture of $K_2[RuCl_5(H_2O)]$ (0.35 g) and ethylenediaminetetraphosphonic acid, edtmp (0.40 g) in water (15 mL) was heated to reflux for one hour. The dark 10 solution was allowed to stand for 2 days then evaporated to approximately 3 mL. Methanol (~15 mL) was added resulting in the formation of green precipitate. The solid was collected by filtration and methanol was added to the filtrate to precipitate a yellow solid. The yellow solid was also collected by filtration, washed with ether and dried *in vacuo* to give the title compound (60 mg, 11%). Anal. Calcd. for 15 $C_6H_{23}N_2P_4O_{15}Ru$: C, 12.24; H, 3.95; N, 4.76. Found: C, 11.82; H, 3.43; N, 4.43.

EXAMPLE 113.

AMD6245: Preparation of [Ru(Hedta)]H₂O.

$K[Ru(Hedta)Cl] \cdot 2H_2O$ (16.0 g, 0.032 mmol) was heated to reflux in de-ionized 20 water (750 mL) for 2 hours. The volume of the solution was reduced to one half the original volume and the solution was seeded with approximately 2-3 mg $Ru(Hedta)(OH_2)$. Upon cooling a precipitate formed which was removed by filtration and washed with ice-cold water, ethanol and diethyl ether. The product was dried *in vacuo* at 40 °C overnight (10.0 g, 77%). Anal. Calcd. for $C_{10}H_{15}N_2O_9Ru$: C, 29.42; H, 3.70; N, 6.86; Cl, 0.0. Found: C, 29.34; H, 3.66; N, 6.92; Cl, 0.0. IR (CsI) ν (cm⁻¹) 3148 (OH); 1741 (CO₂H); 1651 (CO₂). (Mukaida *et al.*, *Nippon Kagaku Zasshi*, 86, 589 (1965))

EXAMPLE 114. Results on the inhibition of tumour growth by AMD6245 and 30 AMD6221

NO is important in controlling tumour growth and vascularisation (Thomsen *et al.*, *Cancer and Metastasis Rev.* 17 107-118, (1998); Jenkins *et al.*, *Proc. Natl. Acad. Sci. USA*, 92, 4392-4396, (1995); Edwards *et al.*, *J. Surg. Res.*, 63, 49-52, (1996)). Nitric oxide synthases have been shown to be expressed in numerous human and 35 rodent cancers including human gynecological cancers (Thomsen *et al.*, *Cancer Res.*,

54, 1352-1354, (1994), Thomsen *et al.*, *Biochem. Pharmacol.*, 56, 1365-1370, (1998)) and the stroma of human breast cancers (Thomsen *et al.*, *Br. J. Cancer*, 72, 41-44, (1995)), human lung cancer (Ambs *et al.*, *Br. J. Cancer*, 78, 233-239, (1998)), human colon cancer (Ambs *et al.*, *Cancer Res.*, 58, 334-341, (1998)), and rat colon 5 tumours (Takahashi *et al.*, *Cancer Res.*, 57, 1233-1237, (1997)). Nitric oxide is an active mediator of angiogenesis (growth of new blood vessels) (Fukumura *et al.*, *Cancer and Metastasis Rev.*, 17, 77-89, (1998); Ziche *et al.*, *J. Clin. Invest.*, 99, 2625-2634, (1997); Gallo *et al.*, *J. Natl. Cancer Inst.*, 90, 587-596(1998)). The establishment of an adequate blood supply is essential to the growth of solid tumours.

10 In addition nitric oxide has been shown to be important for the maintaining the vasodilatory tone of tumours (Tozer *et al.*, *Cancer Res.*, 57, 948-955, (1997)), regulating tumour blood flow (Tozer *et al.*, *Cancer Res.*, 57, 948-955, (1997), Doi *et al.*, *Cancer*, 77, 1598-1604, (1996)) and tumour oxygenation and energy status (Wood *et al.*, *Biochem. Biophys. Res. Commun.*, 192, 505-510, (1993)). The angiogenic 15 process is intimately linked with metastasis of solid tumours. Nitric oxide increased vascular permeability in tumour bearing mice, (Doi *et al.*, *Cancer*, 77, 1598-1604, (1996); Maeda *et al.*, *Jpn. J. Cancer Res.*, 85, 331-334, (1994); Wu *et al.*, *Cancer Res.*, 58, 159-165, (1998)) a prerequisite for metastasis. The inhibition of NO synthesis by a NOS inhibitor has been shown to inhibit an increase in metastases and 20 tumour size associated with increased NO production in the EMT-6 murine breast tumour (Edwards *et al.*, *J. Surg. Res.*, 63, 49-52, (1996)). Administration of a NOS inhibitors has been shown to inhibit the growth of experimental tumours *in vivo* (Kennovin *et al.*, in *Biology of Nitric Oxide*, Vol. 4, (S. Moncada, M. Feelisch, R. Busse, and A.E. Higgs, eds.), Portland Press, London, 1994, pp. 473-479), Thomsen 25 *et al.*, *Cancer Res.*, 57, 3300-3304, (1997)).

The effect of AMD6245 (Example 113) and AMD6221 (Example 8) on tumour growth was assessed using the rat P22 carcinosarcoma grown in BD-IX rats (Kennovin *et al.*, in *Biology of Nitric Oxide*, Vol. 4, (S. Moncada, M. Feelisch, R. Busse, and A.E. Higgs, eds.), Portland Press, London, 1994, pp. 473-479). The 30 tumour was implanted subcutaneously on the dorsal surface of male BD-IX rats on Day 0. Tumour growth was measured daily using calipers and tumour volume

calculated from the equation Volume = $(X^2.Y^2)\pi/6$ where X = the short tumour axis and Y = the long tumour axis. Tumours were measurable by Day 10. AMD6245 and AMD6221 were administered daily by intraperitoneal injection at a dose of 50 mg/kg from Day 10 – Day 28. Tumour vascularisation (Microvascular Density or MVD) was measured by Chalkley point counting after immunostaining with anti-CD31 antibody (Vermeulen *et al.*, *Eur. J. Cancer*, 32A, 2474-2484, (1996)). Nitrite/nitrate was measured by the Griess assay (see Table 4). These anions are the stable end products of NO in solution. Nitrate was first reduced to nitrite by nitrite reductase. The sum of nitrite and nitrate gives the total NO production.

AMD6245 and AMD6221 inhibited the growth of the P22 carcinosarcoma (Figure 3). Tumour vascularisation (MVD) was lower in tumours from AMD6245 treated animals (Mean Chalkey score = 3.0) and AMD6221 treated animals (Mean Chalkey score = 5.3) compared with untreated, control tumours (Mean Chalkey score = 13.0). Nitrite/nitrate levels at Day 28 were lower in AMD6245 treated animals (3.88 μ moles/litre plasma) and AMD6221 treated animals (5.09 μ moles/litre plasma), compared with untreated, control animals (7.75 μ moles/litre plasma). Therefore, AMD6245 and AMD6221 inhibited tumour growth. This was associated with a decrease in tumour blood supply and a decrease in plasma NO levels.

20

Table 4
Results are presented as net decrease in nitrite in the stimulated *in vitro* RAW264 cell culture supernatant as measured by the Griess assay.

AMD #	Δ Nitrite (μ M)	Conc ⁿ (μ M)	AMD #	Δ Nitrite (μ M)	Conc ⁿ (μ M)
7459	19.3	100	8884		
7460	21.4	100	8881		
8676	24.9	100	8900		
8679	38.5	100	8910		
8684			8896	34.5	50
7436	4.9	100	8691	25.3	50
8701	5.1	50	8692		
7494	12.2	100	8707		
7493	13	100	8658	5.1	25
8699	14.9	50	8693		

8677	3.6	50	8694	18.8	25
8893	6.6	25	8730		
8894			8710		
8711	4.4	50	8757	38.1	100
8702	5.2	100	8695		
8849	8.8	50	8696	26.4	100
7461	12.7	100	8704		
7462	7.8	100	8705	37.4	100
8672	15.2	100	8874	26.3	25
8641			8878		
8671	3.5	100	8879		
8670	43.4	50	8813		
8803			8656		
8842			8792		
8731	24	50	8822		
8802	28.9	25	8823		
8801	19	25	8826		
8682	23.9	50	8736	36.5	100
8800	18.6	50	8791		
8811	9.3	50	8795	39.1	25
7044	4.9	100	8845		
7054	15.9	100	8856		
7055	37.7	50	8857		
7086	14.8	25	8865	47.2	50
7036	7.3	100	8873		
7037	4.8	100	8877	15.3	25
7039	18.7	50	8866	15.3	25
7045	24	50	8891		
8657	39.4	50	6245	12.2	100
8660	40.4	100			
8892					
8901					
8883					

Typical result for AMD6221 is 37.6 μ M at 100 μ M, 250 μ M L-NMMA gives similar results to 100 μ M AMD6221. All compounds were tested at 100 μ M unless otherwise stated. The lower concentrations were used because of toxicity at 100 μ M.

Table 5
COMPOUND NAMES SUMMARY

AMD 7040	Dihydrogen chloro[[2,6-(pyridinyl- κN)methyl]bis[N-(carboxymethyl)glycinato- $\kappa N, \kappa O$]] ruthenium (III)
AMD 7043	Dihydrogen dichloro[[N,N'-1,2-ethanediyl]bis[(2-pyridinyl- κN)methylglycinato- κN]] ruthenium (III) chloride
AMD 7056	Aquachloro[[N-2-[(2-pyridinyl- κN)oxo-methyl]aminoethyl]((2-carboxy- κO)methyl)glycinato- $\kappa N, \kappa O$]] ruthenium (III)
AMD 7046	Hydrogen chloro[N-[bis((2-(carboxy- κO)methyl)imino- κN)ethyl]-(2-pyridinyl- κN)methylglycinato- κN]] ruthenium (III)
AMD 7087	Hydrogen aqua[N-bis((2-carboxy- κO)methyl)imino- κN]-1,2-phendiy(2-(carboxy- κO)methyl)glycinato- κN]] ruthenium (III)
AMD 7459	Dihydrogen chloro[[N,N'-[(phenylimethyl)imino- κN]-2,1-ethanediyl]bis[N-(carboxymethyl)glycinato- $\kappa N, \kappa O$]] ruthenium (III)
AMD 7460	Dihydrogen chloro[[N,N'-[(2-pyridinylmethyl)imino- κN]di-2,1-ethanediyl]bis[N-(carboxymethyl)glycinato- $\kappa N, \kappa O$]]] ruthenium (III)
AMD 8676	Dihydrogen [[N,N'-[(butylimino- κN)di-2,1-ethanediyl]bis[N-(carboxymethyl)glycinato- $\kappa N, \kappa O$]]]chloro ruthenium (III)
AMD 8679	Dihydrogen chloro[[N,N'-[(ethylimino- κN)di-2,1-ethanediyl]bis[N-(carboxymethyl)glycinato- $\kappa N, \kappa O$]]] ruthenium (III)
AMD 8684	Dihydrogen chloro[[N,N'-[(phenylimino- κN)di-2,1-ethanediyl]bis[N-(carboxymethyl)glycinato- $\kappa N, \kappa O$]]] ruthenium (III)
AMD 7436	[N-[2-[(carboxy- κO)methyl][(2-pyridinyl- κN)methyl]amino- κN]ethyl-N-[2-[(carboxymethyl][(2-pyridinyl- κN)methyl]amino- κN]ethyl]glycinato- κN]] ruthenium (III) bis(trifluoroacetate)
AMD 8701	Potassium dihydrogen dichloro[[N,N'-1,3-propanediylbis[N-(carboxymethyl)glycinato- $\kappa N, \kappa O$]]] ruthenium (III)
AMD 7494	Hydrogen aqua[6-[[[(carboxy- κO)methyl](carboxymethyl)amino- κN]methyl]-2-pyridinecarboxylato- $\kappa N^1, \kappa O^2$]chloro ruthenium (III)
AMD 7493	Hydrogen aqua[N-(carboxymethyl)-N-[[6-(hydroxymethyl)-2-pyridinyl- κN]methyl]glycinato- $\kappa N, \kappa O$]dichloro ruthenium (III)
AMD 8699	Aqua[N-(carboxy- κO)methyl]-N-[[6-[(phenylmethoxy)methyl]-2-pyridinyl- κN]methyl]glycinato- $\kappa N, \kappa O$]chloro ruthenium (III)
AMD 8677	Potassium chloro[methyl 3-[[2-[bis[(carboxy- κO)methyl]amino- κN]ethyl][(carboxy- κO)methyl]amino- κN]methyl]benzoato ruthenium (III)
AMD 8893	Aqua[N-[2-[bis[(carboxy- κO)methyl]amino- κN]ethyl]-N-[2-oxo-2-(1-pyrrolidinyl)ethyl]glycinato- $\kappa N, \kappa O$]] ruthenium (III)
AMD 8894	Potassium aqua[N-[2-[bis[(carboxy- κO)methyl]amino- κN]ethyl]-N-[(carboxy- κO)methyl]glycyl- κN -L-isoleucinato ruthenium (III)
AMD 8711	Hydrogen aqua[N-[2-[(carboxy- κO)methyl](carboxymethyl)amino- κN]ethyl]-N-(phenylmethyl)glycinato- $\kappa N, \kappa O$]chloro ruthenium (III)
AMD 8702	Dihydrogen aqua[3-[[[(carboxy- κO)methyl][2-[(carboxy- κO)methyl](carboxymethyl)amino- κN]ethyl]amino-

	κN [methyl]benzoato]chloro ruthenium (III)
AMD 8849	Aquachloro[[N,N'-1,2-ethanediylbis[N-[2-oxo-2-(1-pyrrolidinyl)ethyl]glycinato- κN , κO]]] ruthenium (III)
AMD 7461	Dihydrogen aqua[[N,N'-(2-hydroxy-1,3-propanediyl)bis[N-(carboxymethyl)glycinato- κN , κO]]](trifluoromethanesulfonato- κO) ruthenium (III)
AMD 7462	Potassium dichloro[[N,N'-1,2-ethanediylbis[glycinato- κN , κO]]] ruthenium (III)
AMD 8672	Chloro[octahydro-1H-1,4,7-triazonato- κN^1 , κN^4 , κN^7]bis[(sulfinyl- κS)bis[methane] ruthenium (II) chloride
AMD 8641	Trichloro[octahydro-1H-1,4,7-triazonine- κN^1 , κN^4 , κN^7] ruthenium (III)
AMD 8671	Trichloro[hexahydro-1,4,7-trimethyl-1,4,7-triazonine- κN^1 , κN^4 , κN^7] ruthenium (III)
AMD 8670	(Dimethylcarbamodithioato- κS)(dimethylcarbamodithioato- κS , $\kappa S'$)[octahydro-1H-1,4,7-triazonine- κN^1 , κN^4 , κN^7] ruthenium (III) hexafluorophosphate
AMD 8803	(Diethylcarbamodithioato- κS)(diethylcarbamodithioato- κS , $\kappa S'$)[octahydro-1H-1,4,7-triazonine- κN^1 , κN^4 , κN^7] ruthenium (III) hexafluorophosphate
AMD 8842	(1,4-butanediylcarbamodithioato- κS)(1,4-butanediylcarbamodithioato- κS , $\kappa S'$)[octahydro-1H-1,4,7-triazonine- κN^1 , κN^4 , κN^7] ruthenium (III) hexafluorophosphate
AMD 8731	Dihydrogen ((1-carboxy)-1,4-butanediylcarbamodithioato- κS)((1-carboxy)-1,4-butanediylcarbamodithioato- κS , $\kappa S'$)[octahydro-1H-1,4,7-triazonine- κN^1 , κN^4 , κN^7] ruthenium (III) hexafluorophosphate
AMD 8802	((1-carboxymethyl)-1,4-butanediylcarbamodithioato- κS)((1-carboxymethyl)-1,4-butanediylcarbamodithioato- κS , $\kappa S'$)[octahydro-1H-1,4,7-triazonine- κN^1 , κN^4 , κN^7] ruthenium (III) hexafluorophosphate
AMD 8801	Dihydrogen (N-methyl-N-sec-butylcarboxycarbamodithioato- κS)(N-methyl-N-sec-butylcarboxycarbamodithioato- κS , $\kappa S'$)[octahydro-1H-1,4,7-triazonine- κN^1 , κN^4 , κN^7] ruthenium (III) hexafluorophosphate
AMD 8682	(Dimethylcarbamodithioato- κS)(dimethylcarbamodithioato- κS , $\kappa S'$)[hexahydro-1,4,7-trimethyl-1,4,7-triazonine- κN^1 , κN^4 , κN^7] ruthenium (III) hexafluorophosphate
AMD 8800	[(N-(carboxy- κO)-methyl)-N-methylglycinato- κN , κO][octahydro-1H-1,4,7-triazonine- κN^1 , κN^4 , κN^7] ruthenium (III) hexafluorophosphate
AMD 8811	Hydrogen chloro[hexahydro-1,4,7-(tricarboxy- κO , $\kappa O'$ -methyl)-1,4,7-triazonine- κN^1 , κN^4 , κN^7] ruthenium (III)
AMD 7044	Chloro(2,2'-bipyridine- κN^1 , $\kappa N^1'$)(2,2':6'.2"-terpyridine- κN^1 , κN^2 , $\kappa N^1''$) ruthenium (II) hexafluorophosphate
AMD 7054	Chlorobis(2(1H)-pyridinethione- κS^2)(2,2':6'.2"-terpyridine- κN^1 , κN^2 , $\kappa N^1''$) ruthenium (II) hexafluorophosphate
AMD 7055	Chlorobis(2(1H)-pyrimidinethione- κS^2)(2,2':6'.2"-terpyridine- κN^1 , κN^2 , $\kappa N^1''$) ruthenium (II) hexafluorophosphate
AMD	Chloro(dimethylcarbamodithioato- κS , $\kappa S'$)(2,2':6'.2"-terpyridine-

7086	$\kappa N^1, \kappa N^2, \kappa N^{1''}$) ruthenium (III) hexafluorophosphate
AMD 7036	Dichlorobis(2,2'-bipyridine- $\kappa N^1, \kappa N^1$) ruthenium (II) dihydrate
AMD 7037	Dichlorobis(1,10-phenanthroline- $\kappa N^1, \kappa N^{10}$) ruthenium (II) dihydrate
AMD 7039	Bis(2,2'-bipyridine- $\kappa N^1, \kappa N^1$)(2(1 <i>H</i>)-pyridinethionato- $\kappa N^1, \kappa S^2$) ruthenium (II) perchlorate
AMD 7045	Bis(2,2'-bipyridine- $\kappa N^1, \kappa N^1$)(2(1 <i>H</i>)-pyridinethionato- $\kappa N^1, \kappa S^2$) ruthenium (II) hexafluorophosphate
AMD 8657	Bis(acetonitrile)bis(2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (III) trifluoromethanesulfonate
AMD 8660	Bis(acetonitrile)bis(2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (II)
AMD 8892	Bis(acetonitrile)bis(3-methyl-2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (III) trifluoromethanesulfonate
AMD 8901	Bis(acetonitrile)bis(3-methyl-2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (II)
AMD 8883	Bis(acetonitrile)bis(3-chloro-2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (II)
AMD 8884	Bis(acetonitrile)bis(3-chloro-2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (III) trifluoromethanesulfonate
AMD 8881	Bis(acetonitrile)bis(3-bromo-2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (III) trifluoromethanesulfonate
AMD 8900	Bis(acetonitrile)bis(3-bromo-2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (II)
AMD 8910	Bis(acetonitrile)(2,4-pentanedionato- $\kappa O, \kappa O'$)(3-iodo-2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (III) trifluoromethanesulfonate
AMD 8896	Tetrakis(acetonitrile)(3-iodo-2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (II) trifluoromethanesulfonate
AMD 8691	Bis(acetonitrile)bis(1,3-diphenyl-1,3-propanedionato- $\kappa O, \kappa O'$) ruthenium (III) trifluoromethanesulfonate
AMD 8692	Bis(acetonitrile)bis(1,3-diphenyl-1,3-propanedionato- $\kappa O, \kappa O'$) ruthenium (II)
AMD 8707	Bis(acetonitrile)bis(2,2,6,6-tetramethyl-3,5-heptanedionato- $\kappa O, \kappa O'$) ruthenium (III) trifluoromethanesulfonate
AMD 8658	Bis(acetonitrile)bis(1,1,1,5,5-hexafluoro-2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (II)
AMD 8693	<i>sym</i> -Bis(acetonitrile)bis(1,1,1-trifluoro-2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (II)
AMD 8694	<i>asym</i> -Bis(acetonitrile)bis(1,1,1-trifluoro-2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (II)
AMD 8730	<i>sym</i> -Bis(acetonitrile)bis(1,1,1-trifluoro-5,5-dimethyl-2,4-hexanedionato- $\kappa O, \kappa O'$) ruthenium (II)
AMD 8710	<i>asym</i> -Bis(acetonitrile)bis(1,1,1-trifluoro-5,5-dimethyl-2,4-hexanedionato- $\kappa O, \kappa O'$) ruthenium (II)
AMD	Bis(acetonitrile)bis[(3-hydroxy- κO)-2-methyl-4-pyronato- $\kappa O']$ ruthenium


8757	(III) trifluoromethanesulfonate
AMD 8695	Bis(acetonitrile)bis[4-(hydroxy- κO)-3-penten-2-onato](N,N,N',N' -tetramethyl-1,3-propanediamine- $\kappa N,\kappa N'$) ruthenium (III) trifluoromethanesulfonate
AMD 8696	Bis(acetonitrile)bis[4-(hydroxy- κO)-3-penten-2-onato]bis(N,N,N',N' -tetramethyl-1,3-propanediamine- κN) ruthenium (III) trifluoromethanesulfonate
AMD 8704	Bis(acetonitrile)[N,N' -bis[2-(amino- κN)ethyl]amine]bis[4-(hydroxy- κO)-3-penten-2-onato] ruthenium (III) trifluoromethanesulfonate
AMD 8705	Bis(acetonitrile)[N -(2-aminoethyl)-1,2-ethanediamine- $\kappa N,\kappa N'$]bis[4-(hydroxy- κO)-3-penten-2-onato] ruthenium (III) trifluoromethanesulfonate
AMD 8874	Bis(acetonitrile)[2-(2-amino- κN -ethylamino- $\kappa N'$)ethanol]bis[4-(hydroxy- κO)-3-penten-2-onato] ruthenium (III) trifluoromethanesulfonate
AMD 8878	Bis(acetonitrile)[N -(3-aminopropyl)-1,3-propanediamine- $\kappa N,\kappa N'$]bis[4-(hydroxy- κO)-3-penten-2-onato] ruthenium (III) trifluoromethanesulfonate
AMD 8879	Bis(acetonitrile)[N -(2-aminoethyl)-1,3-propanediamine- $\kappa N,\kappa N'$]bis[4-(hydroxy- κO)-3-penten-2-onato] ruthenium (III) trifluoromethanesulfonate
AMD 8813	Bis(acetonitrile)[N,N -bis[2-(amino- κN)ethyl]-L-isoleucyl-L-prolinato]bis[4-(hydroxy- κO)-3-penten-2-onato] ruthenium (III) trifluoromethanesulfonate
AMD 8656	(Dimethylcarbamodithioato- $\kappa S,\kappa S'$)bis(2,4-pentanedionato- $\kappa O,\kappa O'$) ruthenium (III)
AMD 8792	(Dimethylcarbamodithioato- $\kappa S,\kappa S'$)bis(1,3-diphenyl-1,3-propanedionato- $\kappa O,\kappa O'$) ruthenium (III)
AMD 8822	[(1-carboxymethyl)-1,4-butanediylcarbamodithioato- $\kappa S,\kappa S'$]bis(2,4-pentanedionato- $\kappa O,\kappa O'$) ruthenium (III)
AMD 8823	[(1-carboxymethyl)-1,4-butanediylcarbamodithioato- $\kappa S,\kappa S'$]bis(1,3-diphenyl-1,3-propanedionato- $\kappa O,\kappa O'$) ruthenium (III)
AMD 8826	[L-prolinato(1-)- $\kappa N,\kappa O$]bis(1,3-diphenyl-1,3-propanedionato- $\kappa O,\kappa O'$) ruthenium (III)
AMD 8736	Potassium[(1-carboxy)-1,4-butanediylcarbamodithioato- $\kappa S,\kappa S'$]bis(2,4-pentanedionato- $\kappa O,\kappa O'$) ruthenium (III)
AMD 8791	[N -methyl-L-isoleucinato(1-)- $\kappa N,\kappa O$]bis(2,4-pentanedionato- $\kappa O,\kappa O'$) ruthenium (III)
AMD 8795	Bis[μ -[N -methyl-L-isoleucinato(1-)- $\kappa N:\kappa O$]]tetrakis(2,4-pentanedionato- $\kappa O,\kappa O'$) diruthenium (III)
AMD 8845	Bis[μ -[L-prolinato(1-)- $\kappa N:\kappa O$]]tetrakis(1,3-diphenyl-1,3-propanedionato- $\kappa O,\kappa O'$) diruthenium (III)
AMD 8856	bis(2,4-pentanedionato- $\kappa O,\kappa O')$ [2(1 <i>H</i>)-pyridinethionato- κS^2][2(1 <i>H</i>)-pyridinethione- κS^2] ruthenium (III)
AMD 8857	bis(2,4-pentanedionato- $\kappa O,\kappa O')$ [2(1 <i>H</i>)-pyridinethionato- $\kappa N,\kappa S^2$] ruthenium (III)
AMD 8865	bis(2,4-pentanedionato- $\kappa O,\kappa O')$ bis[4-(1 <i>H</i> -imidazol-1-yl- κN^3)phenol] ruthenium (III) trifluoromethanesulfonate
AMD 8873	(Acetonitrile)bis(1,3-diphenyl-1,3-propanedionato- $\kappa O,\kappa O')$ [4-(1 <i>H</i> -imidazol-1-yl- κN^3)phenol] ruthenium (III) trifluoromethanesulfonate

- 100 -

AMD 8877	bis(1,3-diphenyl-1,3-propanedionato- κO , $\kappa O'$)bis[4-(1 <i>H</i> -imidazol-1-yl- κN^3)phenol] ruthenium (III) trifluoromethanesulfonate
AMD 8866	Bis[methyl-1-[(1 <i>H</i> -imidazol-1-yl- κN^3)acetyl]-L-proline]bis(2,4-pentanedionato- κO , $\kappa O'$) ruthenium (III) trifluoromethanesulfonate
AMD 8891	(Acetonitrile)(4-ethylamino-1 <i>H</i> -imidazol- κN^3)bis(2,4-pentanedionato- κO , $\kappa O'$) ruthenium (III)

Claims

1. A compound of the formula



5 wherein:

M is a metal ion or a mixture of metal ions;

X is a cation or a mixture of cations;

L is a ligand, or mixture of ligands each containing at least two different donor atoms selected from the elements of Group IV, Group V or Group VI of the Periodic

10 Table;

Y is a ligand or a mixture of the same or different ligands each containing at least one donor atom or more than one donor atom selected from the elements of Group IV, Group V or Group VI of the Periodic Table; and

15 Z is a halide or pseudohalide ion or a mixture of halide ions and pseudohalide ions; and

wherein: a=1-3; b=0-12; c=0-18; d=0-18; e=0-18; and n=0-10; provided that at least one of c, d and e is 1 or more;


wherein c is 0: b is also 0;

wherein a is 1: c, d and e are not greater than 9; and

20 wherein a is 2: c, d and e are not greater than 12;

including any pharmaceutically acceptable salts thereof and any stereoisomeric forms and mixtures of stereoisomeric forms thereof.

2. A neutral, anionic or cationic metal complex having at least one site for coordination with NO of Formula I:



useful in the manufacture of a medicament for the attenuation of NO levels and other reactive oxygen species when implicated in disease, where:

M is a metal ion or a mixture of metal ions;

30 X is a cation or a mixture of cations;

L is a ligand, or mixture of ligands each containing at least two different donor atoms selected from the elements of Group IV, Group V or Group VI of the Periodic

Table;

Y is a ligand or a mixture of the same or different ligands each containing at least one donor atom or more than one donor atom which donor atom is selected from the elements of Group IV, Group V or Group VI of the Periodic Table:

5 And

Z is a halide or pseudohalide ion or a mixture of halide ions and pseudohalide ions:

a=1-3; b=0-12; c=0-18; d=0-18; e=0-18; and n=0-10; provided that at least one of c, d and e is 1 or more.

10 And where c is 0: b is also 0;

And where a is 1: c, d and e are not greater than 9;


And where a is 2: c, d and e are not greater than 12.

3. The compound or composition of any one of claims 1, 6-10 or the
15 complex of claim 2, wherein M is a first, second or third row transition metal ion or is in oxidation state III or is selected from the group consisting of: Rh, Ru, Os, Mn, Co, Cr and Re.

4. The compound of claim 1 or the complex of claim 2, wherein X is a
20 mono-, di- or tri-valent cation or is selected from the group consisting of: H⁺, K⁺, Na⁺, NH₄⁺ and Ca²⁺.

5. The compound of claim 1 or the complex of claim 2, wherein L is selected from the group consisting of: tropolone; ethylenediamine-N,N'-diacetic acid
25 (edda), ethylenediaminetetraacetic acid (edta), nitrilotriacetic acid (nta), dipicolinic acid (dipic), picolinic acid (pic), diethylenetri-aminepentaacetic acid (dtpa), thiobis(ethylenenitrilo)tetraacetic acid (tedta), dithioethanebis(ethylenenitrilo)tetraacetic acid (dtedta), N-(2-hydroxethyl) ethylenediamine-triacetic acid (hedta), diamide of edta, diamide of dtpa, an amide or
30 ester derivative thereof or a mixture of any one of these or L^{II} is a polydentate aminocarboxylate ligand

6. A composition comprising an optionally hydrated ruthenium complex of Formula II:




where L^{II} a ligand or a mixture of the same or different ligands each selected

- 5 from the group consisting of: tropolone; ethylenediamine-N,N'-diacetic acid (edda), ethylenediaminetetraacetic acid (edta), nitrilotriacetic acid (nta), dipicolinic acid (dipic), picolinic acid (pic), diethylenetri-aminepentaacetic acid (dtpa), thiobis(ethylenenitrilo)tetraacetic acid (tedta), dithioethanebis(ethylenenitrilo)tetraacetic acid (dtedta), N-(2-hydroxethyl)
- 10 ethylenediamine-triacetic acid (hedtra), diamide of edta, diamide of dtpa, an amide or ester derivative thereof or a mixture of any one of these or L^{II} is a polydentate aminocarboxylate ligand;

Y is a ligand or a mixture of the same or different ligands each containing at least one donor atom or more than one donor atom which donor atom is selected from the elements of Group IV, Group V or Group VI of the Periodic Table; including any pharmaceutically acceptable salts thereof and any stereoisomeric forms and mixtures of stereoisomeric forms thereof.

7. A composition comprising an optionally hydrated ruthenium complex of Formula II:



where L^{II} a ligand or a mixture of the same or different ligands each selected from the group consisting of: tropolone; ethylenediamine-N,N'-diacetic acid (edda), ethylenediaminetetraacetic acid (edta), nitrilotriacetic acid (nta), dipicolinic acid (dipic), picolinic acid (pic), diethylenetri-aminepentaacetic acid (dtpa), thiobis(ethylenenitrilo)tetraacetic acid (tedta), dithioethanebis(ethylenenitrilo)tetraacetic acid (dtedta), N-(2-hydroxethyl) ethylenediamine-triacetic acid (hedtra), diamide of edta, diamide of dtpa, an amide or ester derivative thereof or a mixture of any one of these or L^{II} is a polydentate aminocarboxylate ligand;

Y is a ligand or a mixture of the same or different ligands each containing at least one donor atom or more than one donor atom which donor atom is selected from

the group consisting of: acetylacetone (acac) a β -diketonate; water; dimethylsulphoxide (dmso); carboxylate; bidentate carboxylate; catechol; kojiic acid; maltol; hydroxide; tropolone; malonic acid; oxalic acid; 2,3-dihydroxynaphthalene; squaric acid; acetate; a sulphate and a glycolate; and

5 including any pharmaceutically acceptable salts thereof and any stereoisomeric forms and mixtures of stereoisomeric forms thereof.

8. The composition of claim 6 or 7, selected from the group consisting of:

$K[Ru(Hedta)Cl]2H_2O$; $[Ru(H_2edta)(acac)]$; $K[Ru(hedtra)Cl]H_2O$;

10 $K[Ru(dipic)_2]H_2O$; $(H_2pic)[RuCl_2(pic)_2](Hpic)H_2O$; $K[Ru(H_2edta)Cl_2]H_2O$;

$K[Ru(Hnta)_2]\frac{1}{2}H_2O$; $K[Ru(H_2dtpa)Cl]H_2O$; $[Ru(Hhedtra)acac]H_2O$;

$[Ru(Hhedtra)trop]$; and $[Ru(H_3dtpa)Cl]$.

9. An optionally hydrated complex of the formula:

15 $[M_{1-3}Y_{1-18}Cl_{0-18}]^{(0-6)\pm}$ Formula III

wherein:

M is a metal ion or a mixture of metal ions;

Y is a ligand or a mixture of the same or different ligands each containing at

least one donor atom or more than one donor atom selected from the elements of

20 Group IV, Group V or Group VI of the Periodic Table.

10. The complex of claim 9, wherein Y is a sulphur donor ligand.

11. The complex of claim 9 or 10, wherein said complex is $[Ru(mtc)_3]$ or

25 $Ru(S_2CNCH_2CH_2NMeCH_2CH_2)_3\frac{1}{2}H_2O$, wherein mtc is 4-morpholinocarbodithioic acid.


12. An optionally hydrated complex of the formula:

$[M^{III}_{1-3}Y^{III}_{1-18}Cl_{0-18}]^{(0-6)\pm}$ Formula III

30 where M^{III} is ruthenium and Y^{III} is an oxygen-donor ligand, selected from the group consisting of: acetate, lactate, water, oxide, propionate (COEt), oxalate (ox), and maltol (maltol), and a combination thereof.

13. The complex of any one of claims 9-12, wherein said complex is selected from the group consisting of: $[\text{Ru}_3\text{O}(\text{OAc})_6](\text{OAc})$; $[\text{Ru}_3\text{O}(\text{lac})_6](\text{lac})$; $[\text{Ru}_2(\text{OAc})_4]\text{NO}_3$; $[\text{Ru}_2(\text{OCOEt})_4]\text{NO}_3$; $\text{K}_3[\text{Ru}(\text{ox})_3]$; $[\text{Ru}_2(\text{OAc})_4]\text{Cl}$; and
5 $[\text{Ru}(\text{mal tol})_3]$.

14. An optionally hydrated complex of the formula:



where Y^{IV} is a nitrogen-donor ligand.

10

15. The complex of claim 14, wherein Y^{IV} is selected from the group consisting of: ammine; ethylenediamine (en); pyridine (py); 1,10-phenanthroline (phen); 2,2-bipyridine (bipy) or 1,4,8,11-tetraazacyclotetradecane (cyclam); 1,4,7-triazacyclononane; 1,4,7-triazacyclononane tris acetic acid; 2,3,7,8,12,13,17,18-octaethylporphyrin (oep); and a combination thereof.

16. The complex of claim 14 or claim 15, wherein said complex is selected from the group consisting of: $[\text{Ru}(\text{H}_3\text{N})_5\text{Cl}]\text{Cl}_2$; $[\text{Ru}(\text{en})_3]\text{I}_3$; trans- $[\text{RuCl}_2(\text{py})_4]$; $\text{K}[\text{Ru}(\text{phen})\text{Cl}_4]$; $[\text{Ru}(\text{cyclam})\text{Cl}_2]\text{Cl}$; $\text{K}[\text{Ru}(\text{bipy})\text{Cl}_4]$; $[\text{Ru}(\text{NH}_3)_6]\text{Cl}_3$; 20 $[\text{Ru}(\text{NH}_3)_4\text{Cl}_2]\text{Cl}$; $\text{Ru}(\text{oep})\text{Ph}$; and any combination thereof.

17. An optionally hydrated complex of the formula:



where Y^{V} is a combination of donor ligands.

25

18. The complex of claim 17, wherein Y^{V} is selected from the group consisting of: ammine; dmso; oxalate; bipy; acac; methyl cyanide; and any combination thereof.

30

19. The complex of claim 17 or claim 18, wherein said complex is selected from the group consisting of: $[\text{Ru}(\text{NH}_3)(\text{dmso})_2\text{Cl}_3]$; cis- $[\text{Ru}(\text{dmso})_4\text{Cl}_2]$; cis-

[Ru(NH₃)(dmso)₃Cl₂]; [Ru(dmso)₃Cl₃]; [Os(ox)(bipy)₂]H₂O;
[Ru(acac)₂(MeCN)₂]CF₃SO₃; and combinations thereof.

20. A pharmaceutical composition comprising an optionally hydrated

5 complex of formula [Os(ox)(bipy)₂].

21. A pharmaceutical composition comprising an optionally hydrated

complex of formula [Ru(acac)₂(MeCN)₂]⁺.

10 22. An optionally hydrated complex selected from the group consisting of:

(a) AMD 7040, Dihydrogen chloro[[2,6-(pyridinyl- κ N)methyl]bis[N-(carboxymethyl)glycinato- κ N, κ O]] ruthenium (III);

(b) AMD 7043, Dihydrogen dichloro[[N,N'-1,2-ethanediyl]bis[(2-pyridinyl- κ N)methylglycinato- κ N] ruthenium (III) chloride;

(c) AMD 7056, Aquachloro[[N-2-[(2-pyridinyl- κ N)oxo-methyl]aminoethyl][((2-carboxy- κ O)methyl)glycinato- κ N, κ O]] ruthenium (III);

(d) AMD 7046, Hydrogen chloro[N-[bis((2-(carboxy- κ O)methyl)imino- κ N)ethyl]-(2-pyridinyl- κ N)methylglycinato- κ N] ruthenium (III);

(e) AMD 7087, Hydrogen aqua[N-bis((2-carboxy- κ O)methyl)imino- κ N]-1,2-phendiyi(2-(carboxy- κ O)methyl)glycinato- κ N] ruthenium (III);

25 (f) AMD 7459, Dihydrogen chloro[[N,N'-[[phenylmethyl)imino- κ N]-2,1-ethanediyl]bis[N-(carboxymethyl)glycinato- κ N, κ O]] ruthenium (III);

(g) AMD 7460, Dihydrogen chloro[[N,N'-[[[(2-pyridinyl)methyl)imino- κ N]di-2,1-ethanediyl]bis[N-(carboxymethyl)glycinato- κ N, κ O]]] ruthenium (III);

30 (h) AMD 8676, Dihydrogen [[N,N'-[(butylimino- κ N)di-2,1-ethanediyl]bis[N-(carboxymethyl)glycinato- κ N, κ O]]]chloro ruthenium (III);

(i) AMD 8679, Dihydrogen chloro[[N,N'-[(ethylimino- κ N)di-2,1-ethanediyl]bis[N-(carboxymethyl)glycinato- κ N, κ O]]] ruthenium (III);

35 (j) AMD 8684, Dihydrogen chloro[[N,N'-[(phenylimino- κ N)di-2,1-ethanediyl]bis[N-(carboxymethyl)glycinato- κ N, κ O]]] ruthenium (III);

(k) AMD 7436, $[N\text{-}[2\text{-[[carboxy-}\kappa O\text{)methyl]}[(2\text{-pyridinyl-}\kappa N\text{)methyl}]\text{amino-}\kappa N\text{]ethyl-}N\text{-}[2\text{-[(carboxymethyl)][(2\text{-pyridinyl-}\kappa N\text{)methyl}]\text{amino-}\kappa N\text{]ethyl}]\text{glycinato-}\kappa N\text{] ruthenium (III) bis(trifluoroacetate);}$

5 (l) AMD 8701, Potassium dihydrogen dichloro $[[N,N\text{'-1,3-propanediyl}]\text{bis}[N\text{-[(carboxymethyl)glycinato-}\kappa N,\kappa O\text{]]}]\text{ ruthenium (III);}$

(m) AMD 7494, Hydrogen aqua $[6\text{-[[[(carboxy-}\kappa O\text{)methyl]}(\text{carboxymethyl})\text{amino-}\kappa N\text{]methyl-}2\text{-pyridinecarboxylato-}\kappa N^1,\kappa O^2\text{]chloro ruthenium (III);}$

10 (n) AMD 7493, Hydrogen aqua $[N\text{-[(carboxymethyl)-}N\text{-[[6-(hydroxymethyl)-2\text{-pyridinyl-}\kappa N\text{]methyl}]\text{glycinato-}\kappa N,\kappa O\text{]dichloro ruthenium (III);}$

(o) AMD 8699, Aqua $[N\text{-[(carboxy-}\kappa O\text{)methyl]}-N\text{-[[6-[(phenylmethoxy)methyl-}2\text{-pyridinyl-}\kappa N\text{]methyl}]\text{glycinato-}\kappa N,\kappa O\text{]chloro ruthenium (III);}$

15 (p) AMD 8677, Potassium chloro $[\text{methyl 3-[[2-[bis[(carboxy-}\kappa O\text{)methyl]\text{amino-}\kappa N\text{]ethyl]}[(\text{carboxy-}\kappa O\text{)methyl}]\text{amino-}\kappa N\text{]methyl}]\text{benzoato ruthenium (III);}$

(q) AMD 8893, Aqua $[N\text{-[2-[bis[(carboxy-}\kappa O\text{)methyl]\text{amino-}\kappa N\text{]ethyl]}-N\text{-[2-oxo-2-(1-pyrrolidinyl)ethyl}]\text{glycinato-}\kappa N,\kappa O\text{] ruthenium (III);}$

20 (r) AMD 8894, Potassium aqua $[N\text{-[2-[bis[(carboxy-}\kappa O\text{)methyl]\text{amino-}\kappa N\text{]ethyl]}-N\text{-[(carboxy-}\kappa O\text{)methyl}]\text{glycyl-}\kappa N\text{-L-isoleucinato ruthenium (III);}$

25 (s) AMD 8711, Hydrogen aqua $[N\text{-[2-[[carboxy-}\kappa O\text{)methyl]}(\text{carboxymethyl})\text{amino-}\kappa N\text{]ethyl-}N\text{-[(phenylmethyl)glycinato-}\kappa N,\kappa O\text{]chloro ruthenium (III)}$

(t) AMD 8702, Dihydrogen aqua $[3\text{-[[[(carboxy-}\kappa O\text{)methyl]}[2\text{-[[carboxy-}\kappa O\text{)methyl]}(\text{carboxymethyl})\text{amino-}\kappa N\text{]ethyl}]\text{amino-}\kappa N\text{]methyl}]\text{benzoato}]\text{chloro ruthenium (III)}$

30 (u) AMD 8849, Aquachloro $[[N,N\text{'-1,2-ethanediyl}]\text{bis}[N\text{-[2-oxo-2-(1-pyrrolidinyl)ethyl}]\text{glycinato-}\kappa N,\kappa O\text{]]}]\text{ ruthenium (III);}$

(v) AMD 7461, Dihydrogen aqua $[[N,N\text{'-(2-hydroxy-1,3-propanediyl)}]\text{bis}[N\text{-[(carboxymethyl)glycinato-}\kappa N,\kappa O\text{]]}]\text{(trifluoromethanesulfonato-}\kappa O\text{) ruthenium (III)}$

35 (w) AMD 7462, Potassium dichloro $[[N,N\text{'-1,2-ethanediyl}]\text{bis}[N\text{-[(glycinato-}\kappa N,\kappa O\text{)]}]\text{ ruthenium (III)}$

(x) AMD 8672, Chloro $[\text{octahydro-1}H\text{-1,4,7-triazonato-}\kappa N^1,\kappa N^4,\kappa N^7\text{]bis[(sulfinyl-}\kappa S\text{)bis[methane}]\text{ ruthenium (II) chloride}$

40 (y) AMD 8641, Trichloro $[\text{octahydro-1}H\text{-1,4,7-triazonine-}\kappa N^1,\kappa N^4,\kappa N^7\text{] ruthenium (III)}$

(z) AMD 8671, Trichloro[hexahydro-1,4,7-trimethyl-1,4,7-triazonine- $\kappa N^1, \kappa N^4, \kappa N^7$] ruthenium (III)

5 (aa) AMD 8670, (Dimethylcarbamodithioato- κS)(dimethylcarbamodithioato- $\kappa S, \kappa S'$) [octahydro-1H-1,4,7-triazonine- $\kappa N^1, \kappa N^4, \kappa N^7$] ruthenium (III) hexafluorophosphate

(bb) AMD 8803, (Diethylcarbamodithioato- κS)(diethylcarbamodithioato- $\kappa S, \kappa S'$) [octahydro-1H-1,4,7-triazonine- $\kappa N^1, \kappa N^4, \kappa N^7$] ruthenium (III) hexafluorophosphate;

10 (cc) AMD 8842, (1,4-butanediylcarbamodithioato- κS)(1,4-butanediylcarbamodithioato- $\kappa S, \kappa S')$ [octahydro-1H-1,4,7-triazonine- $\kappa N^1, \kappa N^4, \kappa N^7$] ruthenium (III) hexafluorophosphate;

15 (dd) AMD 8731, Dihydrogen ((1-carboxy)-1,4-butanediylcarbamodithioato- κS)((1-carboxy)-1,4-butanediylcarbamodithioato- $\kappa S, \kappa S')$ [octahydro-1H-1,4,7-triazonine- $\kappa N^1, \kappa N^4, \kappa N^7$] ruthenium (III) hexafluorophosphate;

20 (ee) AMD 8802, ((1-carboxymethyl)-1,4-butanediylcarbamodithioato- κS)((1-carboxymethyl)-1,4-butanediylcarbamodithioato- $\kappa S, \kappa S')$ [octahydro-1H-1,4,7-triazonine- $\kappa N^1, \kappa N^4, \kappa N^7$] ruthenium (III) hexafluorophosphate;

25 (ff) AMD 8801, Dihydrogen (*N*-methyl-*N*-sec-butylcarboxycarbamodithioato- κS)(*N*-methyl-*N*-sec-butylcarboxycarbamodithioato- $\kappa S, \kappa S')$ [octahydro-1H-1,4,7-triazonine- $\kappa N^1, \kappa N^4, \kappa N^7$] ruthenium (III) hexafluorophosphate;

(gg) AMD 8682, (Dimethylcarbamodithioato- κS)(dimethylcarbamodithioato- $\kappa S, \kappa S')$ [hexahydro-1,4,7-trimethyl-1,4,7-triazonine- $\kappa N^1, \kappa N^4, \kappa N^7$] ruthenium (III) hexafluorophosphate;

30 (hh) AMD 8800, [(*N*-(carboxy- κO)-methyl)-*N*-methylglycinato- $\kappa N, \kappa O$][octahydro-1H-1,4,7-triazonine- $\kappa N^1, \kappa N^4, \kappa N^7$] ruthenium (III) hexafluorophosphate;

(ii) AMD 8811, Hydrogen chloro[hexahydro-1,4,7-(tricarboxy- $\kappa O, \kappa O'$ -methyl)-1,4,7-triazonine- $\kappa N^1, \kappa N^4, \kappa N^7$] ruthenium (III);

35 (jj) AMD 7044, Chloro(2,2'-bipyridine- $\kappa N^1, \kappa N^1')$ (2,2':6'.2"-terpyridine- $\kappa N^1, \kappa N^2, \kappa N^1")$ ruthenium (II) hexafluorophosphate;

(kk) AMD 7054, Chlorobis(2(1*H*)-pyridinethione- κS^2)(2,2':6'.2"-terpyridine- $\kappa N^1, \kappa N^2, \kappa N^1")$ ruthenium (II) hexafluorophosphate;

40 (ll) AMD 7055, Chlorobis(2(1*H*)-pyrimidinethione- κS^2)(2,2':6'.2"-terpyridine- $\kappa N^1, \kappa N^2, \kappa N^1")$ ruthenium (II) hexafluorophosphate;

45 (mm) AMD 7086, Chloro(dimethylcarbamodithioato- $\kappa S, \kappa S')$ (2,2':6'.2"-terpyridine- $\kappa N^1, \kappa N^2, \kappa N^1")$ ruthenium (III) hexafluorophosphate;

(nn) AMD 7036, Dichlorobis(2,2'-bipyridine- $\kappa N^1, \kappa N^1$) ruthenium (II) dihydrate;

5 (oo) AMD 7037, Dichlorobis(1,10-phenanthroline- $\kappa N^1, \kappa N^{10}$) ruthenium (II) dihydrate;

(pp) AMD 7039, Bis(2,2'-bipyridine- $\kappa N^1, \kappa N^1$)(2(1*H*)-pyridinethionato- $\kappa N^1, \kappa S^2$) ruthenium (II) perchlorate;

10 (qq) AMD 7045, Bis(2,2'-bipyridine- $\kappa N^1, \kappa N^1$)(2(1*H*)-pyridinethionato- $\kappa N^1, \kappa S^2$) ruthenium (II) hexafluorophosphate;

(rr) AMD 8657, Bis(acetonitrile)bis(2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (III) trifluoromethanesulfonate;

15 (ss) AMD 8660, Bis(acetonitrile)bis(2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (II);

(tt) AMD 8892, Bis(acetonitrile)bis(3-methyl-2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (III) trifluoromethanesulfonate;

20 (uu) AMD 8901, Bis(acetonitrile)bis(3-methyl-2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (II);

(vv) AMD 8883, Bis(acetonitrile)bis(3-chloro-2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (II);

25 (ww) AMD 8884, Bis(acetonitrile)bis(3-chloro-2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (III) trifluoromethanesulfonate;

(xx) AMD 8881, Bis(acetonitrile)bis(3-bromo-2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (III) trifluoromethanesulfonate;

30 (yy) AMD 8900, Bis(acetonitrile)bis(3-bromo-2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (II); and

35 (zz) AMD 8910, Bis(acetonitrile)(2,4-pentanedionato- $\kappa O, \kappa O'$)(3-iodo-2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (III) trifluoromethanesulfonate.

23. An optionally hydrated complex selected from the group consisting of:

40 (a) AMD 8896, Tetrakis(acetonitrile)(3-iodo-2,4-pentanedionato- $\kappa O, \kappa O'$) ruthenium (II) trifluoromethanesulfonate;

(b) AMD 8691, Bis(acetonitrile)bis(1,3-diphenyl-1,3-propanedionato- $\kappa O, \kappa O'$) ruthenium (III) trifluoromethanesulfonate;

45

(c) AMD 8692, Bis(acetonitrile)bis(1,3-diphenyl-1,3-propanedionato- $\kappa O,\kappa O'$) ruthenium (II);

5 (d) AMD 8707, Bis(acetonitrile)bis(2,2,6,6-tetramethyl-3,5-heptanedionato- $\kappa O,\kappa O'$) ruthenium (III) trifluoromethanesulfonate;

(e) AMD 8658, Bis(acetonitrile)bis(1,1,1,5,5-hexafluoro-2,4-pentanedionato- $\kappa O,\kappa O'$) ruthenium (II);

10 (f) AMD 8693, *sym*-Bis(acetonitrile)bis(1,1,1-trifluoro-2,4-pentanedionato- $\kappa O,\kappa O'$) ruthenium (II);

(g) AMD 8694, *asym*-Bis(acetonitrile)bis(1,1,1-trifluoro-2,4-pentanedionato- $\kappa O,\kappa O'$) ruthenium (II);

15 (h) AMD 8730, *sym*-Bis(acetonitrile)bis(1,1,1-trifluoro-5,5-dimethyl-2,4-hexanedionato- $\kappa O,\kappa O'$) ruthenium (II);

(i) AMD 8710, *asym*-Bis(acetonitrile)bis(1,1,1-trifluoro-5,5-dimethyl-2,4-hexanedionato- $\kappa O,\kappa O'$) ruthenium (II);

20 (j) AMD 8757, Bis(acetonitrile)bis[(3-hydroxy- κO)-2-methyl-4-pyronato- $\kappa O']$ ruthenium (III) trifluoromethanesulfonate;

25 (k) AMD 8695, Bis(acetonitrile)bis[4-(hydroxy- κO)-3-penten-2-onato](*N,N,N',N'*-tetramethyl-1,3-propanediamine- $\kappa N,\kappa N'$) ruthenium (III) trifluoromethanesulfonate;

(l) AMD 8696, Bis(acetonitrile)bis[4-(hydroxy- κO)-3-penten-2-onato]bis(*N,N,N',N'*-tetramethyl-1,3-propanediamine- κN) ruthenium (III) trifluoromethanesulfonate;

30 (m) AMD 8704, Bis(acetonitrile)[*N,N'*-bis[2-(amino- κN)ethyl]amine]bis[4-(hydroxy- κO)-3-penten-2-onato] ruthenium (III) trifluoromethanesulfonate;

(n) AMD 8705, Bis(acetonitrile)[*N*-(2-aminoethyl)-1,2-ethanediamine- $\kappa N,\kappa N'$]bis[4-(hydroxy- κO)-3-penten-2-onato] ruthenium (III) trifluoromethanesulfonate;

35 (o) AMD 8874, Bis(acetonitrile)[2-(2-amino- κN -ethylamino- $\kappa N'$)ethanol]bis[4-(hydroxy- κO)-3-penten-2-onato] ruthenium (III) trifluoromethanesulfonate;

40 (p) AMD 8878, Bis(acetonitrile)[*N*-(3-aminopropyl)-1,3-propanediamine- $\kappa N,\kappa N'$]bis[4-(hydroxy- κO)-3-penten-2-onato] ruthenium (III) trifluoromethanesulfonate;

45 (q) AMD 8879, Bis(acetonitrile)[*N*-(2-aminoethyl)-1,3-propanediamine- $\kappa N,\kappa N'$]bis[4-(hydroxy- κO)-3-penten-2-onato] ruthenium (III) trifluoromethanesulfonate;

5 (r) AMD 8813, Bis(acetonitrile)[*N,N*-bis[2-(amino- κN)ethyl]-L-isoleucyl-L-prolinato]bis[4-(hydroxy- κO)-3-penten-2-onato] ruthenium (III) trifluoromethanesulfonate;

10 (s) AMD 8656, (Dimethylcarbamodithioato- $\kappa S,\kappa S'$)bis(2,4-pantanediionato- $\kappa O,\kappa O'$) ruthenium (III);

(t) AMD 8792, (Dimethylcarbamodithioato- $\kappa S,\kappa S'$)bis(1,3-diphenyl-1,3-propanediionato- $\kappa O,\kappa O'$) ruthenium (III);

15 (u) AMD 8822, [(1-carboxymethyl)-1,4-butanediylcarbamodithioato- $\kappa S,\kappa S'$]bis(2,4-pantanediionato- $\kappa O,\kappa O'$) ruthenium (III);

(v) AMD 8823, [(1-carboxymethyl)-1,4-butanediylcarbamodithioato- $\kappa S,\kappa S'$]bis(1,3-diphenyl-1,3-propanediionato- $\kappa O,\kappa O'$) ruthenium (III);

20 (w) AMD 8826, [L-prolinato(1-)- $\kappa N,\kappa O$]bis(1,3-diphenyl-1,3-propanediionato- $\kappa O,\kappa O'$) ruthenium (III);

(x) AMD 8736, Potassium[(1-carboxy)-1,4-butanediylcarbamodithioato- $\kappa S,\kappa S'$]bis(2,4-pantanediionato- $\kappa O,\kappa O'$) ruthenium (III);

25 (y) AMD 8791, [*N*-methyl-L-isoleucinato(1-)- $\kappa N,\kappa O$]bis(2,4-pantanediionato- $\kappa O,\kappa O'$) ruthenium (III);

(z) AMD 8795, Bis[μ -[*N*-methyl-L-isoleucinato(1-)- $\kappa N:\kappa O$]]tetrakis(2,4-pantanediionato- $\kappa O,\kappa O'$) diruthenium (III);

30 (aa) AMD 8845, Bis[μ -[L-prolinato(1-)- $\kappa N:\kappa O$]]tetrakis(1,3-diphenyl-1,3-propanediionato- $\kappa O,\kappa O'$) diruthenium (III);

(bb) AMD 8856, bis(2,4-pantanediionato- $\kappa O,\kappa O'$)[2(1*H*)-pyridinethionato- κS^2][2(1*H*)-pyridinethione- κS^2] ruthenium (III);

35 (cc) AMD 8857, bis(2,4-pantanediionato- $\kappa O,\kappa O'$)[2(1*H*)-pyridinethionato- $\kappa N,\kappa S^2$] ruthenium (III);

(dd) AMD 8865, bis(2,4-pantanediionato- $\kappa O,\kappa O'$)bis[4-(1*H*-imidazol-1-yl- κN^3)phenol] ruthenium (III) trifluoromethanesulfonate;

40 (ee) AMD 8873, (Acetonitrile)bis(1,3-diphenyl-1,3-propanediionato- $\kappa O,\kappa O'$)[4-(1*H*-imidazol-1-yl- κN^3)phenol] ruthenium (III) trifluoromethanesulfonate;

45 (ff) AMD 8877, bis(1,3-diphenyl-1,3-propanediionato- $\kappa O,\kappa O'$)bis[4-(1*H*-imidazol-1-yl- κN^3)phenol] ruthenium (III) trifluoromethanesulfonate;

(gg) AMD 8866, Bis[methyl-1-[(1*H*-imidazol-1-yl- κ *N*³)acetyl]-L-proline]bis(2,4-pentanedionato- κ *O*, κ *O*') ruthenium (III) trifluoromethanesulfonate; and

5 (hh) AMD 8891, (Acetonitrile)(4-ethylamino-1*H*-imidazol- κ *N*³)bis(2,4-pentanedionato- κ *O*, κ *O*') ruthenium (III).

24. A method of treating disease in a human or animal subject, wherein
said disease results from overproduction of nitric oxide, comprising administering a
10 pharmaceutical composition comprising an optionally hydrated neutral, anionic or
cationic metal complex of any of Formulae I-V.

25. A method of attenuation of reactive oxygen species when implicated in
diseases of the human body, comprising administering a pharmaceutical composition
15 comprising an optionally hydrated neutral, anionic or cationic metal complex of any
of Formulae I-V.

26. A method of attenuation of nitric oxide when implicated in diseases of
the human body, comprising administering a pharmaceutical composition comprising
20 an optionally hydrated neutral, anionic or cationic metal complex of any of Formulae
I-V.


27. A method of manufacturing a medicament for the treatment of diseases
in which reactive oxygen species are overproduced, comprising formulating a
25 pharmaceutical composition comprising an optionally hydrated neutral, anionic, or
cationic metal complex of any of Formulae I-V.

28. A pharmaceutical composition comprising a therapeutically effective
amount of an active component comprising an optionally hydrated complex of any of
30 Formulae I-V, in admixture with a pharmaceutically acceptable carrier or diluent.

29. The pharmaceutical composition of claim 28, comprising a dosage
range in humans of 1 mg to 10g per day.

30. The complex according to any one of claims 1-11 or 13, wherein said Ruthenium is complexed to a polyaminocarboxylate ligand of general formulae A and B:

5



Where:

V', W', X', Y' and Z' are independently selected from H, phenyl, heteroaryl, C₁-alkyl, C₁-6alkylhydroxy, C₁-6alkylthiol, C₁-6alkylaryl, C₁-6alkylheteroaryl, C₁-alkylheterocyclyl and derivatives thereof;

P' is: CH₂, (CH₂)₂, CHOCH₂, or CH(OC₁-6alkyl)CH₂; and

said ligands may be optionally fused with a heterocyclic ring R (n= 0 or 1).

31. The complex of claim 30, wherein said alkylheterocyclic group is selected from the group consisting of: pyridinylmethylene, pyrazinylmethylene, pyrimidinylmethylene.

32. The complex of claim 30, wherein said aromatic and heteroaromatic groups may be suitably substituted in single or multiple positions with halide, C₁-alkyl, C₁-6alkoxy, C₁-6alkoxyaryl or benzyloxy, hydroxy, C₁-6hydroxyalkyl, thiol, carboxylic acid, carboxyalkylC₁-6, carboxamide, carboxamidoalkylC₁-6, and anilide.

33. The complex of claim 30, wherein said V', W', X', Y' and Z' may also be methylenecarboxylic acid, methylenecarboxyC₁-6alkyl, methylenecarboxamideC₁-alkyl or heterocyclyl, methylenecarboxanilide, methylenecarboxamido derivatives of an aminoacid or peptide, methylenehydroxamic acid, methylene phosphonic acid, and

C₁₋₆alkylthiol.

34. The complex of claim 30, wherein said heterocyclic group is selected from the group consisting of: pyridine, pyrimidine, pyrazine, imidazole, thiazole, and
5 oxazole.

35. A method of inhibiting tumor growth in a mammalian subject, comprising administering to said subject an inhibitory concentration of an optionally hydrated complex of any of Formulae I-V.

10

36. The method of claim 35, wherein, said complex is AMD6221, K[Ru(H₂dtpa)Cl]H₂O; or AMD6245,[Ru(Hedta)]H₂O.




Figure 1




Figure 2




Figure 3




Figure 4A




Figure 4A Continued




Figure 4B




Figure 4B Continued




Figure 4C




Figure 4C Continued




Figure 4D




Figure 4D Continued




Figure 4E




Figure 4E Continued




Figure 4F




Figure 4F Continued




Figure 4G




Figure 5A




Figure 5A Continued




Figure 5B




Figure 5B Continued




Figure 5C

INTERNATIONAL SEARCH REPORT

Inte onal Application No
PCT/CA 00/00294

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07F15/00 C07F19/00 A61K31/28 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07F A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>CHEMICAL ABSTRACTS, vol. 130, no. 1, 4 January 1999 (1999-01-04) Columbus, Ohio, US; abstract no. 256, VILCHEZ, FRANCISCO GONZALEZ ET AL: "Solution studies of the antitumor complex dichloro-1,2- propylenediaminetetraacetate ruthenium (III) and of its interactions with proteins" XP002137685 abstract & J. INORG. BIOCHEM. (1998), 71(1,2), 45-51 ,1998, ----</p> <p style="text-align: center;">-/-</p>	1-23, 27-34

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

15 May 2000

Date of mailing of the international search report

30/05/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Rinkel, L

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 00/00294

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 128, no. 11, 16 March 1998 (1998-03-16) Columbus, Ohio, US; abstract no. 123780, FRICKER, S. P. ET AL: "Ruthenium complexes as nitric oxide scavengers: a potential therapeutic approach to nitric oxide-mediated diseases" XP002137686 abstract & BR. J. PHARMACOL. (1997), 122(7), 1441-1449 ,1997, ----	1-23, 27-34
X	CHEMICAL ABSTRACTS, vol. 128, no. 3, 19 January 1998 (1998-01-19) Columbus, Ohio, US; abstract no. 18655, CHEN, YA ET AL: "'Ru2II(ttha) (H2O)2!2- is a rapid NO scavenger (ttha6- = triethylenetetraminehexaacetate)" XP002137687 abstract & J. INORG. BIOCHEM. (1997), 68(3), 183-193 ,1997, ----	1-23, 27-34
X	CHEMICAL ABSTRACTS, vol. 125, no. 7, 12 August 1996 (1996-08-12) Columbus, Ohio, US; abstract no. 76255, FRICKER, SIMON P. ET AL: "Ruthenium complexes as nitric oxide scavengers: A new therapeutic approach to nitric oxide mediated disease." XP002137688 abstract & PORTLAND PRESS PROC. (1996), 10(BIOLOGY OF NITRIC OXIDE PART 5), 330 ,1996, ----	1-23, 27-34
X	CHEMICAL ABSTRACTS, vol. 124, no. 15, 9 April 1996 (1996-04-09) Columbus, Ohio, US; abstract no. 192968, FRICKER, S. P.: "Ruthenium, nitric oxide and disease. A novel inorganic chemistry approach to drug design" XP002137689 abstract & PLATINUM MET. REV. (1995), VOLUME DATE 1995, 39(4), 150-9 ,1995, ----	1-23, 27-34
		-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/00294

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 123, no. 3, 17 July 1995 (1995-07-17) Columbus, Ohio, US; abstract no. 25315, VAN VLIET, PAUL M. ET AL: "mer-‘Ru(terpy)Cl ₃ ! (terpy = 2,2':6',2''-terpyridine) shows biological activity, forms interstrand cross-links in DNA and binds two guanine derivatives in a trans configuration" XP002137690 abstract & INORG. CHIM. ACTA (1995), 231(1-2), 57-64 ,1995, ---	1-23, 27-34
X	CHEMICAL ABSTRACTS, vol. 120, no. 11, 14 March 1994 (1994-03-14) Columbus, Ohio, US; abstract no. 124166, BREGANT, F. ET AL: "Effects of some ruthenium chelates on MCa mammary carcinoma and on TLX5 lymphoma in mice" XP002137691 abstract & ANTICANCER RES. (1993), 13(4), 1011-17 , 1993, ---	1-23, 27-34
X	CHEMICAL ABSTRACTS, vol. 115, no. 25, 23 December 1991 (1991-12-23) Columbus, Ohio, US; abstract no. 270122, SAVA, GIANNI ET AL: "Metal complexes of ruthenium: a potential class of selective anticancer drugs" XP002137692 abstract & ANTICANCER RES. (1991), 11(3), 1103-7 , 1991, ---	1-23, 27-34
X	CHEMICAL ABSTRACTS, vol. 101, no. 3, 16 July 1984 (1984-07-16) Columbus, Ohio, US; abstract no. 16814, FARRELL, N. P. ET AL: "Trypanocidal and antitumor activity of platinum-metal and platinum-metal-drug dual-function complexes" XP002137693 abstract & BIOCHEM. PHARMACOL. (1984), 33(7), 961-71 ,1984, ---	1-23, 27-34
		-/-

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 00/00294

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>CHEMICAL ABSTRACTS, vol. 124, no. 4, 22 January 1996 (1996-01-22) Columbus, Ohio, US; abstract no. 44080, VILAPLANA, R. ET AL: "Synthesis, structure and antitumor properties of a new 1,2-propylenediaminetetraacetate-ruthenium (III) compound" XP002137694 abstract & MET.-BASED DRUGS (1995), 2(4), 211-19, 1995, ---</p>	1-23, 27-34
X	<p>CHEMICAL ABSTRACTS, vol. 121, no. 26, 26 December 1994 (1994-12-26) Columbus, Ohio, US; abstract no. 314453, VILAPLANA, R. A. ET AL: "The first isolated antineoplastic Ru(IV) complex: synthesis and structure of 'C12(1,2-cyclohexanediaminetetraacetate)Ru !.cntdot.2H2O'" XP002137695 abstract & INORG. CHIM. ACTA (1994), 224(1-2), 15-18, 1994, ---</p>	1-23, 27-34
X	<p>CHEMICAL ABSTRACTS, vol. 116, no. 7, 17 February 1992 (1992-02-17) Columbus, Ohio, US; abstract no. 50998, CAUCI, SABINA ET AL: "Reaction of the octahedral antitumor complex trans-ruthenium(II) chloride-tetra-dimethyl sulfoxide (trans-RuC12(DMSO)4) with 2-deoxyguanosine" XP002137696 abstract & J. INORG. BIOCHEM. (1991), 43(4), 739-51, 1991, ---</p>	1-23, 27-34
X	<p>CHEMICAL ABSTRACTS, vol. 112, no. 9, 26 February 1990 (1990-02-26) Columbus, Ohio, US; abstract no. 69481, KEPPLER, B. K. ET AL: "New ruthenium complexes for the treatment of cancer" XP002137697 abstract & PROG. CLIN. BIOCHEM. MED. (1989), 10(RUTHENIUM OTHER NON-PLATINUM MET. COMPLEXES CANCER CHEMOTHER.), 41-69, 1989, ---</p>	1-23, 27-34
		-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/00294

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 05814 A (JOHNSON MATTHEY PLC, UK) 2 March 1995 (1995-03-02) the whole document ---	1-23, 27-34
X	WO 90 05732 A (COLUMBIA UNIVERSITY, USA) 31 May 1990 (1990-05-31) the whole document ---	1-23, 27-34
X	WO 86 04244 A (COLUMBIA UNIVERSITY, USA) 31 July 1986 (1986-07-31) the whole document ---	1-23, 27-34
X	CHATTERJEE, DEBABRATA ET AL: "Reactivity of 'RuIII(EDTA)(H ₂ O)' with nucleic bases, nucleosides and DNA (calf-thymus) in aqueous solution" J. CHEM. SOC., DALTON TRANS. (1995), (15), 2495-501, 1995, XP002137683 the whole document ---	1-23, 27-34
X	DAVIES, NATHAN A. ET AL: "Kinetics of nitric oxide scavenging by ruthenium(III) polyaminocarboxylates: novel therapeutic agents for septic shock" CHEM. COMMUN. (CAMBRIDGE) (1997), (1), 47-48, 1997, XP002137684 the whole document ---	1-23, 27-34
X, P	WO 99 15535 A (SWED.) 1 April 1999 (1999-04-01) the whole document -----	1-23, 27-34

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA 00/00294

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 24-26, 35, 36

because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Rule 39.1(iv) PCT-Method for treatment of the human or animal body by therapy

2. Claims Nos.: -

because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210

3. Claims Nos.: -

because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.: -

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: -

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-23, 27-34 relate to an extremely large number of possible compounds (e.g. common salt also falls under present claims). In fact, the claims contain so many options, variables, possible permutations and provisos that a lack of clarity and conciseness within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search was carried out for those parts of the application which do appear to be clear and concise.

However, the initial phase of this search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claims may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of those parts of the application which do appear to be clear and concise is impossible.

Consequently, the search has been restricted to: The use of ruthenium complexes wherein the ruthenium is bound to an -at least- bidentate O,N-, O,O- or N,N-ligand in the manufacture of a medicament for the treatment of tumors.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte	onal Application No
PCT/CA 00/00294	

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9505814	A 02-03-1995	AU 698785 B AU 7390794 A CA 2170253 A EP 0714294 A FI 960849 A HU 74947 A JP 9501927 T NO 960754 A NZ 269596 A US 5824673 A ZA 9406262 A		05-11-1998 21-03-1995 02-03-1995 05-06-1996 23-02-1996 28-03-1997 25-02-1997 23-04-1996 26-05-1997 20-10-1998 20-03-1995
WO 9005732	A 31-05-1990	US 5112974 A AU 4647689 A CA 2002380 A US 5439794 A		12-05-1992 12-06-1990 07-05-1990 08-08-1995
WO 8604244	A 31-07-1986	US 4721669 A AU 5352086 A CA 1339306 A EP 0211043 A US 4980473 A US 5112974 A US 5157032 A US 5439794 A US 5225556 A		26-01-1988 13-08-1986 19-08-1997 25-02-1987 25-12-1990 12-05-1992 20-10-1992 08-08-1995 06-07-1993
WO 9915535	A 01-04-1999	AU 9195298 A		12-04-1999